Heterobifunctional compounds as HPK1 degraders

Heterobifunctional compounds targeting HPK1 for degradation offer a novel solution to HPK1-mediated diseases, overcoming resistance and ensuring complete protein elimination, providing a more effective treatment than traditional inhibitors.

JP2024541513APending Publication Date: 2024-11-08MT SINAI SCHOOL OF MEDICINE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024531334
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-23
Filing Date
2022-11-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current treatments for HPK1-mediated diseases, such as traditional enzyme inhibitors, fail to address the protein's scaffolding function and can be ineffective due to genetic mutations causing resistance, necessitating a novel approach to degrade HPK1.

Method used

Development of heterobifunctional compounds, or proteolytic targeting chimeras (PROTACs), that bind to HPK1 and induce its degradation, rather than merely inhibiting its catalytic activity, thereby overcoming resistance and effectively targeting HPK1 for destruction.

Benefits of technology

The HPK1 degrading agents provide a mechanism to suppress HPK1 activity without affecting protein levels, offering a more effective therapeutic strategy than traditional inhibitors by ensuring complete protein elimination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541513000001_ABST
    Figure 2024541513000001_ABST
Patent Text Reader

Abstract

Disclosed are hematopoietic progenitor kinase 1 (HPK1) degradation / destruction compounds, including HPK1 ligands, degradation / destruction tags and linkers, and methods for the use of such compounds in the treatment of HPK1-mediated diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure relates to bivalent compounds (e.g., heterobifunctional compounds) that degrade and / or destroy hematopoietic progenitor kinase 1 (HPK1), compositions comprising one or more of the bivalent compounds, and methods of use thereof for treating HPK1-mediated diseases in subjects in need thereof. This disclosure also relates to methods for designing such bivalent compounds. [Background technology]

[0002] Unlike traditional enzyme inhibitors, which only inhibit the catalytic activity of a target enzyme, heterobifunctional compounds, also known as proteolysis-targeting chimeras (PROTACs), bind to the enzyme and induce its degradation, thus eliminating the protein's potential scaffolding function in addition to inhibiting its enzymatic activity (Buckley and Crews, 2014). The HPK1 degraders disclosed herein provide a novel mechanism for treating HPK1-mediated diseases. Additionally, the degraders' ability to target HPK1 for degradation, as opposed to inhibiting HPK1's catalytic activity, is expected to overcome resistance, whether due to a previous drug used in treatment or acquired resistance caused by genetic mutation, amplification, or otherwise.

[0003] The immune system constantly monitors the host for the emergence of nascent cancer cells and eliminates them before they become tumors (Burnet, 1970). While several lines of evidence have suggested that our immune system is capable of accomplishing this task (Corthay, 2014), the most direct support for this concept comes from the development of immuno-oncology drugs that target inhibitory molecules that impede antitumor immune efforts, enabling the immune system to proactively engage and eliminate previously difficult-to-treat cancers (Ribas and Wolchok, 2018). The success of immune checkpoint inhibitor approaches provides a roadmap for how an exhausted immune system can be induced to reengage cancer cells. This theoretical framework will drive the search for novel immune checkpoint receptors that can serve as novel immune checkpoint targets.

[0004] Hematopoietic progenitor kinase 1 (HPK1, also known as MAP4K1), an intracellular negative regulator of the T cell antigen receptor (TCR) signaling pathway, is a member of the KHS subfamily of Ste20 serine / threonine kinases (Hu et al., 1996; Kiefer et al., 1996). HPK1 is a multimodular domain protein that contains, in addition to its kinase domain, a proline-rich motif and a C-terminal citron homology domain. These additional domains suggest that HPK1 may perform functions other than its kinase function. HPK1 transcripts are detected in all embryonic tissues examined, but its expression profile shifts to a hematopoietic cell-restricted pattern on neonatal day 1 after delivery (Kiefer et al., 1996), leading to speculation that HPK1 may perform specialized functions in hematopoietic cells. This cytosolic Ste20 kinase is recruited to the TCR complex (Ling et al., 2001), and its kinase activity is induced upon TCR engagement (Liou et al., 2000). Overexpression of HPK1 suppresses TCR-induced activation of AP-1-dependent gene transcription in a kinase-dependent manner, suggesting that the kinase activity of HPK1 is required to inhibit the Erk MAPK pathway (Liou et al., 2000). This disruption of the Erk MAPK pathway appears to be an inhibitory mechanism that negatively regulates TCR-induced IL-2 gene transcription. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Berge SM et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1–19 (1997) [Non-patent document 2] Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, Volume 1: Principles and Practice Summary of the Invention [Means for solving the problem]

[0006] The present disclosure generally relates to bivalent compounds (e.g., bifunctional compounds) that degrade and / or disrupt HPK1, and methods for treating HPK1-mediated diseases (i.e., diseases that depend on HPK1; that overexpress HPK1; that depend on HPK1 activity; or that involve elevated levels of HPK1 activity relative to wild-type tissue of the same species and tissue type).It is important to note that because HPK1 degraders / disruptors have dual functions (enzyme inhibition plus protein degradation / destruction), the bivalent compounds of the present disclosure may be significantly more effective therapeutic agents than currently available HPK1 inhibitors, which inhibit the enzymatic activity of HPK1 but do not affect HPK1 protein levels.The present disclosure further provides methods for identifying HPK1 degraders / disruptors as described herein.

[0007] More specifically, the present disclosure provides bivalent compounds comprising an HPK1 ligand conjugated to a degradation / destruction tag.

[0008] In some embodiments, the HPK1 degrader / disruptor has the form "PI-linker-EL," as shown below:

[0009] [ka]

[0010] wherein PI (protein of interest) comprises an HPK1 ligand (e.g., an HPK1 inhibitor) and EL (E3 ligase) comprises a degradation / destruction tag (e.g., an E3 ligase ligand). Exemplary HPK1 ligands (PI), exemplary degradation / destruction tags (EL), and exemplary linkers (linkers) are illustrated below.

[0011] HPK1 ligand In certain embodiments, the (HPK1) ligand comprises a moiety according to Formula 1:

[0012] [ka]

[0013] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); The "linker" portion of the bivalent compound is R 2 If attached to; R 1 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 4 , S.R. 4 , N.R. 4 R 5 , C(O)R 4 , C(O)OR 4 , C(O)NR 4 R 5 , S(O)R 4 , S(O)2R 4 , S(O)NR 4 R 5 , N.R. 6 C(O)OR 4 , N.R. 6 C(O)R 4 , N.R. 6 C(O)NR 4 R 5 , N.R. 6 S(O)R 4 , N.R. 6 S(O)2R 4 , N.R. 6 S(O)NR 4 R 5, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 4 , R 5 , and R 6 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 , R 4 and R 6 , R 5 and R 6 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0014] The "linker" portion of the bivalent compound is R 1 If attached to; R 1 is, at each occurrence, OR 4 , S.R. 4 , N.R. 4 R5 , C(O)R 4 , C(O)OR 4 , C(O)NR 4 R 5 , S(O)R 4 , S(O)2R 4 , S(O)NR 4 R 5 , N.R. 6 C(O)OR 4 , N.R. 6 C(O)R 4 , N.R. 6 C(O)NR 4 R 5 , N.R. 6 S(O)R 4 , N.R. 6 S(O)2R 4 , N.R. 6 S(O)NR 4 R 5 , C1-C8 alkylene, optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted C3-C8 cycloalkoxylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; wherein R 4 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 5 and R 6are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 , R 4 and R 6 , R 5 and R 6 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0015] The "linker" portion of the bivalent compound is R 1 If attached to; R 2 is the absence, hydrogen, C(O)R at each occurrence. 7 , C(O)OR 7 , C(O)NR 7 R 8 , S(O)R 7 , S(O)2R 7 , S(O)NR 7 R 8 , N.R. 9 C(O)OR 7 , N.R. 9 C(O)R 7 , N.R. 9 C(O)NR 7 R 8 , N.R. 9 S(O)R 7 , N.R. 9 S(O)2R 7 , N.R. 9 S(O)NR 7 R 8, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 7 , R 8 , and R 9 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 7 and R 8 , R 7 and R 9 , R 8 and R 9 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0016] The "linker" portion of the bivalent compound is R 2 If attached to; R 2 is, at each occurrence, C(O)R 7 , C(O)OR 7 , C(O)NR7 R 8 , S(O)R 7 , S(O)2R 7 , S(O)NR 7 R 8 , N.R. 9 C(O)OR 7 , N.R. 9 C(O)R 7 , N.R. 9 C(O)NR 7 R 8 , N.R. 9 S(O)R 7 , N.R. 9 S(O)2R 7 , N.R. 9 S(O)NR 7 R 8 , optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted C3-C8 cycloalkoxylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; wherein R 7 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 8 and R 9are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 7 and R 8 , R 7 and R 9 , R 8 and R 9 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0017] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 2:

[0018] [ka]

[0019] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 and R 2 The definition of is the same as for Eq. 1).

[0020] Ar, at each occurrence, is independently selected from absent, aryl, or heteroaryl, each of which is R 1 Substituted with hydrogen, halogen, oxo, CN, NO2, OR 12 , S.R. 12 , N.R. 12 R 13 ,OCOR 12, OCO2R 12 , OCONR 12 R 13 , C.O.R. 12 , CO2R 12 ,CONR 12 R 13 , SOR 12 , SO2R 12 , SO2NR 12 R 13 , N.R. 14 CO2R 12 , N.R. 14 COR 12 , N.R. 14 C(O)NR 12 R 13 , N.R. 14 SOR 12 , N.R. 14 SO2R 12 , N.R. 14 SO2NR 12 R 13 optionally substituted with one or more substituents independently selected from optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 4-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 12 , R 13 , and R 14are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 4-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 12 and R 13 , R 12 and R 14 , R 13 and R 14 together with the atom to which they are attached form a 4- to 20-membered heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0021] In certain embodiments, the (HPK1) ligand comprises a moiety according to Formula 2A:

[0022] [ka]

[0023] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 , R 2 and Ar are defined as for Equation 2).

[0024] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 2B:

[0025] [ka]

[0026] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 and R 2 The definition of is the same as for Eq. 2).

[0027] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 2C:

[0028] [ka]

[0029] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 and R 2 The definition of is the same as for Equation 2; R 3 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 15 , S.R. 15 , N.R. 15 R 16 , C(O)R 16 , C(O)OR 15 , C(O)NR 15 R 16 , S(O)R 15 , S(O)2R 15 , S(O)NR 15 R 16 , N.R. 17 C(O)OR 15 , N.R. 6 C(O)R 15 , N.R. 17 C(O)NR 15 R 16 , N.R. 17 S(O)R 15 , N.R. 17 S(O)2R15 , N.R. 17 S(O)NR 15 R 16 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 15 , R 16 , and R 17 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 15 and R 16 , R 15 and R 17 , R 16 and R 17 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; n is independently selected from 0, 1, 2, 3 and 4; and pharmaceutically acceptable salts thereof.

[0030] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 3:

[0031] [ka]

[0032] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 3 independently attached to (indicated by dotted lines); The "linker" portion of the bivalent compound is R 3 If attached to; R 1 and R 2 is the absence, hydrogen, C(O)R at each occurrence. 10 , C(O)OR 10 , C(O)NR 10 R 11 , S(O)R 10 , S(O)2R 10 , S(O)NR 10 R 11 , N.R. 12 C(O)OR 10 , N.R. 12 C(O)R 10 , N.R. 12 C(O)NR 10 R 11 , N.R. 12 S(O)R 10 , N.R. 12 S(O)2R 10 , N.R. 12 S(O)NR 10 R 11, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 10 , R 11 , and R 12 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 10 and R 11 , R 10 and R 12 , R 11 and R 12 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 and R 2 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 3 is OR 13 , S.R. 13 , N.R. 13R 14 , CH2NR 13 R 14 , CH2CH2NR 13 R 14 , C1-C8 alkylene NR 13 R 14 , C(O)R 13 , C(O)OR 13 , C(O)NR 13 R 14 , S(O)R 13 , S(O)2R 14 , S(O)NR 13 R 14 , N.R. 15 C(O)OR 13 , N.R. 15 C(O)R 13 , N.R. 15 C(O)NR 13 R 14 , N.R. 15 S(O)R 32 , N.R. 15 S(O)2R 32 , N.R. 15 S(O)NR 13 R 14 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 13 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 14 and R 15 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 13 and R 14 , R 13 and R 15 , R 14 and R 15 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 4 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 16 , S.R. 16 , N.R. 16 R 17 , C(O)R 16 , C(O)OR 16 , C(O)NR 16 R 17 , S(O)R 16 , S(O)2R 16 , S(O)NR 16 R 17 , N.R. 18 C(O)OR 16 , N.R. 18 C(O)R 16 , N.R. 18 C(O)NR 16 R 17 , N.R. 18 S(O)R 16 , N.R. 18 S(O)2R 16 , N.R. 18 S(O)NR 16 R 15, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 16 , R 17 , and R 18 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 16 and R 17 , R 16 and R 18 , R 17 and R 18 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0033] The "linker" portion of the bivalent compound is R 1 If attached to; R 1 is OR 19 , S.R. 19 , N.R. 19 R20 , CH2NR 19 R 20 , CH2CH2NR 19 R 20 , C1-C8 alkylene NR 19 R 20 , C(O)R 19 , C(O)OR 19 , C(O)NR 19 R 20 , S(O)R 19 , S(O)2R 20 , S(O)NR 19 R 20 , N.R. 21 C(O)OR 19 , N.R. 21 C(O)R 19 , N.R. 21 C(O)NR 19 R 20 , N.R. 21 S(O)R 19 , N.R. 21 S(O)2R 19 , N.R. 21 S(O)NR 19 R 20 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 19 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 20 and R 21 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 19 and R 20 , R 19 and R 21 , R 20 and R 21 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 2 is the absence, hydrogen, C(O)R at each occurrence. 10 , C(O)OR 10 , C(O)NR 10 R 11 , S(O)R 10 , S(O)2R 10 , S(O)NR 10 R 11 , N.R. 12 C(O)OR 10 , N.R. 12 C(O)R 10 , N.R. 12 C(O)NR 10 R 11 , N.R. 12 S(O)R 10 , N.R. 12 S(O)2R 10 , N.R. 12 S(O)NR 10 R 11, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 10 , R 11 , and R 12 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 10 and R 11 , R 10 and R 12 , R 11 and R 12 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 3 and R 4 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 16 , S.R. 16 , N.R. 16 R 17 , C(O)R 16 , C(O)OR 16 , C(O)NR 16 R17 , S(O)R 16 , S(O)2R 16 , S(O)NR 16 R 17 , N.R. 18 C(O)OR 16 , N.R. 18 C(O)R 16 , N.R. 18 C(O)NR 16 R 17 , N.R. 18 S(O)R 16 , N.R. 18 S(O)2R 16 , N.R. 18 S(O)NR 16 R 15 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 16 , R 17 , and R 18 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 16 and R17 , R 16 and R 18 , R 17 and R 18 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0034] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 3A:

[0035] [ka]

[0036] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 3 independently attached to (indicated by dotted lines); R 1 , R 2 and R 3 The definition of is the same as for Equation 3; R 5 is the absence, hydrogen, C(O)R at each occurrence. 22 , C(O)OR 22 , C(O)NR 22 R 23 , S(O)R 22 , S(O)2R 22 , S(O)NR 22 R 23 , N.R. 24 C(O)OR 22 , N.R. 24 C(O)R 22 , N.R. 24 C(O)NR 22 R 23 , N.R. 24 S(O)R 22 , N.R. 24 S(O)2R 22 , N.R. 24 S(O)NR 22 R 23, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 22 , R 23 , and R 24 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 22 and R 23 , R 22 and R 24 , R 23 and R 24 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 6 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 25 , S.R. 25 , N.R. 25 R 26 , C(O)R 25 , C(O)OR 25 , C(O)NR 25 R 26, S(O)R 25 , S(O)2R 25 , S(O)NR 25 R 26 , N.R. 27 C(O)OR 25 , N.R. 27 C(O)R 25 , N.R. 21 C(O)NR 25 R 26 , N.R. 27 S(O)R 25 , N.R. 27 S(O)2R 25 , N.R. 27 S(O)NR 25 R 26 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 25 , R 26 , and R 27 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 25 and R 26 , R25 and R 26 , R 26 and R 27 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0037] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 3B:

[0038] [ka]

[0039] (In the formula, The "linker" portion of a bivalent compound is R 1 or R 7 independently attached to (indicated by dotted lines); R 5 and R 6 The definitions are the same as for formula 3A; The "linker" portion of the bivalent compound is R 1 If attached to; R 1 is OR 28 , S.R. 28 , N.R. 28 R 29 , CH2NR 28 R 29 , CH2CH2NR 28 R 29 , C1-C8 alkylene NR 28 R 29 , C(O)R 28 , C(O)OR 28 , C(O)NR 28 R 29 , S(O)R 28 , S(O)2R 29 , S(O)NR 28 R 29 , N.R. 30 C(O)OR 28 , N.R. 30 C(O)R 28 , N.R. 30 C(O)NR28 R 29 , N.R. 30 S(O)R 28 , N.R. 30 S(O)2R 28 , N.R. 30 S(O)NR 28 R 29 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 28 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 29 and R 30 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 28 and R 29 , R 28 and R 29, R 29 and R 30 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 2 , R 7 and R 8 is the absence, hydrogen, C(O)R at each occurrence. 31 , C(O)OR 31 , C(O)NR 31 R 32 , S(O)R 31 , S(O)2R 31 , S(O)NR 31 R 32 , N.R. 33 C(O)OR 31 , N.R. 33 C(O)R 31 , N.R. 33 C(O)NR 31 R 32 , N.R. 33 S(O)R 31 , N.R. 33 S(O)2R 31 , N.R. 33 S(O)NR 31 R 32 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 31 , R 32 , and R 33is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 31 and R 32 , R 31 and R 33 , R 32 and R 33 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 7 and R 8 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0040] The "linker" portion of the bivalent compound is R 7 If attached to; R 7 is OR 28 , S.R. 28 , N.R. 28 R 29 , CH2NR 28 R 29 , CH2CH2NR 28 R 29 , C1-C8 alkylene NR 28 R 29 , C(O)R 28 , C(O)OR 28 , C(O)NR 28 R 29 , S(O)R 28 , S(O)2R 29 , S(O)NR 28R 29 , N.R. 30 C(O)OR 28 , N.R. 30 C(O)R 28 , N.R. 30 C(O)NR 28 R 29 , N.R. 30 S(O)R 28 , N.R. 30 S(O)2R 28 , N.R. 30 S(O)NR 28 R 29 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 28 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 29 and R 30are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 28 and R 29 , R 28 and R 29 , R 29 and R 30 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 , R 2 and R 8 is the absence, hydrogen, C(O)R at each occurrence. 31 , C(O)OR 31 , C(O)NR 31 R 32 , S(O)R 31 , S(O)2R 31 , S(O)NR 31 R 32 , N.R. 33 C(O)OR 31 , N.R. 33 C(O)R 31 , N.R. 33 C(O)NR 31 R 32 , N.R. 33 S(O)R 31 , N.R. 33 S(O)2R 31 , N.R. 33 S(O)NR 31 R 32, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 31 , R 32 , and R 33 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 31 and R 32 , R 31 and R 33 , R 32 and R 33 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 and R 2 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0041] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 4:

[0042] [ka]

[0043] (In the formula, The "linker" portion of a bivalent compound is R 3 independently attached to (indicated by dotted lines); R 1、 R 2 and R 4 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 5 , S.R. 5 , N.R. 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , S(O)R 5 , S(O)2R 5 , S(O)NR 5 R 6 , N.R. 7 C(O)OR 5 , N.R. 7 C(O)R 5 , N.R. 7 C(O)NR 5 R 26 , N.R. 7 S(O)R 5 , N.R. 7 S(O)2R 5 , N.R. 7 S(O)NR 5 R 6, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 5 , R 6 , and R 7 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 5 and R 6 , R 5 and R 7 , R 6 and R 7 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; n is independently selected from 0, 1, 2, 3, and 4; R 3 is OR 8 , S.R. 8 , N.R. 8 R 9 , CH2NR 8 R 9 , CH2CH2NR 8 R9 , C1-C8 alkylene NR 8 R 9 , C(O)R 8 , C(O)OR 9 , C(O)NR 8 R 9 , S(O)R 8 , S(O)2R 9 , S(O)NR 8 R 9 , N.R. 10 C(O)OR 9 , N.R. 10 C(O)R 9 , N.R. 10 C(O)NR 8 R 9 , N.R. 10 S(O)R 8 , N.R. 10 S(O)2R 8 , N.R. 10 S(O)NR 8 R 9 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 8 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 9 and R 10are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 8 and R 9 , R 8 and R 10 , R 9 and R 10 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0044] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 4A:

[0045] [ka]

[0046] (In the formula, The "linker" portion of a bivalent compound is R 3 independently attached to (indicated by dotted lines); R 3 The definition of is the same as for Equation 4)

[0047] Disassembly / Destruction Tags Degradation / destruction tags (EL) include, but are not limited to:

[0048] In certain embodiments, the degradation / destruction tag comprises a moiety according to Formulas 12A, 12B, 12C, and 12D:

[0049] [ka]

[0050] (In the formula, V, W, and X are CR 2 and N are independently selected; Y is CO, CR 3 R 4 and N=N; Z is absent, CO, CR 5 R 6 , N.R. 5 , O, optionally substituted C1 to C 10 Alkylene, optionally substituted C1-C 10 Alkenylene, optionally substituted C-C 10 Alkynylene, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, optionally substituted C-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl, optionally substituted C-C 13 is selected from spiroheterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; preferably, Z is selected from absent, CH, CH=CH, C≡C, NH, and O; R 1 , and R 2 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; R 3 , and R 4are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 3 and R 4 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; R 5 and R 6 is independently selected from absent, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 5 and R 6 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl).

[0051] In certain embodiments, the degradation / destruction tag comprises a moiety according to one of formulas 12E, 12F, 12G, 12H, and 12I:

[0052] [ka]

[0053] (In the formula, U, V, W, and X are CR 2 and N are independently selected; Y is CR 3 R 4 , N.R. 3 and O; preferably, Y is selected from CH2, NH, NCH3 and O; Z is absent, CO, CR 5 R 6 , N.R. 5 , O, optionally substituted C1 to C 10 Alkylene, optionally substituted C1-C 10Alkenylene, optionally substituted C-C 10 Alkynylene, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, optionally substituted C-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl, optionally substituted C-C 13 is selected from spiroheterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; preferably, Z is selected from absent, CH, CH=CH, C≡C, NH, and O; R 1 , and R 2 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; R 3 , and R 4 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 3 and R 4 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; R 5 and R 6is independently selected from absent, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 5 and R 6 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl); and and pharmaceutically acceptable salts thereof.

[0054] In one embodiment, the degradation / destruction tag comprises a moiety according to Formula 13A:

[0055] [ka]

[0056] (In the formula, R 1 and R 2 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 aminoalkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl; R 3is selected from hydrogen, optionally substituted C(O)C1-C8 alkyl, optionally substituted C(O)C1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)C1-C8 haloalkyl, optionally substituted C(O)C1-C8 hydroxyalkyl, optionally substituted C(O)C1-C8 aminoalkyl, optionally substituted C(O)C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)C3-C7 cycloalkyl, optionally substituted optionally substituted C(O)(3-7 membered heterocyclyl), optionally substituted C(O)C2-C8 alkenyl, optionally substituted C(O)C2-C8 alkynyl, optionally substituted C(O)OC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)OC1-C8 haloalkyl, optionally substituted C(O)OC1-C8 hydroxyalkyl, optionally substituted C(O)OC1-C8 aminoalkyl, optionally substituted C(O)OC1-C8 alkylamino C1-C8 alkyl, optionally substituted C(O)OC3-C7 cycloalkyl, optionally substituted C(O)O(3-7 membered heterocyclyl), optionally substituted C(O)OC2-C8 alkenyl, optionally substituted C(O)OC2-C8 alkynyl, optionally substituted C(O)NC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)NC1-C8 haloalkyl, optionally substituted C(O)NC1-C8 hydroxyalkyl, optionally substituted C(O)NC1-C8 aminoalkyl, optionally substituted C(O)NC1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)NC3-C7 cycloalkyl, optionally substituted C(O)N(3-7 membered heterocyclyl), optionally substituted C(O)NC2-C8 alkenyl, optionally substituted C(O)NC2-C8 alkynyl, optionally substituted P(O)(OH)2, optionally substituted P(O)(OC1-C8 alkyl)2,and optionally substituted P(O)(OC1-C8 aryl)2).

[0057] In certain embodiments, the degradation / destruction tag comprises a moiety according to Formulas 13B, 13C, 13D, 13E, and 13F:

[0058] [ka]

[0059] (In the formula, R 1 and R 2 are independently selected from hydrogen, halogen, OH, NH, CN, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 aminoalkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl; (preferably, R 1 is selected from iso-propyl or tert-butyl; R 2 is selected from hydrogen or methyl); R 3is selected from hydrogen, optionally substituted C(O)C1-C8 alkyl, optionally substituted C(O)C1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)C1-C8 haloalkyl, optionally substituted C(O)C1-C8 hydroxyalkyl, optionally substituted C(O)C1-C8 aminoalkyl, optionally substituted C(O)C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)C3-C7 cycloalkyl, optionally substituted optionally substituted C(O)(3-7 membered heterocyclyl), optionally substituted C(O)C2-C8 alkenyl, optionally substituted C(O)C2-C8 alkynyl, optionally substituted C(O)OC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)OC1-C8 haloalkyl, optionally substituted C(O)OC1-C8 hydroxyalkyl, optionally substituted C(O)OC1-C8 aminoalkyl, optionally substituted C(O)OC1-C8 alkylamino C1-C8 alkyl, optionally substituted C(O)OC3-C7 cycloalkyl, optionally substituted C(O)O(3-7 membered heterocyclyl), optionally substituted C(O)OC2-C8 alkenyl, optionally substituted C(O)OC2-C8 alkynyl, optionally substituted C(O)NC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)NC1-C8 haloalkyl, optionally substituted C(O)NC1-C8 hydroxyalkyl, optionally substituted C(O)NC1-C8 aminoalkyl, optionally substituted C(O)NC1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)NC3-C7 cycloalkyl, optionally substituted C(O)N(3-7 membered heterocyclyl), optionally substituted C(O)NC2-C8 alkenyl, optionally substituted C(O)NC2-C8 alkynyl, optionally substituted P(O)(OH)2, optionally substituted P(O)(OC1-C8 alkyl)2,and optionally substituted P(O)(OC1-C8 aryl)2; R 4 and R 5 is hydrogen, COR 6 , CO2R 6 ,CONR 6 R 7 , SOR 6 , SO2R 6 , SO2NR 6 R 7 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 ;R 6 and R 7 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; Ar is selected from aryl and heteroaryl, each of which is selected from F, Cl, CN, NO, OR 8 , N.R. 8 R 9 , C.O.R. 8 , CO2R 8 ,CONR 8 R 9 , SOR8 , SO2R 8 , SO2NR 9 R 10 , N.R. 9 COR 10 , N.R. 8 C(O)NR 9 R 10 , N.R. 9 SOR 10 , N.R. 9 SO2R 10 optionally substituted with one or more substituents independently selected from optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxyalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 alkylaminoC1-C6 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted aryl, and optionally substituted C4-C5 heteroaryl; R 8 , R 9 , and R 10 are independently selected from absent, hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 8 and R 9 ;R 9 and R 10 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; and and pharmaceutically acceptable salts thereof.

[0060] In one embodiment, the degradation / destruction tag comprises a moiety according to Formula 14A:

[0061] [ka]

[0062] (In the formula, V, W, X, and Z are CR 4 and N are independently selected; R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl).

[0063] In one embodiment, the degradation / destruction tag comprises a moiety according to Formula 14B:

[0064] [ka]

[0065] (In the formula, R 1 , R 2 , and R 3are independently selected from hydrogen, halogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl; R 4 and R 5 is hydrogen, COR 6 , CO2R 6 ,CONR 6 R 7 , SOR 6 , SO2R 6 , SO2NR 6 R 7 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted aryl-C1-C8 alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 6 and R 7together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; and and pharmaceutically acceptable salts thereof.

[0066] In one embodiment, the degradation / destruction tag is selected from the group consisting of:

[0067] [ka]

[0068] [ka]

[0069] and pharmaceutically acceptable salts thereof.

[0070] Linker In any of the compounds described above, the HPK1 ligand can be conjugated to the degradation / destruction tag via a linker. The linker can include, for example, acyclic or cyclic, saturated or unsaturated carbon groups of different lengths, ethylene glycol groups, amide groups, amino groups, ether groups, urea groups, carbamate groups, aromatic groups, heteroaromatic groups, heterocyclic groups, and / or carbonyl-containing groups.

[0071] In certain embodiments, the linker is a moiety according to Formula 16:

[0072] [ka]

[0073] (In the formula, A, W, and B are the absence, CO, CO2, and C(O)NR at each occurrence. 1 , C(S)NR 1 , O, S, SO, SO2, SO2NR 1 , N.R. 1 , N.R. 1 CO, NR 1 CONR2 , N.R. 1 C(S), optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl and optionally substituted C-C 13 spiroheterocyclyl; R 1 and R 2 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; m is 0 to 15).

[0074] In certain embodiments, the linker is a moiety according to Formula 16A:

[0075] [ka]

[0076] (In the formula, R 1 , R 2 , R 3 , and R 4 is independently selected at each occurrence from hydrogen, halogen, CN, OH, NH2, optionally substituted C1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; A, W, and B are the absence, CO, CO2, and C(O)NR at each occurrence. 5 , C(S)NR 5 , O, S, SO, SO2, SO2NR 5 , N.R. 5 , N.R. 5 CO, NR 5 CONR 6 , N.R. 5C(S), optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl and optionally substituted C-C 13 spiroheterocyclyl; R 5 and R 6 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; m is 0 to 15; n, for each occurrence, is between 0 and 15; o is between 0 and 15).

[0077] In certain embodiments, the linker is a moiety according to Formula 16B:

[0078] [ka]

[0079] (In the formula, R 1 and R 2 is independently selected at each occurrence from hydrogen, halogen, CN, OH, NH2, and optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, or C1-C8 alkylaminoC1-C8 alkyl; A and B are the absence, CO, CO2, and C(O)NR at each occurrence. 3 , C(S)NR 3 , O, S, SO, SO2, SO2NR 3 , N.R. 3 , N.R. 3 CO, NR 3 CONR 4 , N.R. 3C(S) and optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl or C3-C 13 spiroheterocyclyl; R 3 and R 4 are independently selected from hydrogen and optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, or C1-C8 alkylaminoC1-C8 alkyl; Each m is from 0 to 15; where n is 0 to 15).

[0080] In certain embodiments, the linker is a moiety according to Formula 16C:

[0081] [ka]

[0082] (In the formula, X is O, NH, or NR 7 Selected from; R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is independently selected at each occurrence from hydrogen, halogen, CN, OH, NH, optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; A and B are absent in each occurrence, CO, NH, NH-CO, CO-NH, CH2-NH-CO, CH2-CO-NH, NH-CO-CH2, CO-NH-CH2, CH2-NH-CH2-CO-NH, CH2-NH-CH2-NH-CO, -CO-NH, CO-NH-CH2-NH-CH2, CH2-NH-CH2, CO2, C(O)NR 7 , C(S)NR 7 , O, S, SO, SO2, SO2NR 7 , N.R. 7 , N.R. 7 CO, NR 7 CONR 8 , N.R. 7C(S), optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl and optionally substituted C-C 13 spiroheterocyclyl; R 7 and R 8 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; m, in each occurrence, is 0 to 15; n is 0 to 15 for each occurrence; o is from 0 to 15; p is 0 to 15); and and pharmaceutically acceptable salts thereof.

[0083] In certain embodiments, the linker is selected from the group consisting of a ring selected from the group consisting of a 3- to 13-membered ring; a 3- to 13-membered fused ring; a 3- to 13-membered bridged ring; and a 3- to 13-membered spiro ring; and pharmaceutically acceptable salts thereof.

[0084] In certain embodiments, the linker is a moiety according to one of formulas C1, C2, C3, C4, and C5:

[0085] [ka]

[0086] and pharmaceutically acceptable salts thereof.

[0087] In one embodiment, the HPK1 degrading agent according to the present invention is selected from the group consisting of: MS-5-006, MS-5-007, MS-5-008, MS-5-009, MS-5-010, MS-5-011, MS-5-015, MS-5-016, MS-5-017, MS-5-01 8, MS-5-019, MS-5-021, MS-5-022, MS-5-024, MS-5-026, MS-5-027, MS-5-028, MS-5-029, MS-5-030, MS-5-0 33, MS-5-034, MS-5-035, MS-5-036, MS-5-037, MS-5-038, MS-5-039, MS-5-040, MS-5-041, MS-5-042, MS-5- 043, MS-5-044, MS-5-045, MS-5-046, MS-6-003, MS-6-004, MS-6-005, MS-6-006, MS-6-007, MS-6-008, MS-6 -009, MS-6-013, MS-6-014, MS-6-015, MS-6-016, MS-6-017, MS-6-018, MS-6-019, MS-6-020, MS-6-021, MS- 6-022, MS-6-023, MS-6-024, MS-6-025, MS-6-026, MS-6-027, MS-6-028, MS-6-029, MS-6-037, MS-6-038, MS -6-039, MS-6-040, MS-6-041, MS-6-043, MS-6-044, MS-6-045, MS-6-046, MS-6-047, MS-6-048, MS-6-049, M S-6-050, MS-6-051, MS-6-052, MS-6-053, MS-6-054, MS-6-055, MS-6-058, MS-6-059, MS-6-060, MS-6-061.

[0088] In one embodiment, the HPK1 degrading agent according to the present invention is selected from the group consisting of: MS-5-006, MS-5-007, MS-5-008, MS-5-009, MS-5-010, MS-5-011, MS-5-015, MS-5-016, MS -5-017, MS-5-018, MS-5-019, MS-5-021, MS-5-022, MS-5-024, MS-5-026, MS-5-027, MS-5 -028, MS-5-029, MS-5-030, MS-5-033, MS-5-034, MS-5-035, MS-5-036, MS-5-037, MS-5-0 38, MS-5-039, MS-5-040, MS-5-041, MS-5-042, MS-5-043, MS-5-044, MS-5-045, MS-5-046.

[0089] In one embodiment, the HPK1 degrading agent according to the present invention is selected from the group consisting of: MS-6-003, MS-6-004, MS-6-005, MS-6-006, MS-6-007, MS-6-008, MS-6-009, MS-6-013, MS-6-014, MS-6-015, MS-6-016, MS-6 -017, MS-6-018, MS-6-019, MS-6-020, MS-6-021, MS-6-022, MS-6-023, MS-6-024, MS-6-025, MS-6-026, MS-6-027, MS-6-028, MS-6-029, MS-6-037, MS-6-038, MS-6-039, MS-6-040, MS-6-041, MS-6-043, MS-6-044, MS-6-045, MS-6-046, MS-6-047, MS-6 -048, MS-6-049, MS-6-050, MS-6-051, MS-6-052, MS-6-053, MS-6-054, MS-6-055, MS-6-058, MS-6-059, MS-6-060, MS-6-061.

[0090] In one embodiment, preferred compounds according to the present invention include: a) 2-(4-(3-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)propyl)piperazin-1-yl)-N-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)acetamide (MS-5-007). b) 2-(4-(3-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)propyl)piperazin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide (MS-5-008). c) 4-((5-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (MS-5-009). d) 4-((6-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)hexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5MS-5-010). e) 4-((8-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)octyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (MS-5-011).

[0091] In one embodiment, preferred compounds according to the present invention include: a) 2-(2,6-dioxopiperidin-3-yl)-4-((3-(((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)(methyl)amino)propyl)amino)isoindoline-1,3-dione (MS-6-007). b) 2-(2,6-dioxopiperidin-3-yl)-4-((4-(((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)(methyl)amino)butyl)amino)isoindoline-1,3-dione (MS-6-008). c) 2-(2,6-dioxopiperidin-3-yl)-4-((6-(((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)(methyl)amino)hexyl)amino)isoindoline-1,3-dione (MS-6-009). d) 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)-N-methylacetamide (MS-6-024).

[0092] In some aspects, this disclosure provides a method for treating an HPK1-mediated disease, the method comprising administering one or more bivalent compounds comprising an HPK1 ligand conjugated to a degradation / destruction tag to a subject in need thereof who has an HPK1-mediated disease. The HPK1-mediated disease may be a disease caused by HPK1 amplification. The HPK1-mediated disease may have elevated HPK1 enzyme activity relative to wild-type tissue of the same species and tissue type. Non-limiting examples of HPK1-mediated diseases, or diseases whose clinical symptoms can be treated by HPK1 degrader / disrupter-mediated therapy, include all solid and liquid cancers, chronic infectious diseases that produce an exhausted immune response, infection-mediated immunosuppression, age-related decline in immune response, age-related decline in cognitive function, and infertility.

[0093] Illustrative types of cancer that can be prevented or therapeutically treated by manipulating HPK1 levels with degraders / destructors include, but are not limited to, all solid and liquid cancers, including cancers of the breast, respiratory tract, brain, reproductive organs, gastrointestinal tract, urinary tract, eye, liver, skin, head and neck, thyroid, and parathyroid glands, and their distant metastases. Examples of liquid cancers include lymphoma, sarcoma, and leukemia. Listed below are types of cancer that immunotherapy using HPK1 degraders / destructors should be able to prevent or treat.

[0094] Examples of breast cancer include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

[0095] Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

[0096] Examples of brain cancers include, but are not limited to, brain stem and hypothalamic glioma, cerebellar and cerebral astrocytoma, glioblastoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.

[0097] Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer.

[0098] Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, endovaginal, and vulvar cancer, as well as sarcoma of the uterus.

[0099] Examples of ovarian cancer include, but are not limited to, serous tumors, endometrioid tumors, mucinous cystadenocarcinoma, granulosa cell tumors, Sertoli-Leydig cell tumors, and virilizing tumors.

[0100] Examples of cervical cancer include, but are not limited to, squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, vitreous cell carcinoma, and choriocarcinoma. Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small intestine, and salivary gland cancer.

[0101] Examples of esophageal cancer include, but are not limited to, esophageal cell carcinoma and adenocarcinoma, as well as squamous cell carcinoma, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma, and lymphoma.

[0102] Examples of gastric cancer include, but are not limited to, intestinal-type and diffuse-type gastric adenocarcinoma.

[0103] Examples of pancreatic cancer include, but are not limited to, ductal adenocarcinoma, adenosquamous carcinoma, and pancreatic endocrine tumors.

[0104] Examples of tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral, ​​and human papillary renal carcinoma.

[0105] Examples of kidney cancer include, but are not limited to, renal cell carcinoma, urothelial cell carcinoma, juxtaglomerular cell tumor (nephroma), angiomyolipoma, oncocytoma of the kidney, Bellini ductal carcinoma, clear cell sarcoma of the kidney, mesoblastic nephroma, and Wilms' tumor.

[0106] Examples of bladder cancer include, but are not limited to, transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma, and small cell carcinoma. Eye cancer includes, but is not limited to, intraocular melanoma and retinoblastoma.

[0107] Examples of liver cancer include, but are not limited to, hepatocellular carcinoma (with or without the fibrolamellar variant), biliary adenocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular-biliary adenocarcinoma.

[0108] Examples of skin cancer include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

[0109] Examples of head and neck cancers include, but are not limited to, squamous cell carcinoma of the head and neck, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer, and squamous cell carcinoma.

[0110] Examples of lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.

[0111] Examples of sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[0112] Examples of leukemia include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

[0113] HPK1 degraders / disruptors can treat the above cancer types as stand-alone agents or should be used as agents in combination with existing standards of treatment and other FDA-approved cancer therapies.

[0114] The therapeutic use of HPK1 has been broadened to include diseases and therapies amenable to treatment by stimulating / augmenting the immune response, including the prolongation of the immune response during vaccination for immunizable diseases such as influenza A and coronaviruses, including Covid 19. Moreover, because HPK1 is expressed at high levels in two other anatomical locations—the brain and testes—HPK1 degraders / disruptors should be able to treat or prevent diseases related to the brain and testes that are caused by or can be treated by HPK1 degraders / disruptors. These potential diseases include, but are not limited to, Alzheimer's disease, age-related dementia, and infertility, regardless of whether these possible diseases are caused by HPK1 or by other pathogenic causes.

[0115] The therapeutic use of HPK1 has been further expanded to include therapies involving ex vivo treatment of immune cells, including, but not limited to, all T cell subsets, genetically engineered T cells, chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes, dendritic cells, macrophages, mast cells, granulocytes (including basophils, eosinophils, and neutrophils), natural killer cells, NK T cells, and B cells. These cells are therapeutically treated with an HPK1-degrading agent and then reintroduced back into a patient being treated for a condition that would benefit from a reduction in HPK1 expression. Sources of cells for such ex vivo treatment include, but are not limited to, autologous bone marrow cells from the patient themselves or from the patient's cryobanked umbilical cord blood stem cells, peripheral blood or bone marrow stem cells from MHC-matched or MHC-mismatched donors.

[0116] Treating patients by administering specific immune cells treated with an HPK1-degrading agent offers many additional advantages over in vivo use. By treating specific immune cell types with an HPK1-degrading agent ex vivo, it is possible to specifically target immune cell types that would benefit from the reduction of endogenous HPK1 levels by the HPK1-degrading agent, while sparing HPK1 expression levels in other immune cell types that are not involved in the disease state.

[0117] This therapeutic approach provides cell-type-specific targeting of immune cells in a manner not possible with the use of HPK1 degraders in an in vivo setting. Thus, the ex vivo approach likely limits potential toxicity that may result from reduced HPK1 levels in immune cell types that do not benefit from reduced HPK1 levels.

[0118] Furthermore, by administering the HPK1 degrading agent in an ex vivo cell setting, the risk of the patient experiencing toxicity or possible adverse outcomes should the HPK1 degrading agent be administered systemically is eliminated.

[0119] HPK1 is also known to be expressed in non-hematopoietic tissues such as the brain and testis. Due to this tissue-specific expression pattern of HPK1, HPK1 degrading agents may be able to treat or prevent brain- and testis-related diseases caused by HPK1. These potential treatments include, but are not limited to, treatment of Alzheimer's disease, age-related dementia, and infertility, regardless of whether these possible diseases are caused by HPK1 or other pathogenic causes.

[0120] The use of HPK1 expression status of tumors as a biomarker allows for stratification of patients into appropriate treatment groups receiving HPK1 degrading agents in vivo or ex vivo based on HPK1 expression in the tumor.

[0121] Furthermore, using HPK1 degraders in an ex vivo setting offers an additional advantage over gene editing approaches such as CRISPR in that it allows for the therapeutic use of HPK1 degraders as a non-permanent treatment, allowing the therapeutic regimen to be adjusted over time via dosage levels and via alterations in administration schedules.

[0122] In addition, HPK1 degrading agents can be used in settings where stimulation / enhancement of immune responses is required or when prolongation of immune responses is required. Improving immune responses to vaccination is one setting in which HPK1 degrading agents can be used therapeutically. HPK1 degrading agents can also be used to enhance the antigen-presenting ability of dendritic cell-based cancer vaccines.

[0123] Other utilities of HPK1 degrading agents include treatment of dendritic cells with HPK1 degrading agents to increase resistance to maturation-induced apoptosis, and therefore increase the yield of dendritic cell production.

[0124] In certain embodiments, the HPK1-degrading agents of the present invention can be used in combination with treatment using checkpoint inhibitors, including, but not limited to, anti-programmed cell death protein (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1). Examples of anti-PD-1 and anti-PD-L1 agents include monoclonal antibodies that target either PD-1 or PD-L1. Such antibodies include, but are not limited to, pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo) (PD-1 inhibitors); and atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi) (PD-L1 inhibitors). The use of such anti-PD1 and / or anti-PD-L1 agents in immunotherapy, particularly cancer immunotherapy, can be enhanced by combination treatment with the HPK1-degrading agents of the present invention. Such combination therapy of an anti-PD-1 agent and an HPK1-degrading agent of the present invention is particularly useful in the treatment of melanoma, lung cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, colon cancer, and liver cancer. Such combination therapy of an anti-PD-L1 agent and an HPK1-degrading agent of the present invention is particularly useful in the treatment of non-small cell lung carcinoma, multiple myeloma, urothelial cancer, and head and neck cancer. (Hernandez 2018).

[0125] Similar combination therapies can use the HPK1 degrading agents of the invention with anti-CTLA-4 (cytotoxic T-lymphocyte associated protein 4) agents, such as the monoclonal antibody ipilimumab, for the treatment of melanoma, lung cancer, renal cell carcinoma, glioblastoma, hepatocellular carcinoma, large B-cell lymphoma, Hodgkin's lymphoma, head and neck cancer, colon cancer, and liver cancer, among others.

[0126] In one embodiment, the HPK1 degraders of the present invention can be used in the treatment of tumor types with elevated expression of cyclooxygenase-2 (COX-2). Elevated COX-2 leads to overproduction of prostaglandin E2 (PGE2). PGE2 produced by these tumors is known to inhibit anti-tumor immune responses. T cells lacking HPK1 are resistant to PGE2-mediated inhibition (Alzabin 2010). Cancer types known to have high expression levels of COX-2 include, but are not limited to, colon cancer, lung cancer, sarcoma, and breast cancer.

[0127] In any of the methods described above, the HPK1 degrading agent may be any of MS-5-006, MS-5-007, MS-5-008, MS-5-009, MS-5-010, MS-5-011, MS-5-015, MS-5-016, MS-5-017, MS-5-018, MS-5-019, MS-5-021, MS-5-022, MS-5-024, MS-5-026, MS-5-027, MS-5-028, MS- 5-029, MS-5-030, MS-5-033, MS-5-034, MS-5-035, MS-5-036, MS-5-037, MS-5-038, MS-5-039, MS-5-040, MS-5-0 41, MS-5-042, MS-5-043, MS-5-044, MS-5-045, MS-5-046, MS-6-003, MS-6-004, MS-6-005, MS-6-006, MS-6-007, M S-6-008, MS-6-009, MS-6-013, MS-6-014, MS-6-015, MS-6-016, MS-6-017, MS-6-018, MS-6-019, MS-6-020, MS-6 -021, MS-6-022, MS-6-023, MS-6-024, MS-6-025, MS-6-026, MS-6-027, MS-6-028, MS-6-029, MS-6-037, MS-6-038 , MS-6-039, MS-6-040, MS-6-041, MS-6-043, MS-6-044, MS-6-045, MS-6-046, MS-6-047, MS-6-048, MS-6-049, MS-6-050, MS-6-051, MS-6-052, MS-6-053, MS-6-054, MS-6-055, MS-6-058, MS-6-059, MS-6-060, MS-6-061.

[0128] In some aspects of the disclosed methods, the divalent compound can be administered by any of several routes of administration, including, for example, orally, parenterally, intradermally, subcutaneously, topically, and / or rectally.

[0129] Any of the methods described above can further include treating the subject with one or more additional therapeutic regimens for treating cancer. The one or more additional therapeutic regimens for treating cancer can be, for example, one or more of surgery, chemotherapy, radiation therapy, hormone therapy, or immunotherapy.

[0130] The disclosure additionally provides a method for identifying a bivalent compound that mediates the degradation / destruction of HPK1, the method including providing a heterobifunctional test compound including an HPK1 ligand conjugated to a degradation / destruction tag, and contacting the heterobifunctional test compound with a cell that contains a ubiquitin ligase and HPK1 (e.g., a cancer cell, such as an HPK1-mediated cancer cell).

[0131] As used herein, the terms "about" and "approximately" are defined as within plus or minus 10% of a given value or condition, preferably within plus or minus 5% of said value or condition.

[0132] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0133] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims. [Brief explanation of the drawings]

[0134] [Figure 1]FIG. 1 shows the effect of synthetic compounds on TCR-induced IL-2 production by Jurkat T cells and the effect of selected compounds on HPK1 expression levels in Jurkat T cells. [Figure 2] FIG. 1 shows the effect of synthetic compounds on TCR-induced IL-2 production by Jurkat T cells and the effect of selected compounds on HPK1 expression levels in Jurkat T cells. [Figure 3] FIG. 1 shows the effect of synthetic compounds on TCR-induced IL-2 production by Jurkat T cells and the effect of selected compounds on HPK1 expression levels in Jurkat T cells. [Figure 4] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-006. [Figure 5] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-007. [Figure 6] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-016. [Figure 7] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-017. [Figure 8] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-019. [Figure 9] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-027. [Figure 10] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-028. [Figure 11] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-029. [Figure 12] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-035. [Figure 13] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-039. [Figure 14] FIG. 1 illustrates the reaction scheme for the synthesis of MS-5-041. [Figure 15] FIG. 1 illustrates the reaction scheme for the synthesis of MS-6-017. [Figure 16]FIG. 1 illustrates the reaction scheme for the synthesis of MS-6-027. [Figure 17] FIG. 1 illustrates the reaction scheme for the synthesis of MS-6-028. [Figure 18] FIG. 1 illustrates the reaction scheme for the synthesis of MS-6-029. [Figure 19] FIG. 1 illustrates the reaction scheme for the synthesis of MS-6-046. DETAILED DESCRIPTION OF THE INVENTION

[0135] The present disclosure is based in part on the discovery that novel heterobifunctional molecules that degrade HPK1, HPK1 fusion proteins, and / or HPK1 mutant proteins are useful in the treatment of HPK1-mediated diseases.

[0136] Non-limiting examples of HPK1 mediated diseases, or diseases whose clinical symptoms are treated by HPK1 degrader / disruptor mediated therapy, include: all solid and liquid cancers, chronic infections that produce an exhausted immune response, infection-mediated immunosuppression, age-related decline in immune response, age-related decline in cognitive function, and infertility.

[0137] Illustrative types of cancer that can be prevented or therapeutically treated by manipulating HPK1 levels with degraders / destructors include, but are not limited to, all solid and liquid cancers, including cancers of the breast, respiratory tract, brain, reproductive organs, gastrointestinal tract, urinary tract, eye, liver, skin, head and neck, thyroid, and parathyroid glands, and their distant metastases. Examples of liquid cancers include lymphoma, sarcoma, and leukemia. Listed below are cancer types that immunotherapy using HPK1 degraders / destructors should be able to prevent or treat.

[0138] Examples of breast cancer include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

[0139] Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

[0140] Examples of brain cancers include, but are not limited to, brain stem and hypothalamic glioma, cerebellar and cerebral astrocytoma, glioblastoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.

[0141] Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer.

[0142] Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, endovaginal, and vulvar cancer, as well as sarcoma of the uterus.

[0143] Examples of ovarian cancer include, but are not limited to, serous tumor, endometrioid tumor, mucinous cystadenocarcinoma, granulosa cell tumor, Sertoli-Leydig cell tumor, and virilizing tumor.

[0144] Examples of cervical cancer include, but are not limited to, squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, vitreous cell carcinoma, and choriocarcinoma. Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small intestine, and salivary gland cancer.

[0145] Examples of esophageal cancer include, but are not limited to, esophageal cell carcinoma and adenocarcinoma, as well as squamous cell carcinoma, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma, and lymphoma.

[0146] Examples of gastric cancer include, but are not limited to, intestinal-type and diffuse-type gastric adenocarcinoma.

[0147] Examples of pancreatic cancer include, but are not limited to, ductal adenocarcinoma, adenosquamous carcinoma, and pancreatic endocrine tumors.

[0148] Examples of tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral, ​​and human papillary renal carcinoma.

[0149] Examples of kidney cancer include, but are not limited to, renal cell carcinoma, urothelial cell carcinoma, juxtaglomerular cell tumor (nephroma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear cell sarcoma of the kidney, mesoblastic nephroma, and Wilms' tumor.

[0150] Examples of bladder cancer include, but are not limited to, transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma, and small cell carcinoma. Eye cancer includes, but is not limited to, intraocular melanoma and retinoblastoma.

[0151] Examples of liver cancer include, but are not limited to, hepatocellular carcinoma (with or without fibrolamellar variant), biliary adenocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular-biliary adenocarcinoma.

[0152] Examples of skin cancer include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

[0153] Examples of head and neck cancers include, but are not limited to, squamous cell carcinoma of the head and neck, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer and squamous cell carcinoma.

[0154] Examples of lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.

[0155] Examples of sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[0156] Examples of leukemia include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

[0157] HPK1 degraders / disruptors can treat the above cancer types as stand-alone agents or should be used as agents in combination with existing standard treatment therapies and other FDA-approved cancer therapies.

[0158] Therapeutic uses of HPK1 include diseases and treatments amenable to treatment by stimulating / enhancing the immune response, including extending the immune response during vaccination for immunizable diseases. Moreover, because HPK1 is expressed at high levels in two other anatomical locations—the brain and testes—HPK1 degraders / disruptors should be able to treat or prevent brain- and testes-related diseases caused by or treatable by HPK1 degraders / disruptors. These potential diseases include, but are not limited to, Alzheimer's disease, age-related dementia, and infertility, regardless of whether these potential diseases are caused by HPK1 or by other pathogenic causes.

[0159] A successful strategy for selective degradation / destruction of target proteins triggered by bifunctional molecules involves recruiting an E3 ubiquitin ligase and mimicking protein misfolding using a hydrophobic tag (Buckley and Crews, 2014). PROTACs (Protein Degradation Targeting Chimeras) are bivalent molecules with one moiety that binds an E3 ubiquitin ligase and another that binds the protein target of interest (Buckley and Crews, 2014). The induced proximity leads to the selective ubiquitination of the target and its subsequent degradation in the proteasome. Several types of high-affinity small molecule E3 ligase ligands have been identified / developed: (1) cereblon (CRBN or CRL4), a component of the cullin-ring ubiquitin ligase (CRL) complex; CRBN(2) immunomodulatory drugs (IMiDs), such as thalidomide and pomalidomide, which bind VHL (VHL) or CRL2, a component of another CRL complex. VHL (3) compound 7, which selectively binds KEAPl, a component of the CRL3 complex (Davies et al., 2016); (4) AMG232, which selectively binds MDM2, a heterodimeric ring E3 ligase (Sun et al., 2014); and (5) LCL161, which selectively binds IAP, a homodimeric ring E3 ligase (Ohoka et al., 2017; Okuhira et al., 2011; Shibata et al., 2017). Degrader science has been successfully applied to the degradation of multiple targets (Bondeson et al., 2015; Buckley et al., 2015; Lai et al., 2016; Lu et al., 2015; Winter et al., 2015; Zengerle et al., 2015), but not to the degradation of HPK1. In addition, a hydrophobic tagging method utilizing bulky and hydrophobic adamantyl groups has been developed to mimic protein misfolding, which leads to degradation of the target protein by the proteasome (Buckley and Crews, 2014). This method has also been successfully applied to the selective degradation of the pseudokinase Her3 (Xie et al., 2014), but not to the degradation of HPK1 protein.

[0160] As discussed in the Examples below, this disclosure provides specific examples of novel HPK1 degraders / disruptors and examines the effects of exemplary degraders / disruptors on reducing HPK1 protein levels, inhibiting / disrupting HPK1 activity, and increasing TCR-induced IL-2 production by Jurkat T cells. The results indicated that these novel compounds may be beneficial in treating cancer. Exemplary types of cancer that can be prevented or therapeutically treated by manipulating HPK1 levels with degraders / disruptors include, but are not limited to, all solid and liquid cancers, including cancers of the breast, respiratory tract, brain, reproductive organs, gastrointestinal tract, urinary tract, eye, liver, skin, head and neck, thyroid, and parathyroid glands, as well as their distant metastases. Examples of liquid cancers include lymphoma, sarcoma, and leukemia. Listed below are types of cancer that immunotherapy using HPK1 degraders / disruptors can prevent or treat as described above.

[0161] Current compounds targeting HPK1 generally focus on inhibiting its catalytic activity. In this disclosure, a different approach was taken to develop compounds that directly and selectively target not only HPK1's catalytic function but also its protein levels in cells. Strategies for inducing protein degradation include recruiting E3 ubiquitin ligases, mimicking protein misfolding using hydrophobic tags, and inhibiting chaperones. For example, the thalidomide-JQ1 bivalent compound was used to hijack the cereblon E3 ligase to induce highly selective BET protein degradation in vitro and in vivo, demonstrating delayed leukemia progression in mice (Winter et al., 2015). Similarly, BET protein degradation has also been induced via another E3 ligase, VHL (Zengerle et al., 2015). Partial degradation of Her3 protein has been induced using an adamantane-modified compound (Xie et al., 2014). These approaches, based on the use of bivalent molecules, allow for more flexible modulation of protein levels in vitro and in vivo compared to techniques such as gene knockout or knockdown via RNA interference. Unlike gene knockout or knockdown, this chemical approach offers the opportunity to study dose- and time-dependencies in disease models by varying the concentration and frequency of administration of the relevant compound.

[0162] This disclosure includes all stereoisomers, geometric isomers, tautomers, and isotopes of the depicted structures and compounds named herein. This disclosure also includes the compounds described herein, regardless of how they are prepared, for example, synthetically, through a biological process (e.g., metabolic or enzymatic transformation), or a combination thereof.

[0163] This disclosure includes pharmaceutically acceptable salts of the depicted structures and compounds named herein.

[0164] One or more constituent atoms of the compounds depicted herein can be replaced or substituted with an isotope of the atom, at natural or non-natural abundance. In some embodiments, the compound contains at least one deuterium atom. In some embodiments, the compound contains two or more deuterium atoms. In some embodiments, the compound contains 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 deuterium atoms. In some embodiments, all of the hydrogen atoms in the compound can be replaced or substituted with deuterium atoms. In some embodiments, the compound contains at least one fluorine atom. In some embodiments, the compound contains two or more fluorine atoms. In some embodiments, the compound contains 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 fluorine atoms. In some embodiments, all of the hydrogen atoms in the compound can be replaced or substituted with fluorine atoms.

[0165] Decomposer In some aspects, the present disclosure provides bivalent compounds, also referred to herein as degradation agents, that include an HPK1 ligand (or targeting moiety) conjugated to a degradation tag. The linkage of the HPK1 ligand to the degradation tag can be direct or indirect via a linker.

[0166] As used herein, the terms "protein arginine transferase 5 (HPK1) ligand" or "HPK1 ligand" or "HPK1 targeting moiety" should be interpreted broadly and encompass a wide variety of molecules ranging from small molecules to large proteins that associate with or bind to HPK1. An HPK1 ligand or targeting moiety can be, for example, a small molecule compound (i.e., a molecule with a molecular weight of less than about 1.5 kilodaltons (kDa)), a peptide or polypeptide, a nucleic acid or oligonucleotide, a carbohydrate, e.g., an oligosaccharide, or an antibody or fragment thereof.

[0167] HPK1 ligands or targeting moieties can be derived from HPK1 inhibitors (e.g., Sutent and its analogs) that can interfere with the enzymatic activity of HPK1. As used herein, "inhibitor" refers to an agent that suppresses, delays, or otherwise inhibits a physiological, chemical, or enzymatic action or function. As used herein, an inhibitor causes a decrease in enzymatic activity of at least 5%. An inhibitor can also or alternatively refer to a drug, compound, or agent that prevents or reduces the expression, transcription, or translation of a gene or protein. An inhibitor can reduce or prevent the function of a protein, for example, by binding to or activating / inactivating another protein or receptor.

[0168] Illustrative HPK1 ligands include, but are not limited to, the compounds listed below:

[0169] [ka]

[0170] As used herein, the term "degradation / destruction tag" refers to a compound that associates with or binds to a ubiquitin ligase for recruitment of the corresponding ubiquitination machinery to HPK1, or that induces HPK1 protein misfolding and subsequent degradation in the proteasome or loss of function.

[0171] In some aspects, degradation / destruction tags of the present disclosure include, for example, thalidomide, pomalidomide, lenalidomide, VHL-1, adamantane, 1-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonane, nutlin-3a, RG7112, RG7338, AMG232, AA-115, bestatin, MV-1, LCL161, and / or analogs thereof.

[0172] As used herein, a "linker" is a bond, molecule, or group of molecules that connects two separate entities to one another. The linker can provide optimal spacing between the two entities. In some embodiments, the term "linker" refers to any agent or molecule that bridges the HPK1 ligand to the degradation / destruction tag. Those skilled in the art will recognize that sites on the HPK1 ligand or degradation / destruction tag that are not necessary for the function of the degradation agent of the present disclosure are ideal sites for attaching a linker, provided that the linker, once attached to the conjugate of the present disclosure, does not interfere with the function of the degradation agent, i.e., its ability to target HPK1 and its ability to recruit ubiquitin ligase.

[0173] The linker length of the bivalent compound can be adjusted to minimize the molecular weight of the disruptor / degrader and avoid either any potential clash between the HPK1 ligand or targeting moiety and the ubiquitin ligase, or simultaneously induce HPK1 misfolding by the hydrophobic tag.

[0174] In some embodiments, degradation / destruction tags of the present disclosure include, for example, thalidomide, pomalidomide, lenalidomide, VHL-1, adamantane, 1-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonane, nutlin-3a, RG7112, RG7338, AMG232, AA-115, bestatin, MV-1, LCL161, and analogs thereof. Degradation / destruction tags can be attached to any part of the structure of the HPK1 ligand or targeting moiety (e.g., sutent) with linkers of different types and lengths to generate effective bivalent compounds. In particular, attachment of VHL1, pomalidomide, or LCL161 to any part of the molecule can recruit E3 ligase to HPK1.

[0175] The bivalent compounds disclosed herein can increase TCR-induced IL-2 production by Jurkat T cells.

[0176] Additional bivalent compounds (i.e., HPK1 degraders / disruptors) can be developed using the methods and principles disclosed herein. For example, other linkers, degradation tags, and HPK1 binding / inhibitory moieties can be synthesized and tested. Non-limiting examples of HPK1 disrupters / degraders (e.g., bivalent compounds) are shown in Table 1 (below). The left portion of each HPK1 disrupter / degrader compound as shown binds to HPK1 (as does Sutent (sunitinib)), and the right portion of each compound recruits the HPK1 ubiquitination machinery, which triggers polyubiquitination and degradation of HPK1 in the proteasome.

[0177] More specifically, the present disclosure provides bivalent compounds comprising an HPK1 ligand conjugated to a degradation / destruction tag.

[0178] In some embodiments, the HPK1 degrader / disruptor has the form "PI-linker-EL" as shown below:

[0179] [ka]

[0180] (wherein PI (protein of interest) comprises an HPK1 ligand (e.g., an HPK1 inhibitor) and EL (E3 ligase) comprises a degradation / destruction tag (e.g., an E3 ligase ligand). Exemplary HPK1 ligands (PI), exemplary degradation / destruction tags (EL), and exemplary linkers (linkers) are illustrated below:

[0181] HPK1 ligand In certain embodiments, the (HPK1) ligand comprises a moiety according to Formula 1:

[0182] [ka]

[0183] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); The "linker" portion of the bivalent compound is R 2 If attached to; R 1 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 4 , S.R. 4 , N.R. 4 R 5 , C(O)R 4 , C(O)OR 4 , C(O)NR 4 R 5 , S(O)R 4 , S(O)2R 4 , S(O)NR 4 R 5 , N.R. 6 C(O)OR 4 , N.R. 6 C(O)R 4 , N.R. 6 C(O)NR 4 R 5 , N.R. 6 S(O)R 4 , N.R. 6 S(O)2R 4 , N.R. 6 S(O)NR 4 R 5 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 4 , R 5 , and R 6is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 , R 4 and R 6 , R 5 and R 6 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring and pharmaceutically acceptable salts thereof.

[0184] The "linker" portion of the bivalent compound is R 1 If attached to; R 1 is, at each occurrence, OR 4 , S.R. 4 , N.R. 4 R 5 , C(O)R 4 , C(O)OR 4 , C(O)NR 4 R 5 , S(O)R 4 , S(O)2R 4 , S(O)NR 4 R 5 , N.R. 6 C(O)OR 4 , N.R. 6 C(O)R 4 , N.R. 6 C(O)NR 4 R 5 , N.R. 6 S(O)R 4 , N.R. 6 S(O)2R 4 , N.R. 6S(O)NR 4 R 5 , C1-C8 alkylene, optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted C3-C8 cycloalkoxylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; wherein R 4 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 5 and R 6 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 , R 4 and R 6 , R 5 and R 6together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0185] The "linker" portion of the bivalent compound is R 1 If attached to; R 2 is the absence, hydrogen, C(O)R at each occurrence. 7 , C(O)OR 7 , C(O)NR 7 R 8 , S(O)R 7 , S(O)2R 7 , S(O)NR 7 R 8 , N.R. 9 C(O)OR 7 , N.R. 9 C(O)R 7 , N.R. 9 C(O)NR 7 R 8 , N.R. 9 S(O)R 7 , N.R. 9 S(O)2R 7 , N.R. 9 S(O)NR 7 R 8 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 7 , R 8 , and R 9is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 7 and R 8 , R 7 and R 9 , R 8 and R 9 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0186] The "linker" portion of the bivalent compound is R 2 If attached to; R 2 is, at each occurrence, C(O)R 7 , C(O)OR 7 , C(O)NR 7 R 8 , S(O)R 7 , S(O)2R 7 , S(O)NR 7 R 8 , N.R. 9 C(O)OR 7 , N.R. 9 C(O)R 7 , N.R. 9 C(O)NR 7 R 8 , N.R. 9 S(O)R 7 , N.R. 9 S(O)2R 7 , N.R. 9 S(O)NR 7 R 8, optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted C3-C8 cycloalkoxylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; wherein R 7 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 8 and R 9 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 7 and R 8 , R 7 and R 9 , R 8 and R 9together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0187] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 2:

[0188] [ka]

[0189] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 and R 2 The definition of is the same as for Eq. 1).

[0190] Ar, at each occurrence, is independently selected from absent, aryl, or heteroaryl, each of which is R 1 Substituted with hydrogen, halogen, oxo, CN, NO2, OR 12 , S.R. 12 , N.R. 12 R 13 ,OCOR 12 , OCO2R 12 , OCONR 12 R 13 , C.O.R. 12 , CO2R 12 ,CONR 12 R 13 , SOR 12 , SO2R 12 , SO2NR 12 R 13 , N.R. 14 CO2R 12 , N.R. 14 COR 12 , N.R. 14 C(O)NR 12 R 13 , N.R. 14 SOR 12 , N.R. 14 SO2R12 , N.R. 14 SO2NR 12 R 13 optionally substituted with one or more substituents independently selected from optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 4-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 12 , R 13 , and R 14 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 4-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 12 and R 13 , R 12 and R 14 , R 13 and R 14 together with the atom to which they are attached form a 4- to 20-membered heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0191] In certain embodiments, the (HPK1) ligand comprises a moiety according to Formula 2A:

[0192] [ka]

[0193] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 , R 2 and Ar are defined as for Equation 2).

[0194] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 2B:

[0195] [ka]

[0196] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1 and R 2 The definition of is the same as for Eq. 2).

[0197] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 2C:

[0198] [ka]

[0199] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 2 independently attached to (indicated by dotted lines); R 1and R 2 The definition of is the same as for Equation 2; R 3 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 15 , S.R. 15 , N.R. 15 R 16 , C(O)R 16 , C(O)OR 15 , C(O)NR 15 R 16 , S(O)R 15 , S(O)2R 15 , S(O)NR 15 R 16 , N.R. 17 C(O)OR 15 , N.R. 6 C(O)R 15 , N.R. 17 C(O)NR 15 R 16 , N.R. 17 S(O)R 15 , N.R. 17 S(O)2R 15 , N.R. 17 S(O)NR 15 R 16 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 15 , R 16 , and R 17is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 15 and R 16 , R 15 and R 17 , R 16 and R 17 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; n is independently selected from 0, 1, 2, 3 and 4 and pharmaceutically acceptable salts thereof.

[0200] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 3:

[0201] [ka]

[0202] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 3 independently attached to (indicated by dotted lines); The "linker" portion of the bivalent compound is R 3 If attached to; R 1 and R 2 is the absence, hydrogen, C(O)R at each occurrence. 10 , C(O)OR 10 , C(O)NR 10 R 11 , S(O)R 10, S(O)2R 10 , S(O)NR 10 R 11 , N.R. 12 C(O)OR 10 , N.R. 12 C(O)R 10 , N.R. 12 C(O)NR 10 R 11 , N.R. 12 S(O)R 10 , N.R. 12 S(O)2R 10 , N.R. 12 S(O)NR 10 R 11 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 10 , R 11 , and R 12 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 10 and R 11 , R 10 and R12 , R 11 and R 12 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 and R 2 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 3 is OR 13 , S.R. 13 , N.R. 13 R 14 , CH2NR 13 R 14 , CH2CH2NR 13 R 14 , C1-C8 alkylene NR 13 R 14 , C(O)R 13 , C(O)OR 13 , C(O)NR 13 R 14 , S(O)R 13 , S(O)2R 14 , S(O)NR 13 R 14 , N.R. 15 C(O)OR 13 , N.R. 15 C(O)R 13 , N.R. 15 C(O)NR 13 R 14 , N.R. 15 S(O)R 32 , N.R. 15 S(O)2R 32 , N.R. 15 S(O)NR 13 R 14selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 13 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 14 and R 15 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 13 and R 14 , R 13 and R 15 , R 14 and R 15 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 4 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR16 , S.R. 16 , N.R. 16 R 17 , C(O)R 16 , C(O)OR 16 , C(O)NR 16 R 17 , S(O)R 16 , S(O)2R 16 , S(O)NR 16 R 17 , N.R. 18 C(O)OR 16 , N.R. 18 C(O)R 16 , N.R. 18 C(O)NR 16 R 17 , N.R. 18 S(O)R 16 , N.R. 18 S(O)2R 16 , N.R. 18 S(O)NR 16 R 15 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 16 , R 17 , and R 18 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 16 and R 17 , R 16 and R 18 , R 17 and R 18 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0203] The "linker" portion of the bivalent compound is R 1 If attached to; R 1 is OR 19 , S.R. 19 , N.R. 19 R 20 , CH2NR 19 R 20 , CH2CH2NR 19 R 20 , C1-C8 alkylene NR 19 R 20 , C(O)R 19 , C(O)OR 19 , C(O)NR 19 R 20 , S(O)R 19 , S(O)2R 20 , S(O)NR 19 R 20 , N.R. 21 C(O)OR 19 , N.R. 21 C(O)R 19 , N.R. 21 C(O)NR 19 R 20 , N.R. 21 S(O)R 19 , N.R. 21 S(O)2R 19 , N.R. 21 S(O)NR 19 R20 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 19 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 20 and R 21 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 19 and R 20 , R 19 and R 21 , R 20 and R 21 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 2 is the absence, hydrogen, C(O)R at each occurrence.10 , C(O)OR 10 , C(O)NR 10 R 11 , S(O)R 10 , S(O)2R 10 , S(O)NR 10 R 11 , N.R. 12 C(O)OR 10 , N.R. 12 C(O)R 10 , N.R. 12 C(O)NR 10 R 11 , N.R. 12 S(O)R 10 , N.R. 12 S(O)2R 10 , N.R. 12 S(O)NR 10 R 11 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 10 , R 11 , and R 12 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 10 and R 11 , R 10 and R 12 , R 11 and R 12 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 3 and R 4 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 16 , S.R. 16 , N.R. 16 R 17 , C(O)R 16 , C(O)OR 16 , C(O)NR 16 R 17 , S(O)R 16 , S(O)2R 16 , S(O)NR 16 R 17 , N.R. 18 C(O)OR 16 , N.R. 18 C(O)R 16 , N.R. 18 C(O)NR 16 R 17 , N.R. 18 S(O)R 16 , N.R. 18 S(O)2R 16 , N.R. 18 S(O)NR 16 R 15, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 16 , R 17 , and R 18 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 16 and R 17 , R 16 and R 18 , R 17 and R 18 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0204] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 3A:

[0205] [ka]

[0206] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 3 independently attached to (indicated by dotted lines); R 1 , R 2 and R 3 The definition of is the same as for Equation 3; R 5 is the absence, hydrogen, C(O)R at each occurrence. 22 , C(O)OR 22 , C(O)NR 22 R 23 , S(O)R 22 , S(O)2R 22 , S(O)NR 22 R 23 , N.R. 24 C(O)OR 22 , N.R. 24 C(O)R 22 , N.R. 24 C(O)NR 22 R 23 , N.R. 24 S(O)R 22 , N.R. 24 S(O)2R 22 , N.R. 24 S(O)NR 22 R 23 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 22 , R 23 , and R24 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 22 and R 23 , R 22 and R 24 , R 23 and R 24 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 6 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 25 , S.R. 25 , N.R. 25 R 26 , C(O)R 25 , C(O)OR 25 , C(O)NR 25 R 26 , S(O)R 25 , S(O)2R 25 , S(O)NR 25 R 26 , N.R. 27 C(O)OR 25 , N.R. 27 C(O)R 25 , N.R. 21 C(O)NR 25 R 26 , N.R. 27 S(O)R 25 , N.R. 27 S(O)2R 25 , N.R. 27 S(O)NR 25 R 26, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 25 , R 26 , and R 27 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 25 and R 26 , R 25 and R 26 , R 26 and R 27 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring and pharmaceutically acceptable salts thereof.

[0207] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 3B:

[0208] [ka]

[0209] (In the formula, The "linker" portion of the bivalent compound is R 1 or R 7 independently attached to (indicated by dotted lines); R 5 and R 6 The definitions are the same as for formula 3A; The "linker" portion of the bivalent compound is R 1 If attached to; R 1 is OR 28 , S.R. 28 , N.R. 28 R 29 , CH2NR 28 R 29 , CH2CH2NR 28 R 29 , C1-C8 alkylene NR 28 R 29 , C(O)R 28 , C(O)OR 28 , C(O)NR 28 R 29 , S(O)R 28 , S(O)2R 29 , S(O)NR 28 R 29 , N.R. 30 C(O)OR 28 , N.R. 30 C(O)R 28 , N.R. 30 C(O)NR 28 R 29 , N.R. 30 S(O)R 28 , N.R. 30 S(O)2R 28 , N.R. 30 S(O)NR 28 R 29selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 28 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 29 and R 30 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 28 and R 29 , R 28 and R 29 , R 29 and R 30 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 2 , R 7 and R 8is the absence, hydrogen, C(O)R at each occurrence. 31 , C(O)OR 31 , C(O)NR 31 R 32 , S(O)R 31 , S(O)2R 31 , S(O)NR 31 R 32 , N.R. 33 C(O)OR 31 , N.R. 33 C(O)R 31 , N.R. 33 C(O)NR 31 R 32 , N.R. 33 S(O)R 31 , N.R. 33 S(O)2R 31 , N.R. 33 S(O)NR 31 R 32 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 31 , R 32 , and R 33 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 31 and R 32 , R 31 and R 33 , R 32 and R 33 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 7 and R 8 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring. and pharmaceutically acceptable salts thereof.

[0210] The "linker" portion of the bivalent compound is R 7 If attached to; R 7 is OR 28 , S.R. 28 , N.R. 28 R 29 , CH2NR 28 R 29 , CH2CH2NR 28 R 29 , C1-C8 alkylene NR 28 R 29 , C(O)R 28 , C(O)OR 28 , C(O)NR 28 R 29 , S(O)R 28 , S(O)2R 29 , S(O)NR 28 R 29 , N.R. 30 C(O)OR 28 , N.R. 30 C(O)R 28 , N.R. 30 C(O)NR 28 R 29, N.R. 30 S(O)R 28 , N.R. 30 S(O)2R 28 , N.R. 30 S(O)NR 28 R 29 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 28 is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 29 and R 30 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 28 and R 29 , R 28 and R 29 , R 29 and R30 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 , R 2 and R 8 is the absence, hydrogen, C(O)R at each occurrence. 31 , C(O)OR 31 , C(O)NR 31 R 32 , S(O)R 31 , S(O)2R 31 , S(O)NR 31 R 32 , N.R. 33 C(O)OR 31 , N.R. 33 C(O)R 31 , N.R. 33 C(O)NR 31 R 32 , N.R. 33 S(O)R 31 , N.R. 33 S(O)2R 31 , N.R. 33 S(O)NR 31 R 32 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 31 , R 32 , and R 33 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 31 and R 32 , R 31 and R 33 , R 32 and R 33 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 and R 2 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; and pharmaceutically acceptable salts thereof.

[0211] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 4:

[0212] [ka]

[0213] (In the formula, The "linker" portion of the bivalent compound is R 3 independently attached to (indicated by dotted lines); R 1、 R 2 and R 4 is, at each occurrence, hydrogen, halogen, oxo, CN, NO2, OR 5 , S.R. 5 , N.R. 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , S(O)R 5 , S(O)2R5 , S(O)NR 5 R 6 , N.R. 7 C(O)OR 5 , N.R. 7 C(O)R 5 , N.R. 7 C(O)NR 5 R 26 , N.R. 7 S(O)R 5 , N.R. 7 S(O)2R 5 , N.R. 7 S(O)NR 5 R 6 , optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 5 , R 6 , and R 7 is hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C 10 independently selected from cycloalkyl, optionally substituted 3-20 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 5 and R 6 , R 5 and R 7 , R6 and R 7 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; n is independently selected from 0, 1, 2, 3, and 4; R 3 is OR 8 , S.R. 8 , N.R. 8 R 9 , CH2NR 8 R 9 , CH2CH2NR 8 R 9 , C1-C8 alkylene NR 8 R 9 , C(O)R 8 , C(O)OR 9 , C(O)NR 8 R 9 , S(O)R 8 , S(O)2R 9 , S(O)NR 8 R 9 , N.R. 10 C(O)OR 9 , N.R. 10 C(O)R 9 , N.R. 10 C(O)NR 8 R 9 , N.R. 10 S(O)R 8 , N.R. 10 S(O)2R 8 , N.R. 10 S(O)NR 8 R 9 selected from optionally substituted C1-C8 alkylene, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C1-C8 alkoxyC1-C8 alkylene, optionally substituted C1-C8 alkylaminoC1-C8 alkylene, optionally substituted 3-8 membered cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 8is absent or a divalent moiety selected from optionally substituted C1-C8 alkylenyl, optionally substituted C2-C8 alkenylene, optionally substituted C2-C8 alkynylene, optionally substituted C3-C8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 9 and R 10 are independently selected from optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 8 and R 9 , R 8 and R 10 , R 9 and R 10 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring) and pharmaceutically acceptable salts thereof.

[0214] In another embodiment, the (HPK1) ligand comprises a moiety according to Formula 4A:

[0215] [ka]

[0216] (In the formula, The "linker" portion of the bivalent compound is R 3 independently attached to (indicated by dotted lines); R 3The definition of is the same as for Equation 4.

[0217] In certain embodiments, the (HPK1) ligand is selected from the group consisting of:

[0218] [ka]

[0219] and and pharmaceutically acceptable salts thereof.

[0220] Disassembly / Destruction Tags Degradation / destruction tags (EL) include, but are not limited to:

[0221] In certain embodiments, the degradation / destruction tag comprises a moiety according to Formulas 12A, 12B, 12C, and 12D:

[0222] [ka]

[0223] (In the formula, V, W, and X are CR 2 and N are independently selected; Y is CO, CR 3 R 4 and N=N; Z is absent, CO, CR 5 R 6 , N.R. 5 , O, optionally substituted C1 to C 10 Alkylene, optionally substituted C1-C 10 Alkenylene, optionally substituted C-C 10 Alkynylene, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, optionally substituted C-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl, optionally substituted C-C 13 is selected from spiroheterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; preferably, Z is selected from absent, CH, CH=CH, C≡C, NH, and O; R 1 , and R 2 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; R 3 , and R 4 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 3 and R 4 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; R 5 and R 6 is independently selected from absent, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 5 and R 6 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl).

[0224] In certain embodiments, the degradation / destruction tag comprises a moiety according to one of formulas 12E, 12F, 12G, 12H, and 12I:

[0225] [ka]

[0226] (In the formula, U, V, W, and X are CR 2 and N are independently selected; Y is CR 3 R 4 , N.R. 3 and O; preferably, Y is selected from CH2, NH, NCH3 and O; Z is absent, CO, CR 5 R 6 , N.R. 5 , O, optionally substituted C1 to C 10 Alkylene, optionally substituted C1-C 10 Alkenylene, optionally substituted C-C 10 Alkynylene, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, optionally substituted C-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl, optionally substituted C-C 13 is selected from spiroheterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; preferably, Z is selected from absent, CH, CH=CH, C≡C, NH, and O; R 1 , and R 2are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; R 3 , and R 4 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 3 and R 4 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; R 5 and R 6 is independently selected from absent, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C1-C6 alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 5 and R 6 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl); and and pharmaceutically acceptable salts thereof.

[0227] In one embodiment, the degradation / destruction tag comprises a moiety according to Formula 13A:

[0228] [ka]

[0229] (In the formula, R 1 and R 2are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 aminoalkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl; R 3is selected from hydrogen, optionally substituted C(O)C1-C8 alkyl, optionally substituted C(O)C1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)C1-C8 haloalkyl, optionally substituted C(O)C1-C8 hydroxyalkyl, optionally substituted C(O)C1-C8 aminoalkyl, optionally substituted C(O)C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)C3-C7 cycloalkyl, optionally substituted optionally substituted C(O)(3-7 membered heterocyclyl), optionally substituted C(O)C2-C8 alkenyl, optionally substituted C(O)C2-C8 alkynyl, optionally substituted C(O)OC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)OC1-C8 haloalkyl, optionally substituted C(O)OC1-C8 hydroxyalkyl, optionally substituted C(O)OC1-C8 aminoalkyl, optionally substituted C(O)OC1-C8 alkylamino C1-C8 alkyl, optionally substituted C(O)OC3-C7 cycloalkyl, optionally substituted C(O)O(3-7 membered heterocyclyl), optionally substituted C(O)OC2-C8 alkenyl, optionally substituted C(O)OC2-C8 alkynyl, optionally substituted C(O)NC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)NC1-C8 haloalkyl, optionally substituted C(O)NC1-C8 hydroxyalkyl, optionally substituted C(O)NC1-C8 aminoalkyl, optionally substituted C(O)NC1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)NC3-C7 cycloalkyl, optionally substituted C(O)N(3-7 membered heterocyclyl), optionally substituted C(O)NC2-C8 alkenyl, optionally substituted C(O)NC2-C8 alkynyl, optionally substituted P(O)(OH)2, optionally substituted P(O)(OC1-C8 alkyl)2,and optionally substituted P(O)(OC1-C8 aryl)2).

[0230] In certain embodiments, the degradation / destruction tag comprises a moiety according to Formulas 13B, 13C, 13D, 13E, and 13F:

[0231] [ka]

[0232] (In the formula, R 1 and R 2 are independently selected from hydrogen, halogen, OH, NH, CN, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 aminoalkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl; (preferably, R 1 is selected from iso-propyl or tert-butyl; R 2 is selected from hydrogen or methyl); R 3is selected from hydrogen, optionally substituted C(O)C1-C8 alkyl, optionally substituted C(O)C1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)C1-C8 haloalkyl, optionally substituted C(O)C1-C8 hydroxyalkyl, optionally substituted C(O)C1-C8 aminoalkyl, optionally substituted C(O)C1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)C3-C7 cycloalkyl, optionally substituted optionally substituted C(O)(3-7 membered heterocyclyl), optionally substituted C(O)C2-C8 alkenyl, optionally substituted C(O)C2-C8 alkynyl, optionally substituted C(O)OC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)OC1-C8 haloalkyl, optionally substituted C(O)OC1-C8 hydroxyalkyl, optionally substituted C(O)OC1-C8 aminoalkyl, optionally substituted C(O)OC1-C8 alkylamino C1-C8 alkyl, optionally substituted C(O)OC3-C7 cycloalkyl, optionally substituted C(O)O(3-7 membered heterocyclyl), optionally substituted C(O)OC2-C8 alkenyl, optionally substituted C(O)OC2-C8 alkynyl, optionally substituted C(O)NC1-C8 alkoxyC1-C8 alkyl, optionally substituted C(O)NC1-C8 haloalkyl, optionally substituted C(O)NC1-C8 hydroxyalkyl, optionally substituted C(O)NC1-C8 aminoalkyl, optionally substituted C(O)NC1-C8 alkylaminoC1-C8 alkyl, optionally substituted C(O)NC3-C7 cycloalkyl, optionally substituted C(O)N(3-7 membered heterocyclyl), optionally substituted C(O)NC2-C8 alkenyl, optionally substituted C(O)NC2-C8 alkynyl, optionally substituted P(O)(OH)2, optionally substituted P(O)(OC1-C8 alkyl)2,and optionally substituted P(O)(OC1-C8 aryl)2; R 4 and R 5 is hydrogen, COR 6 , CO2R 6 ,CONR 6 R 7 , SOR 6 , SO2R 6 , SO2NR 6 R 7 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 ;R 6 and R 7 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; Ar is selected from aryl and heteroaryl, each of which is selected from F, Cl, CN, NO, OR 8 , N.R. 8 R 9 , C.O.R. 8 , CO2R 8 ,CONR 8 R 9 , SOR8 , SO2R 8 , SO2NR 9 R 10 , N.R. 9 COR 10 , N.R. 8 C(O)NR 9 R 10 , N.R. 9 SOR 10 , N.R. 9 SO2R 10 optionally substituted with one or more substituents independently selected from optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxyalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 alkylaminoC1-C6 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted aryl, and optionally substituted C4-C5 heteroaryl; R 8 , R 9 , and R 10 are independently selected from absent, hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 8 and R 9 ;R 9 and R 10 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; and and pharmaceutically acceptable salts thereof.

[0233] In one embodiment, the degradation / destruction tag comprises a moiety according to Formula 14A:

[0234] [ka]

[0235] (In the formula, V, W, X, and Z are CR 4 and N are independently selected; R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl).

[0236] In one embodiment, the degradation / destruction tag comprises a moiety according to Formula 14B:

[0237] [ka]

[0238] (In the formula, R 1 , R 2 , and R 3are independently selected from hydrogen, halogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C2-C8 alkenyl, and optionally substituted C2-C8 alkynyl; R 4 and R 5 is hydrogen, COR 6 , CO2R 6 ,CONR 6 R 7 , SOR 6 , SO2R 6 , SO2NR 6 R 7 , optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted aryl-C1-C8 alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 alkylaminoC1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 6 and R 7together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; and and pharmaceutically acceptable salts thereof.

[0239] In one embodiment, the degradation / destruction tag is selected from the group consisting of:

[0240] [ka]

[0241] [ka]

[0242] and pharmaceutically acceptable salts thereof.

[0243] Linker In any of the compounds described above, the HPK1 ligand can be conjugated to the degradation / destruction tag via a linker. The linker can include, for example, acyclic or cyclic, saturated or unsaturated carbon groups of different lengths, ethylene glycol groups, amide groups, amino groups, ether groups, urea groups, carbamate groups, aromatic groups, heteroaromatic groups, heterocyclic groups, and / or carbonyl-containing groups.

[0244] In certain embodiments, the linker is a moiety according to Formula 16:

[0245] [ka]

[0246] (In the formula, A, W, and B are the absence, CO, CO2, and C(O)NR at each occurrence. 1 , C(S)NR 1 , O, S, SO, SO2, SO2NR 1 , N.R. 1 , N.R. 1 CO, NR 1 CONR2 , N.R. 1 C(S), optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl and optionally substituted C-C 13 spiroheterocyclyl; R 1 and R 2 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; m is 0 to 15).

[0247] In certain embodiments, the linker is a moiety according to Formula 16A:

[0248] [ka]

[0249] (In the formula, R 1 , R 2 , R 3 , and R 4 is independently selected at each occurrence from hydrogen, halogen, CN, OH, NH2, optionally substituted C1-C8 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; A, W, and B are the absence, CO, CO2, and C(O)NR at each occurrence. 5 , C(S)NR 5 , O, S, SO, SO2, SO2NR 5 , N.R. 5 , N.R. 5 CO, NR 5 CONR 6 , N.R. 5C(S), optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl and optionally substituted C-C 13 spiroheterocyclyl; R 5 and R 6 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; m is 0 to 15; n, for each occurrence, is between 0 and 15; o is between 0 and 15).

[0250] In certain embodiments, the linker is a moiety according to Formula 16B:

[0251] [ka]

[0252] (In the formula, R 1 and R 2 is independently selected at each occurrence from hydrogen, halogen, CN, OH, NH2, and optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, or C1-C8 alkylaminoC1-C8 alkyl; A and B are the absence, CO, CO2, and C(O)NR at each occurrence. 3 , C(S)NR 3 , O, S, SO, SO2, SO2NR 3 , N.R. 3 , N.R. 3 CO, NR 3 CONR 4 , N.R. 3C(S) and optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl or C3-C 13 spiroheterocyclyl; R 3 and R 4 are independently selected from hydrogen and optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, or C1-C8 alkylaminoC1-C8 alkyl; Each m is from 0 to 15; where n is 0 to 15).

[0253] In certain embodiments, the linker is a moiety according to Formula 16C:

[0254] [ka]

[0255] (In the formula, X is O, NH, or NR 7 Selected from; R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is independently selected at each occurrence from hydrogen, halogen, CN, OH, NH, optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; A and B are absent in each occurrence, CO, NH, NH-CO, CO-NH, CH2-NH-CO, CH2-CO-NH, NH-CO-CH2, CO-NH-CH2, CH2-NH-CH2-CO-NH, CH2-NH-CH2-NH-CO, -CO-NH, CO-NH-CH2-NH-CH2, CH2-NH-CH2, CO2, C(O)NR 7 , C(S)NR 7 , O, S, SO, SO2, SO2NR 7 , N.R. 7 , N.R. 7 CO, NR 7 CONR 8 , N.R. 7C(S), optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyC1-C8 alkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C 13 Fused Cycloalkyl, Optionally Substituted C-C 13 Fused heterocyclyl, optionally substituted C-C 13 Bridged Cycloalkyl, Optionally Substituted C-C 13 Bridged heterocyclyl, optionally substituted C-C 13 Spirocycloalkyl and optionally substituted C-C 13 spiroheterocyclyl; R 7 and R 8 are independently selected from hydrogen, optionally substituted C1-C8 alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C3-C8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C1-C8 alkoxy, optionally substituted C1-C8 alkoxyalkyl, optionally substituted C1-C8 haloalkyl, optionally substituted C1-C8 hydroxyalkyl, optionally substituted C1-C8 alkylamino, and optionally substituted C1-C8 alkylaminoC1-C8 alkyl; m, in each occurrence, is 0 to 15; n is 0 to 15 for each occurrence; o is from 0 to 15; p is 0 to 15); and and pharmaceutically acceptable salts thereof.

[0256] In certain embodiments, the linker is selected from the group consisting of a ring selected from the group consisting of a 3- to 13-membered ring; a 3- to 13-membered fused ring; a 3- to 13-membered bridged ring; and a 3- to 13-membered spiro ring; and pharmaceutically acceptable salts thereof.

[0257] In certain embodiments, the linker is a moiety according to one of formulas C1, C2, C3, C4, and C5:

[0258] [ka]

[0259] and pharmaceutically acceptable salts thereof.

[0260] Synthesis and testing of divalent compounds The binding affinity of the novel synthetic bivalent compounds (i.e., HPK1 degraders / disruptors) can be determined using standard biophysical assays known in the art (e.g., isothermal titration calorimetry (ITC)). Cellular assays can then be used to determine the ability of the bivalent compounds to induce HPK1 degradation and inhibit cancer cell growth. In addition to assessing bivalent compound-induced changes in HPK1 protein expression, enzymatic activity can also be determined. Suitable assays for use in any or all of these steps are known in the art and include, for example, Western blotting, quantitative mass spectrometry (MS) analysis, flow cytometry, enzymatic inhibition, ITC, SPR, cell growth inhibition, and xenograft and PDX models. Suitable cell lines for use in any or all of these steps are known in the art and include, for example, HPK1-deficient Jurkat clones created by CRISPR-mediated frameshift mutations resulting in loss of HPK1 expression in Jurkat T cells. Such systems can serve as a platform for counterscreening potential HPK1 degraders / disruptors for non-HPK1-specific effects. By way of non-limiting example, detailed synthesis protocols are described in the Examples for certain illustrative HPK1 degraders / disruptors.

[0261] Pharmaceutically acceptable isotopic variations of the compounds disclosed herein are contemplated and can be synthesized using conventional methods known in the art or methods corresponding to those described in the Examples (substituting appropriate reagents with appropriate isotopic variations of those reagents). In particular, isotopic variations are compounds in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Useful isotopes are known in the art and include, for example, isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine. Illustrative isotopes, therefore, include, for example, 2 H, 3 H, 13 C.14 C. 15 N, 17 O. 18 O. 32 P, 35 S, 18 F, and 36 Examples include Cl.

[0262] Isotopic variables (e.g., 2 Isotopic variations containing H) can offer therapeutic advantages due to greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements. In addition, certain isotopic variations, particularly those containing radioactive isotopes, can be used in drug or substrate tissue distribution studies. The radioactive isotope tritium ( 3 H) and carbon 14 ( 14 C) are particularly useful for this purpose given their ease of incorporation and readily available means of detection.

[0263] Pharmaceutically acceptable solvates of the compounds disclosed herein are contemplated.Solvates can be produced, for example, by substituting isotopic variations for the solvent used to crystallize the compounds disclosed herein (for example, by substituting DO for HO, d6-acetone for acetone, or d6-DMSO for DMSO).

[0264] Pharmaceutically acceptable fluorinated variants of the compounds disclosed herein are contemplated and can be synthesized using conventional methods known in the art or methods corresponding to those described in the Examples (substituting appropriate reagents with appropriate fluorinated variants of those reagents). In particular, fluorinated variants are compounds in which at least one hydrogen atom has been replaced by a fluoro atom. Fluorinated variants can offer therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements.

[0265] Definition of Terms As used herein, the terms "comprising" and "including" are used in their open, non-limiting sense.

[0266] "Alkyl" refers to a straight or branched hydrocarbon chain radical containing no unsaturation and consisting solely of carbon and hydrogen atoms. An alkyl can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 carbon atoms. In certain embodiments, an alkyl contains 1 to 15 carbon atoms (e.g., C1-C 15 In certain embodiments, alkyl comprises 1 to 13 carbon atoms (e.g., C1-C 13 In certain embodiments, alkyl comprises 1 to 8 carbon atoms (e.g., C1-C8 alkyl). In other embodiments, alkyl comprises 5 to 15 carbon atoms (e.g., C5-C 15 In other embodiments, the alkyl contains 5 to 8 carbon atoms (e.g., C5-C8 alkyl). The alkyl is attached to the rest of the molecule by a single bond, for example, methyl (Me), ethyl (Et), n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), pentyl, 3-methylhexyl, 2-methylhexyl, and the like.

[0267] "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms containing at least one double bond. An alkenyl can contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 carbon atoms. In certain embodiments, an alkenyl contains from 2 to 12 carbon atoms (e.g., C2-C6). 12alkenyl). In certain embodiments, an alkenyl contains 2 to 8 carbon atoms (e.g., C2-C8 alkenyl). In certain embodiments, an alkenyl contains 2 to 6 carbon atoms (e.g., C2-C6 alkenyl). In other embodiments, an alkenyl contains 2 to 4 carbon atoms (e.g., C2-C4 alkenyl). An alkenyl is attached to the remainder of the molecule by a single bond, such as ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.

[0268] The term "allyl," as used herein, means a -CH2CH=CH2 group.

[0269] As used herein, the term "alkynyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms containing at least one triple bond. Alkynyl can contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 carbon atoms. In certain embodiments, alkynyl contains 2 to 12 carbon atoms (e.g., C2-C6). 12 alkynyl). In certain embodiments, alkynyl contains 2 to 8 carbon atoms (e.g., C2-C8 alkynyl). In other embodiments, alkynyl has 2 to 6 carbon atoms (e.g., C2-C6 alkynyl). In other embodiments, alkynyl has 2 to 4 carbon atoms (e.g., C2-C4 alkynyl). Alkynyl is attached to the remainder of the molecule by a single bond. Examples of such groups include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, and the like.

[0270] The term "alkoxy," as used herein, refers to an alkyl group, as defined herein, attached to the remainder of the molecule via an oxygen atom. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.

[0271] The term "aryl," as used herein, refers to a group derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon atoms. An aryl can contain 6 to 18 carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic delocalized (4n+2)p electron system according to the Hückel theory. In certain embodiments, an aryl contains 6 to 14 carbon atoms (C6-C8). 14 In certain embodiments, aryl contains 6 to 10 carbon atoms (C6-C 10 aryl). Examples of such groups include, but are not limited to, phenyl, fluorenyl, and naphthyl. The terms "Ph" and "phenyl" as used herein refer to a -CH group.

[0272] The term "heteroaryl" refers to a group derived from a 3- to 18-membered aromatic ring group containing 2 to 17 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl group may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one ring in the ring system is fully unsaturated, i.e., it contains a cyclic delocalized (4n+2)p electron system according to the Hückel theory. Heteroaryl includes fused or bridged ring systems. Heteroatoms in heteroaryl groups are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. A heteroaryl is attached to the rest of the molecule through any atom of the ring. Examples of such groups include, but are not limited to, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, and the like. In certain embodiments, a heteroaryl is attached to the remainder of the molecule via a ring carbon atom. In certain embodiments, a heteroaryl is attached to the remainder of the molecule via a nitrogen atom (N-attached) or a carbon atom (C-attached). For example, a group derived from pyrrole can be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached), and a group derived from imidazole can be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).

[0273] The term "heterocyclyl," as used herein, refers to a non-aromatic monocyclic, bicyclic, tricyclic, or tetracyclic group having a total of 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 atoms in its ring system, containing 3 to 12 carbon atoms and 1 to 4 heteroatoms, each independently selected from O, S, and N, provided that no ring of the group contains two adjacent O atoms or two adjacent S atoms. Heterocyclyl groups can include fused, bridged, or spirocyclic ring systems. In certain embodiments, heterocyclyl groups contain 3 to 10 ring atoms (3- to 10-membered heterocyclyl). In certain embodiments, heterocyclyl groups contain 3 to 8 ring atoms (3- to 8-membered heterocyclyl). In certain embodiments, heterocyclyl groups contain 4 to 8 ring atoms (4- to 8-membered heterocyclyl). In certain embodiments, heterocyclyl groups contain from 3 to 6 ring atoms (3-6 membered heterocyclyl). Heterocyclyl groups can contain an oxo substituent at any available atom that results in a stable compound. For example, such groups can contain an oxo atom at an available carbon or nitrogen atom. Such groups can contain more than one oxo substituent, if chemically feasible. Additionally, when such heterocyclyl groups contain a sulfur atom, it should be understood that the sulfur atom can be oxidized with one or two oxygen atoms to provide either a sulfoxide or a sulfone. An example of a 4-membered heterocyclyl group is azetidinyl (derived from azetidine). An example of a 5-membered cycloheteroalkyl group is pyrrolidinyl. An example of a 6-membered cycloheteroalkyl group is piperidinyl. An example of a 9-membered cycloheteroalkyl group is indolinyl. An example of a 10-membered cycloheteroalkyl group is 4H-quinolidinyl.Further examples of such heterocyclyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, Examples of heteroaryl groups include 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, quinolizinyl, 3-oxopiperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, and 1-oxo-2,8,diazaspiro[4.5]dec-8-yl. Heteroaryl groups can be attached to the rest of the molecule via a carbon atom (C-attached) or a nitrogen atom (N-attached). For example, a group derived from piperazine can be piperazin-1-yl (N-attached) or piperazin-2-yl (C-attached).

[0274] The term "cycloalkyl" refers to a saturated monocyclic, bicyclic, tricyclic, or tetracyclic group having a total of 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 carbon atoms in its ring system. Cycloalkyls can be fused, bridged, or spirocyclic. In certain embodiments, cycloalkyls contain from 3 to 8 carbon ring atoms (C3-C8 cycloalkyl). In certain embodiments, cycloalkyls contain from 3 to 6 carbon ring atoms (C3-C6 cycloalkyl). Examples of such groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, adamantyl, and the like.

[0275] The term "cycloalkylene" refers to a bidentate group obtained by removing a hydrogen atom from a cycloalkyl ring, as defined above. Examples of such groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cycloheptylene, and the like.

[0276] The term "spirocyclic" as used herein has its conventional meaning, i.e., any ring system containing two or more rings, wherein two of the rings have one ring carbon in common. Each ring of a spirocyclic ring system, as defined herein, independently contains from 3 to 20 ring atoms. Preferably, they have from 3 to 10 ring atoms. Non-limiting examples of spirocyclic systems include spiro[3.3]heptane, spiro[3.4]octane, and spiro[4.5]decane.

[0277] The term "cyano" refers to the group --C.ident.N.

[0278] An "aldehyde" group refers to a -C(O)H group.

[0279] An "alkoxy" group refers to an --O-alkyl, as defined herein.

[0280] "Alkoxycarbonyl" refers to -C(O)-alkoxy as defined herein.

[0281] An "alkylaminoalkyl" group refers to an -alkyl-NR-alkyl group, as defined herein.

[0282] An "alkylsulfonyl" group refers to an -SO2 alkyl, as defined herein.

[0283] An "amino" group refers to an optionally substituted --NH.sub.2.

[0284] An "aminoalkyl" group refers to an -alkyl-amino group, as defined herein.

[0285] "Aminocarbonyl" refers to --C(O)-amino, as defined herein.

[0286] An "arylalkyl" group refers to an -alkylaryl, where alkyl and aryl are defined herein.

[0287] An "aryloxy" group refers to both an --O-aryl and an --O-heteroaryl group, as defined herein.

[0288] "Aryloxycarbonyl" refers to -C(O)-aryloxy as defined herein.

[0289] An "arylsulfonyl" group refers to an -SO2aryl, as defined herein.

[0290] A "carbonyl" group refers to a -C(O)- group, as defined herein.

[0291] A "carboxylic acid" group refers to a -C(O)OH group.

[0292] "Cycloalkoxy" refers to an --O-cycloalkyl group, as defined herein.

[0293] A "halo" or "halogen" group refers to fluorine, chlorine, bromine, or iodine.

[0294] A "haloalkyl" group refers to an alkyl group that is substituted with one or more halogen atoms.

[0295] A "hydroxy" group refers to an --OH group.

[0296] A "nitro" group refers to a -NO2 group.

[0297] An "oxo" group refers to a ═O substituent.

[0298] A "trihalomethyl" group refers to a methyl that is substituted with three halogen atoms.

[0299] The term "substituted" means that the specified group or moiety is substituted with C1-C4 alkyl, aryl, heteroaryl, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl, -OC1-C4 alkyl, -OC1-C4 alkylphenyl, -C1-C4 alkyl-OH, -OC1-C4 haloalkyl, halo, -OH, -NH2, -C1-C4 alkyl-NH2, -N(C1-C4 alkyl)(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(C1-C4 alkyl)(C1-C4 alkylphenyl), -NH(C1-C4 alkylphenyl), cyano, nitro, oxo, -CO2H, -C(O)OC1-C4 alkyl, -CON(C1-C4 alkyl)(C1-C4 alkyl), -CONH(C1 -C4 alkyl), -CONH, -NHC(O)(C1-C4 alkyl), -NHC(O)(phenyl), -N(C1-C4 alkyl)C(O)(C1-C4 alkyl), -N(C1-C4 alkyl)C(O)(phenyl), -C(O)C1-C4 alkyl, -C(O)C1-C4 alkylphenyl, -C(O)C1-C4 haloalkyl, -OC(O)C1-C4 alkyl, -SO2(C1-C4 alkyl), -SO2(phenyl), -SO2(C1-C4 haloalkyl), -SONH, -SONH(C1-C4 alkyl), -SONH(phenyl), -NHSO2(C1-C4 alkyl), -NHSO2(phenyl), and -NHSO2(C1-C4 haloalkyl).

[0300] The term "optionally substituted" means that the specified group may be either unsubstituted or substituted by one or more substituents as defined herein. In the compounds of the present invention, when a group is described as "unsubstituted" or "substituted" with fewer groups than satisfy the valences of all atoms in the compound, it is understood that the remaining valences on such group are satisfied by hydrogen. For example, if a C aryl group, also referred to herein as "phenyl," is substituted with one additional substituent, those skilled in the art will understand that such a group leaves four open positions on the carbon atoms of the C aryl ring (six original positions, one to which the remainder of the compound of the present invention is attached, and the additional substituent, leaving four open positions). In such a case, the remaining four carbon atoms are each bonded to one hydrogen atom to satisfy their valences. Similarly, when a C aryl group in the present compounds is described as "disubstituted," those skilled in the art will understand that this means that the C aryl has three remaining unsubstituted carbon atoms. These three unsubstituted carbon atoms are each bonded to one hydrogen atom to satisfy their valences.

[0301] "Pharmaceutically acceptable salts" include both acid and base addition salts. A pharmaceutically acceptable salt of any one of the divalent compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0302] "Pharmaceutically acceptable acid addition salts" refer to salts which retain the biological effectiveness and properties of the free base and which are not biologically or otherwise undesirable, such as those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, etc. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, including, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. Illustrative salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate, gluconate, and galacturonate (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997), hereby incorporated by reference in its entirety.) Acid addition salts of basic compounds can be prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt, according to methods and techniques familiar to those skilled in the art.

[0303] "Pharmaceutically acceptable base addition salts" refer to salts that retain the biological effectiveness and properties of the free acid and are not biologically or otherwise undesirable. These salts are prepared from the addition of an inorganic or organic base to the free acid. Pharmaceutically acceptable base addition salts can be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally substituted amines, cyclic amines, and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., supra.

[0304] Pharmaceutical Composition In some aspects, the compositions and methods described herein include the manufacture and use of pharmaceutical compositions and medicaments comprising one or more divalent compounds as disclosed herein. Also included are pharmaceutical compositions thereof.

[0305] In some embodiments, the compositions disclosed herein contain other compounds, drugs, or agents used for the treatment of cancer. For example, in some cases, the pharmaceutical compositions disclosed herein can be combined with one or more (e.g., 1, 2, 3, 4, 5, or less than 10) compounds. Such additional compounds include, for example, conventional chemotherapeutic agents known in the art. When co-administered, the HPK1 degrading / disrupting agents disclosed herein can act in conjunction with conventional chemotherapeutic agents to produce mechanistically additive or synergistic therapeutic effects.

[0306] In some aspects, the pH of the compositions disclosed herein can be adjusted with a pharmaceutically acceptable acid, base, or buffer to enhance the stability of the HPK1 degrader / disruptor or its delivery form.

[0307] Pharmaceutical compositions typically include a pharmaceutically acceptable carrier, adjuvant, or vehicle. As used herein, the phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are generally considered physiologically tolerable and that typically do not cause allergic or similar adverse reactions, such as stomach upset, dizziness, etc., when administered to humans. A pharmaceutically acceptable carrier, adjuvant, or vehicle is a composition that can be administered to a patient together with a compound of the present invention and is non-toxic when administered in a dosage sufficient to deliver a therapeutic amount of the compound without destroying its pharmacological activity. Illustrative conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles include saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., that are compatible with pharmaceutical administration.

[0308] In particular, pharmaceutically acceptable carriers, adjuvants, and vehicles that can be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS), such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms, such as Tween or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium monohydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat. Cyclodextrins, such as alpha, beta, and gamma cyclodextrin, can also be advantageously used to enhance delivery of compounds of the formulae described herein.

[0309] As used herein, the HPK1 degraders / disruptors disclosed herein are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. "Pharmaceutically acceptable derivative" refers to any pharmaceutically acceptable salt, solvate, or prodrug of a compound or agent disclosed herein, such as a carbamate, ester, phosphate ester, salt of an ester, or other derivative, that, upon administration to a recipient, is capable of providing (directly or indirectly) a compound described herein, or an active metabolite or residue thereof. Particularly advantageous derivatives and prodrugs are those that increase the bioavailability of the compounds disclosed herein when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives in which groups that enhance water solubility or active transport across intestinal membranes are added to the structures of the formulas described herein. Such derivatives are recognizable to those of ordinary skill in the art without undue experimentation. Nonetheless, reference is made to the teachings of Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, Volume 1: Principles and Practice, which is incorporated herein by reference insofar as it teaches such derivatives.

[0310] The HPK1 degraders / disruptors disclosed herein include pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereomeric racemates, mixtures of diastereomeric racemates, as well as meso forms and pharmaceutically acceptable salts, solvent complexes, morphological forms, or deuterated derivatives thereof.

[0311] In particular, pharmaceutically acceptable salts of the HPK1 degraders / disruptors disclosed herein include, for example, those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecyl sulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate, trifluoromethylsulfonate, and undecanoate. Salts derived from appropriate bases include, for example, HPK1 alkali metal (e.g., sodium) salts, HPK1 alkaline earth metal (e.g., magnesium) salts, ammonium salts, and N-(HPK1yl)4+ salts. The present invention further contemplates the quaternization of any basic nitrogen-containing groups of the HPK1 decomposers / disruptors disclosed herein. Water- or oil-soluble or dispersible products may be obtained by such quaternization.

[0312] In some embodiments, the pharmaceutical compositions disclosed herein can comprise an effective amount of one or more HPK1 degraders / disruptors. The terms "effective amount" and "effective to treat," as used herein, refer to an amount or concentration of one or more compounds or pharmaceutical compositions described herein utilized for a period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration to cause an intended effect or physiological result (e.g., cell growth, cell proliferation, or treatment or prevention of cancer). In some embodiments, the pharmaceutical composition can further comprise one or more additional compounds, drugs, or agents (e.g., conventional chemotherapeutic agents) used for the treatment of cancer in an amount effective to cause an intended effect or physiological result (e.g., cell growth, cell proliferation, or treatment or prevention of cancer).

[0313] In some aspects, the pharmaceutical compositions disclosed herein can be formulated for sale in the United States, import into the United States, or export from the United States.

[0314] Administration of the Pharmaceutical Composition The pharmaceutical compositions disclosed herein can be formulated or adapted for administration to a subject via any route, for example, any route approved by the Food and Drug Administration (FDA). Exemplary methods are described in the FDA Data Standards Manual (DSM) (available at http: / / www.fda.gov / Drugs / DevelopmentApprovalProcess / FormsSubmissionRequirements / ElectronicSubmissions / DataStandardsManualmonographs). In particular, the pharmaceutical compositions can be formulated for and administered via oral, parenteral, or transdermal delivery. The term "parenteral" as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraperitoneal, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.

[0315] For example, the pharmaceutical compositions disclosed herein can be administered, for example, topically, rectally, nasally (e.g., by inhalation spray or nebulizer), buccally, vaginally, subdermally (e.g., by injection or via an implanted reservoir), or ophthalmically.

[0316] For example, the pharmaceutical composition of this invention can be orally administered in any orally acceptable dosage form, including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.In the case of tablets for oral use, commonly used carriers include lactose and cornstarch.Lubricants such as magnesium stearate are also typically added.For oral administration in capsule form, useful diluents include lactose and dried cornstarch.When aqueous suspensions or emulsions are orally administered, the active ingredient that can be suspended or dissolved in an oily phase is combined with an emulsifying or suspending agent.If desired, certain sweeteners, flavorings or coloring agents can be added.

[0317] For example, the pharmaceutical composition of this invention can be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the compound of this invention with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, thereby melting in the rectum and releasing the active ingredient. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycol.

[0318] For example, the pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, or other solubilizing or dispersing agents known in the art.

[0319] For example, the pharmaceutical compositions of this invention can be administered by injection (e.g., as a solution or powder). Such compositions can be formulated according to techniques known in the art using suitable dispersing or wetting agents (e.g., Tween 80, etc.) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvents or suspending media. For this purpose, any sterile, fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives, are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethylcellulose or similar dispersing agent commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and / or suspensions. Other commonly used surfactants such as Tween, Spann, or other similar emulsifiers, or bioavailability enhancers commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes.

[0320] In some embodiments, the effective dose of the pharmaceutical composition of the present invention may be, but is not limited to, about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8 , 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2500, 5000, or 10000 mg / kg / day, or according to the requirements of the particular pharmaceutical composition.

[0321] When the pharmaceutical compositions disclosed herein include a combination of a compound of the formulae described herein (e.g., an HPK1 degrader / disruptor) and one or more additional compounds (e.g., one or more additional compounds, drugs, or agents used to treat cancer or any other condition or disease, including conditions or diseases known to be associated with or caused by cancer), both the compound and the additional compounds should be present at dosage levels between about 1% and 100%, and more preferably between about 5% and 95%, of the dosage normally administered in a monotherapy regimen. The additional agents can be administered separately from the compounds of this invention as part of a multiple-dose regimen. Alternatively, the agents are mixed together with the compounds of this invention in a single composition as part of a single dosage form.

[0322] In some aspects, the pharmaceutical compositions disclosed herein may be included in a container, pack, or dispenser together with instructions for administration.

[0323] Treatment method The methods disclosed herein contemplate the administration of an effective amount of a compound or composition to achieve a desired or specified effect. Typically, the compounds or compositions of the present invention are administered about once to about six times per day, or alternatively or additionally, as a continuous infusion. Such administration can be used as a chronic or acute treatment. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending on the host treated and the particular mode of administration. Typical preparations contain from about 5% to about 95% active compound (w / w). Alternatively, such preparations may contain from about 20% to about 80% active compound.

[0324] In some aspects, the present disclosure provides methods for using compositions comprising HPK1 degraders / disruptors, including pharmaceutical compositions disclosed herein (shown below as "X"), in the following methods: Substance X for use as a medicament in the treatment of one or more diseases or conditions disclosed herein (e.g., cancer, referred to as "Y" in the examples below); use of substance X for the manufacture of a medicament for the treatment of Y; and substance X for use in the treatment of Y.

[0325] In some aspects, the disclosed methods include administering a therapeutically effective amount of one or more of the compounds or compositions described herein to a subject (e.g., a mammalian subject, e.g., a human subject) in need of or determined to be in need of such treatment. In some aspects, the disclosed methods include selecting a subject and administering to the subject an effective amount of one or more of the compounds or compositions described herein, and optionally repeating the administration as needed to prevent or treat cancer.

[0326] In some embodiments, subject selection involves obtaining a sample from a subject (e.g., a candidate subject) and testing the sample for signs that the subject is suitable for selection. In some embodiments, the subject can be confirmed or identified, e.g., by a healthcare professional, as having or having a condition or disease. In some embodiments, suitable subjects include, for example, subjects who have or had the condition or disease but have resolved the disease or aspects thereof, exhibit reduced symptoms of the disease (e.g., relative to other subjects (e.g., a majority of subjects) with the same condition or disease), or survive with the condition or disease for an extended period of time (e.g., relative to other subjects (e.g., a majority of subjects) with the same condition or disease), e.g., in an asymptomatic state (e.g., relative to other subjects (e.g., a majority of subjects) with the same condition or disease). In some embodiments, indications of a positive immune response to the condition or disease can be made from patient records, family history, or detecting signs of a positive immune response. In some embodiments, multiple parties can be involved in subject selection. For example, a first party can obtain a sample from a candidate subject, and a second party can test the sample. In some aspects, the subject may be selected or referred by a medical practitioner (e.g., a general practitioner). In some aspects, subject selection may include obtaining a sample from the selected subject and storing the sample or using it in the methods disclosed herein. The sample may include, for example, a cell or a population of cells.

[0327] In some embodiments, methods of treatment can include single, multiple, and repeated administration of one or more compounds disclosed herein as needed for the prevention or treatment of a disease or condition (e.g., HPK1-mediated cancer) from which a subject suffers. In some embodiments, methods of treatment can include determining the level of disease in the subject before, during, or after treatment. In some embodiments, treatment can be continued until a decrease in the level of disease in the subject is detected.

[0328] The term "subject," as used herein, refers to any animal. In some instances, a subject is a mammal. In some instances, the term "subject," as used herein, refers to a human (e.g., a man, woman, or child).

[0329] The terms "administer," "administering," or "administration," as used herein, refer to implanting, ingesting, injecting, inhaling, or otherwise absorbing a compound or composition, regardless of form. For example, the methods disclosed herein include administering an effective amount of a compound or composition to achieve a desired or specified effect.

[0330] The terms "treat," "treating," or "treatment," as used herein, refer to partially or completely alleviating, inhibiting, ameliorating, or alleviating a disease or condition from which a subject suffers. This refers to any manner in which one or more of the symptoms of a disease or disorder (e.g., cancer) are ameliorated or otherwise beneficially altered. As used herein, amelioration of symptoms of a particular disorder (e.g., cancer) refers to any reduction, whether permanent or temporary, persistent or transient, that may result from or be associated with treatment with the compositions and methods of the present invention. In some aspects, treatment can promote or result in, for example, a decrease in the number of tumor cells (e.g., in a subject) relative to the number of tumor cells prior to treatment; a decrease in tumor cell viability (e.g., average / mean viability) (e.g., in a subject) relative to the viability of tumor cells prior to treatment; a decrease in tumor cell growth rate; a decrease in the rate of local or distant tumor metastasis; or a reduction in one or more symptoms associated with one or more tumors in a subject relative to the subject's symptoms prior to treatment.

[0331] As used herein, the term "treating cancer" means causing a partial or complete reduction in tumor growth rate, and / or in tumor size, and / or in the rate of local or distant tumor metastasis and / or overall tumor burden in a subject, and / or any reduction in tumor survival, in the presence of a degrading / disrupting agent described herein (e.g., an HPK1 degrading / disrupting agent).

[0332] The terms "prevent," "preventing," and "prevention," as used herein, refer to a reduction in the appearance of a disease or a reduction in the risk of acquiring a disease or its associated symptoms in a subject. Prevention can be complete, e.g., the total absence of the disease or pathological cells in the subject. Prevention can also be partial, such that the appearance of the disease or pathological cells in the subject is less, appears later, or develops more slowly than would appear without the present invention.

[0333] Illustrative types of cancer that can be prevented or therapeutically treated by manipulating HPK1 levels with degraders / destructors include, but are not limited to, all solid and liquid cancers, including cancers of the breast, respiratory tract, brain, reproductive organs, gastrointestinal tract, urinary tract, eye, liver, skin, head and neck, thyroid, and parathyroid, and their distant metastases. Examples of liquid cancers include lymphoma, sarcoma, and leukemia. Listed below are types of cancer that immunotherapy using HPK1 degraders / destructors should be able to prevent or treat.

[0334] Examples of breast cancer include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

[0335] Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

[0336] Examples of brain cancers include, but are not limited to, brain stem and hypothalamic glioma, cerebellar and cerebral astrocytoma, glioblastoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.

[0337] Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer.

[0338] Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, endovaginal, and vulvar cancer, as well as sarcoma of the uterus.

[0339] Examples of ovarian cancer include, but are not limited to, serous tumor, endometrioid tumor, mucinous cystadenocarcinoma, granulosa cell tumor, Sertoli-Leydig cell tumor, and virilizing tumor.

[0340] Examples of cervical cancer include, but are not limited to, squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, vitreous cell carcinoma, and choriocarcinoma. Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small intestine, and salivary gland cancer.

[0341] Examples of esophageal cancer include, but are not limited to, esophageal carcinoma and adenocarcinoma, as well as squamous cell carcinoma, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma, and lymphoma.

[0342] Examples of gastric cancer include, but are not limited to, intestinal-type and diffuse-type gastric adenocarcinoma.

[0343] Examples of pancreatic cancer include, but are not limited to, ductal adenocarcinoma, adenosquamous carcinoma, and pancreatic endocrine tumors.

[0344] Examples of tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral, ​​and human papillary renal carcinoma.

[0345] Kidney cancers include, but are not limited to, renal cell carcinoma, urothelial cell carcinoma, juxtaglomerular cell tumor (nephroma), angiomyolipoma, renal oncocytoma, Bellini ductal carcinoma, clear cell sarcoma of the kidney, mesodermal nephroma, and Wilms' tumor.

[0346] Examples of bladder cancer include, but are not limited to, transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma, and small cell carcinoma. Eye cancer includes, but is not limited to, intraocular melanoma and retinoblastoma.

[0347] Examples of liver cancer include, but are not limited to, hepatocellular carcinoma (with or without fibrolamellar variant), biliary adenocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular-biliary adenocarcinoma.

[0348] Examples of skin cancer include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

[0349] Examples of head and neck cancers include, but are not limited to, squamous cell carcinoma of the head and neck, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer and squamous cell carcinoma.

[0350] Examples of lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.

[0351] Examples of sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[0352] Examples of leukemia include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

[0353] HPK1 degraders / disruptors can treat the above cancer types as stand-alone agents or should be used as agents in combination with existing standard treatment therapies and other FDA-approved cancer therapies.

[0354] Therapeutic uses of HPK1 include diseases and therapies amenable to treatment by stimulating / enhancing the immune response, including extending the immune response during vaccination for immunizable diseases. Moreover, because HPK1 is expressed at high levels in two other anatomical locations—the brain and the testes—HPK1 degraders / disruptors should be able to treat or prevent diseases associated with the brain and testes that are caused by or can be treated by HPK1 degraders / disruptors. These potential diseases include, but are not limited to, Alzheimer's disease, age-related dementia, and infertility, regardless of whether these potential diseases are caused by HPK1 or by other pathogenic causes.

[0355] As used herein, the term "preventing disease" (e.g., preventing cancer) in a subject means stopping the onset of one or more symptoms of a disease in a subject, for example, before they appear or become detectable, for example, by the patient or their physician. Blood tests measuring the level of HPK1 in each immune cell subtype can be achieved by intracellular staining with an anti-HPK1 antibody and analyzed by clinical FACS analysis. Such detection methods can identify immune cell types with abnormal levels of HPK1 and indicate that such patients may be good candidates for HPK1 degrader / disruptor-based therapy. This detection of abnormal HPK1 expression levels can be an early warning biomarker that can indicate which patients may respond well to their disease state if an HPK1 degrader / disruptor is used as a standalone or as part of a combination therapy. Preferably, the disease (e.g., cancer) does not develop at all, i.e., the symptoms of the disease are not detectable. However, it can also mean delaying or slowing the onset of one or more symptoms of the disease. Alternatively, or in addition, it can mean reducing the severity of one or more symptoms that subsequently develop.

[0356] The specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptom, the patient's disposition to the disease, condition or symptom, and the judgment of the treating physician.

[0357] An effective amount can be administered in one or more administrations, applications, or dosages. The therapeutically effective amount (i.e., effective dosage) of a therapeutic compound will depend on the therapeutic compound selected. Furthermore, treatment of a subject with a therapeutically effective amount of a compound or composition described herein can include a single treatment or a series of treatments. For example, an effective amount can be administered at least once. The composition can be administered one or more times per day to one or more times per week; including once every other day. One of skill in the art will understand that certain factors can affect the dosage and timing required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the subject's general health or age, and other diseases present.

[0358] Following administration, subjects can be evaluated to detect, assess, or determine their disease level. In some cases, treatment can be continued until a change (e.g., a reduction) in the level of disease in the subject is detected. Upon improvement of the patient's condition (e.g., a change (e.g., a reduction) in the level of disease in the subject), a maintenance dose of a compound or composition disclosed herein can be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, can be reduced, e.g., as a function of symptoms, to a level at which the improved condition is maintained. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

[0359] The HPK1 degraders / disruptors disclosed herein include pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereomeric racemates, mixtures of diastereomeric racemates, as well as meso forms and pharmaceutically acceptable salts, solvent complexes, morphological forms, or deuterated and fluoro derivatives thereof. [Example]

[0360] The following examples describe the synthesis of illustrative HPK1 degrader / disruptor compounds in accordance with the present invention.

[0361] Example 1 Synthesis of MS-5-006 The reaction scheme for the synthesis of MS-5-006 is shown in FIG. The procedure for preparing 66-4 is described in the synthesis of MS-6-006.

[0362] Procedure for the preparation of compound 56-2. To a solution of compound 56-1 (25 g, 117.36 mmol, 1 equiv.) in THF (250 mL) was added MeMgBr (3 M, 117.36 mL, 3 equiv.) at 0 °C. The mixture was stirred at 20 °C for 3 h. The reaction was quenched by the addition of aqueous NH Cl (500 mL). The aqueous phase was extracted with DCM (250 mL × 3). The combined organic extracts were washed with brine (50 mL), dried, filtered, and concentrated. The residue was purified by flash silica gel chromatography (SiO, PE / EA = 100 / 1 to 1 / 1) to give compound 56-2 (19.6 g, 79.96 mmol, 68.14% yield) as a white solid. 1 H NMR (400 MHz, CDCl3): δ = 7.43 (d, J = 2.0 Hz, 1H), 7.36 (dd, J = 8.4, 2.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 4.76 (s, 2H), 3.69 - 3.12 (m, 2H), 1.66 (s, 6H).

[0363] Procedure for the preparation of compound 56-3. To a solution of compound 56-2 (19 g, 77.52 mmol, 1 equiv.) in THF (130 mL) was added MnO2 (67.39 g, 775.15 mmol, 10 equiv.). The mixture was stirred at 70 °C for 3 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give compound 56-3 (18.55 g, 76.95 mmol, 99.26% yield) as a yellow solid. LCMS: t R = 434 min, MS (ESI+) m / z = 240.7 [M+1] + . 1H NMR (400 MHz, CDCl3): δ = 7.80 - 7.69 (m, 1H), 7.69 - 7.61 (m, 1H), 7.57 (s, 1H), 1.67 (s, 6H).

[0364] Procedure for the preparation of compound 56-4. A mixture of compound 56-3 (18 g, 74.66 mmol, 1 equiv.), BocNH (10.50 g, 89.60 mmol, 1.2 equiv.), Pd(dba) (3.42 g, 3.73 mmol, 0.05 equiv.), CsCO (48.65 g, 149.33 mmol, 2 equiv.), and Xantphos (4.32 g, 7.47 mmol, 0.1 equiv.) in dioxane (180 mL) was degassed and purged with N three times, and then the mixture was stirred at 100 °C under a N atmosphere for 12 h. The reaction mixture was washed with brine (250 mL) and extracted with EtOAc (250 mL × 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO2, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 56-4 (21.5 g) as a yellow solid. LCMS: t R = 0.450 min, MS (ESI+) m / z = 278.1[M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 9.97 (s, 1H), 7.88 (d, J = 1.2 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.42 (dd, J = 8.4, 2.0 Hz, 1H), 1.57 (s, 6H), 1.49 (s, 9H).

[0365] Procedure for the preparation of compound 56-5. To a solution of compound 56-4 (21.5 g, 77.53 mmol, 1 eq.) in DCM (120 mL) was added HCl / dioxane (4 M, 58.15 mL, 3 eq.). The mixture was stirred at 20 °C for 2 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give compound 56-5 (10.93 g, 51.16 mmol, 65.98% yield, HCl) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): δ = 7.40 (d, J = 8.4 Hz, 1H), 6.67 (dd, J = 8.0, 1.6 Hz, 1H), 6.58 (d, J = 2.0 Hz, 1H), 1.51 (s, 6H).

[0366] Procedure for the preparation of compound 56-6. To a solution of compound 56-20 (40 g, 180.96 mmol, 1 eq.) and compound 56-21 (26.07 g, 190.01 mmol, 1.05 eq.) in ACN (600 mL) was added DIEA (46.78 g, 361.92 mmol, 63.04 mL, 2 eq.). The mixture was stirred at 20 °C for 3 h. The reaction mixture was quenched by the addition of water (800 mL), and the mixture was filtered to give compound 56-6 (54.2 g, crude) as a yellow solid. LCMS: t R = 0.447 min, MS (ESI+) m / z = 322.7 [M+1] + . 1 H NMR (400 MHz, CDCl3): δ = 9.15 (d, J = 7.6 Hz, 1H), 8.69 (s, 1H), 7.39 (d, J = 4.4 Hz, 4H), 7.36 - 7.29 (m, 1H), 5.48 (m, 1H), 4.39 (m, 2H), 4.07 - 3.91 (m, 2H), 1.41 (t, J = 7.2 Hz, 3H).

[0367] Procedure for the preparation of compound 56-7. To a solution of compound 56-5 (10.9 g, 51.02 mmol, 1 eq., HCl) and compound 56-6 (19.79 g, 61.51 mmol, 1.21 eq.) in NMP (70 mL) was added HCl / dioxane (4 M, 23.07 mL, 1.81 eq.). The mixture was stirred at 80 °C for 12 h. The reaction was cooled to room temperature, quenched by the addition of triethylamine (25 mL), and diluted with EtOAc (150 mL) and ethanol (7.5 mL). The mixture was washed with brine (150 mL × 3), dried over NaSO, filtered, and concentrated under reduced pressure to give compound 56-7 (24.95 g, crude) as a yellow solid. LCMS: tR = 0.445 min, MS (ESI+) m / z = 463.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.30 (s, 1H), 9.00 (d, J = 7.6 Hz, 1H), 8.68 (s, 1H), 8.01 - 7.84 (m, 1H), 7.76 - 7.65 (m, 1H), 7.64 - 7.56 (m, 1H), 7.44 - 7.31 (m, 4H), 7.30 - 7.22 (m, 1H), 5.39 - 5.26 (m, 1H), 5.19 (t, J = 4.8 Hz, 1H), 4.37 - 4.22 (m, 2H), 3.93 - 3.84 (m, 1H), 3.80 (m, 1H), 1.57 (s, 3H), 1.51 (s, 3H), 1.34 (t, J = 6.8 Hz, 3H).

[0368] Procedure for the preparation of compound 56-19. To a solution of compound 56-17 (10 g, 84.65 mmol, 1 equiv.) in DCM (100 mL), PPTS (1.06 g, 4.23 mmol, 0.05 equiv.) and compound 56-18 (9.97 g, 118.51 mmol, 10.84 mL, 1.4 equiv.) were added. The mixture was stirred at 20 °C for 3 h. The reaction mixture was partitioned between DCM (150 mL × 2) and water (150 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO2, PE / EA = 100 / 1 to 4 / 1) to give compound 56-19 (10.5 g, 51.92 mmol, 61.33% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 4.63 (t, J = 2.8 Hz, 1H), 4.21 - 4.09 (m, 2H), 4.00 (td, J =10.0, 6.4 Hz, 1H), 3.93 -3.78 (m, 1H), 3.69 (td, J = 10.0, 6.4 Hz, 1H), 3.59 - 3.44 (m, 1H), 2.60 (t, J = 6.4 Hz, 2H), 1.87 - 1.75 (m, 1H), 1.74 - 1.64 (m,1H), 1.62 - 1.45 (m, 4H), 1.31 - 1.22 (m, 3H).

[0369] Procedure for the preparation of compound 56-9. To a solution of compound 56-19 (10.5 g, 51.92 mmol, 1 eq.) in THF (100 mL) was added NaOH (2 M, 51.92 mL, 2 eq.). The mixture was stirred at 25 °C for 2 h. The reaction mixture was washed with citric acid (5%, 100 mL) and extracted with EtOAc (50 mL × 3). The combined organic layer was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give compound 56-9 (5.71 g, 32.78 mmol, 63.14% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3): δ= 4.65 (t, J = 3.2 Hz, 1H), 4.01 (td, J = 10.0, 6.0 Hz, 1H), 3.93 - 3.81 (m, 1H), 3.71 (td, J = 10.0, 6.4 Hz, 1H), 3.62 - 3.41 (m, 1H), 2.66 (t, J = 6.4 Hz, 2H), 1.86 - 1.75 (m, 1H), 1.75 - 1.66 (m, 1H), 1.66 - 1.45 (m, 4H).

[0370] Procedure for the preparation of compound 56-8. To a solution of compound 56-7 (5 g, 10.81 mmol, 1 equiv) in EtOH (250 mL) at 20 °C, NH2NH2·H2O (17.73 g, 354.17 mmol, 17.21 mL, 32.76 equiv) was slowly added. The mixture was stirred at 90 °C for 72 h. The reaction mixture was concentrated to give the crude product, which was purified by preparative HPLC (HCl condition) and lyophilized to give compound 56-8 (5.25 g, crude) as a yellow solid. LCMS: t R = 0.340 min, MS (ESI+) m / z = 449.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.06 (s, 2H), 9.62 (d, J = 8.0 Hz, 1H), 8.57 (s, 1H), 7.96 (d, J = 1.2 Hz, 1H), 7.74 - 7.65 (m, 1H), 7.64 - 7.56 (m, 1H), 7.41 - 7.30 (m, 4H), 7.29 - 7.19 (m, 1H), 5.80 - 4.48 (m, 4H), 3.89 - 3.79 (m, 1H), 3.78 - 3.66 (m, 1H), 1.54 (d, J = 18..8 Hz, 6H).

[0371] Procedure for the preparation of compound 56-10. To a solution of compound 56-9 (1.17 g, 6.69 mmol, 1 equiv.) in DCM (45 mL) was added EDCI (1.28 g, 6.69 mmol, 1 equiv.), HOBt (903.89 mg, 6.69 mmol, 1 equiv.), and TEA (744.58 mg, 7.36 mmol, 1.02 mL, 1.1 equiv.) at 0 °C for 30 min. Compound 56-8 (3 g, 6.69 mmol, 1 equiv.) was then added. The reaction mixture was partitioned between DCM (50 mL × 2) and HO (50 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by preparative HPLC (22% to 53% ACN in water (0.225% FA), 20 min) and lyophilized to give compound 56-10 (2.43 g, 3.45 mmol, 51.62% yield, 86% purity) as a white solid. LCMS: t R= 0.392 min, MS (ESI+) m / z = 605.2 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ= 10.25 (s, 1H), 10.14 (s, 1H), 9.85 (s, 1H), 9.54 (d, J = 7.6 Hz, 1H), 8.68 (s, 1H), 7.97 (s, 1H), 7.73 - 7.66 (m, 1H), 7.65 - 7.59 (m, 1H), 7.36 (d, J = 4.0 Hz, 4H), 7.25 (m, 1H), 5.30 (m, 1H), 5.14 (t, J = 4.8 Hz, 1H), 4.62 - 4.55 (m, 1H), 3.96 - 3.53 (m, 6H), 3.49 - 3.39 (m, 1H), 2.48 - 2.45 (m, 1H), 1.81 - 1.62 (m, 2H), 1.58 (s, 3H), 1.53 (s, 3H), 1.50 - 1.41 (m, 4H).

[0372] Procedure for the preparation of compound 56-11. To a solution of compound 56-10 (2.4 g, 3.97 mmol, 1 equiv) in DCM (25 mL) was added TsCl (832.39 mg, 4.37 mmol, 1.1 equiv) and TEA (602.46 mg, 5.95 mmol, 828.70 μL, 1.5 equiv). The mixture was stirred at 25 °C for 12 h. The reaction mixture was acidified by adding NaHCO (50 mL) with shaking until the pH reached approximately 8, and then extracted with DCM (30 mL × 2). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated to give a residue. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 56-11 (2.51 g, crude) as a yellow solid. LCMS: t R = 0.464 min, MS (ESI+) m / z = 587.1 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.30 (s, 1H), 8.87 (d, J = 8.0 Hz, 1H), 8.65 (s, 1H), 7.97 (s, 1H), 7.79 - 7.67 (m, 1H), 7.67 - 7.60 (m, 1H), 7.45 - 7.33 (m, 4H), 7.30 - 7.23 (m, 1H), 5.52 - 5.35 (m, 1H), 5.24 (t, J = 4.8 Hz, 1H), 4.73 - 4.62 (m, 1H), 4.10 - 4.01 (m, 1H), 3.97 - 3.89 (m, 1H), 3.89 - 3.79 (m, 2H), 3.74 - 3.64 (m, 1H), 3.49 - 3.40 (m, 1H), 3.23 (t, J = 6.4 Hz, 2H), 1.72 - 1.61 (m, 2H), 1.58 (s, 3H), 1.53 (s, 3H), 1.50 - 1.37 (m, 4H).

[0373] Procedure for the preparation of compound 56-12. To a solution of compound 56-11 (2.4 g, 4.09 mmol, 1 equiv) in DMF (24 mL) was added TBDPSCl (3.37 g, 12.27 mmol, 3.15 mL, 3 equiv) and imidazole (1.11 g, 16.36 mmol, 4 equiv). The mixture was stirred at 25 °C for 12 h. The reaction mixture was partitioned between EtOAc (30 mL × 2) and HO (30 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 56-12 (2.69 g, 3.26 mmol, 79.70% yield) as a colorless solid. LCMS: t R = 0.664 min, MS (ESI+) m / z = 825.1 [M+1] + . 1H NMR (400 MHz, CDCl3): δ = 9.31 (d, J = 7.6 Hz, 1H), 8.63 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.61 (dd, J = 8.0, 1.2 Hz, 3H), 7.55 (dd, J = 8.4, 1.6 Hz, 1H), 7.45 - 7.35 (m, 8H), 7.35 - 7.25 (m, 6H), 5.57 - 5.45 (m, 1H), 4.73 (s, 1H), 4.23 (m, 1H), 4.12 - 4.05 (m, 1H), 4.03 - 3.91 (m, 2H), 3.91 - 3.81 (m, 1H), 3.61 - 3.51 (m, 1H), 3.30 (t, J = 6.4 Hz, 2H), 1.85 - 1.67 (m, 3H), 1.63 (d, J = 2.0 Hz, 6H), 1.60 - 1.47 (m, 3H), 1.02 (s, 9H).

[0374] Procedure for the preparation of compound 56-13. To a solution of compound 56-12 (2.6 g, 3.15 mmol, 1 equiv.) in MeOH (26 mL) was added PPTS (79.19 mg, 315.14 μmol, 0.1 equiv.). The mixture was stirred at 40° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH=100 / 1 to 10 / 1) to give compound 56-13 (1.91 g, 2.58 mmol, 81.80% yield) as a colorless solid. LCMS: t R = 0.597 min, MS (ESI+) m / z = 741.2 [M+1] + . 1H NMR (400 MHz, CDCl3): δ = 9.30 (d, J = 8.0 Hz, 1H), 8.61 (s, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.64 - 7.57 (m, 3H), 7.56 - 7.50 (m, 2H), 7.43 - 7.26 (m, 13H), 5.58 - 5.40 (m, 1H), 4.18 (t, J = 5.6 Hz, 2H), 4.13 - 4.05 (m, 1H), 3.98 (dd, J = 10.0, 4.8 Hz, 1H), 3.21 (t, J = 5.6 Hz, 2H), 2.76 - 2.49 (m, 1H), 1.62 (s, 6H), 1.01 (s, 9H).

[0375] Procedure for the preparation of compound 56-14. To a solution of compound 56-13 (1 g, 1.35 mmol, 1 equiv) in DCM (20 mL) was added TEA (273.14 mg, 2.70 mmol, 375.71 μL, 2 equiv) and MsCl (309.21 mg, 2.70 mmol, 208.93 μL, 2 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h under N atmosphere. The reaction mixture was quenched with HO (30 mL) and extracted with DCM (20 mL × 2), and the organic layer was concentrated under reduced pressure to give compound 56-14 (1.83 g, crude) as a yellow oil. LCMS: t R =0.604 min, MS(ESI+)m / z=819.1[M+1] + .

[0376] Procedure for the preparation of compound 56-16. To a solution of compound 56-14 (516.22 mg, 630.30 μmol, 1 equiv.) and compound 66-4 (300 mg, 630.30 μmol, 1 equiv., HCl) in DMAc (5 mL) was added DIEA (325.84 mg, 2.52 mmol, 439.13 μL, 4 equiv.). The mixture was stirred at 100° C. for 12 h. The residue was purified by preparative HPLC (31% to 61% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 56-16 (200 mg, 172.06 μmol, 27.30% yield) as a yellow solid. LCMS: t R= 0.479 min, MS (ESI+) m / z = 1162.8 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.07 (s, 1H), 10.29 (s, 1H), 9.23 (d, J = 8.0 Hz, 1H), 8.70 (s, 1H), 7.88 (s, 1H), 7.76 - 7.72 (m, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 6.8 Hz, 2H), 7.43 - 7.23 (m, 15H), 5.63 - 5.53 (m, 1H), 5.07 (m, 1H), 4.15 (dd, J = 10.0, 3.2 Hz, 1H), 3.99 (dd, J = 11.6, 4.4 Hz, 1H), 3.56 (m, 2H), 3.42 (d, J = 4.8 Hz, 12H), 2.56 (s, 6H), 2.28 - 2.11 (m, 3H), 2.05 - 2.00 (m, 1H), 1.82 (d, J = 10.8 Hz, 3H), 1.52 (d, J = 6.0 Hz, 6H), 0.93 (s, 9H).

[0377] Procedure for the preparation of MS-5-006. To a solution of compound 56-16 (150 mg, 129.04 μmol, 1 equiv.) in DMSO (1.5 mL) was added CsF (196.02 mg, 1.29 mmol, 47.58 μL, 10 equiv.). The mixture was stirred at 50° C. for 1 h. The residue was purified by preparative HPLC (20% to 25% ACN in water (0.225% FA), 10 min) and lyophilized to give MS-5-006 (26.74 mg, 27.48 μmol, 21.30% yield, 99.7% purity, FA) as a yellow solid. LCMS: t R = 1.134 min, MS (ESI+) m / z = 924.6 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 10.30 (s, 1H), 8.88 (d, J = 8.0 Hz, 1H), 8.65 (s, 1H), 8.14 (s, 1H), 7.97 (s, 1H), 7.81 - 7.55 (m, 3H), 7.51 - 7.31 (m, 5H), 7.30 - 7.15 (m, 2H), 5.53 - 5.37 (m, 1H), 5.34 - 5.15 (m, 1H), 5.07 (dd, J = 12.8, 5.2 Hz, 1H), 3.94 - 3.88 (m, 1H), 3.87 - 3.81 (m, 1H), 3.13 (t, J = 7.2 Hz, 4H), 3.01 - 2.74 (m, 6H), 2.63 - 2.52 (m, 2H), 2.46 (s, 4H), 2.16 (d, J = 6.8 Hz, 2H), 2.10 - 1.91 (m, 3H), 1.70 (d, J = 11.6 Hz, 2H), 1.55 (d, J = 20.0 Hz, 7H), 1.09 (q, J = 10.8 Hz, 2H).

[0378] Example 2 Synthesis of MS-5-007 The reaction scheme for the synthesis of MS-5-007 is shown in FIG.

[0379] Procedure for the preparation of compound 57-3. A flask was purged with nitrogen and charged with a mixture of compound 57-1 (5 g, 25.38 mmol, 1 equiv.), compound 57-2 (5.12 g, 30.45 mmol, 1.2 equiv.), dioxane (80 mL), and HO (8 mL). To the solution was added KCO (7.72 g, 55.83 mmol, 2.2 equiv.) and Pd(dppf)Cl (1.86 g, 2.54 mmol, 0.1 equiv.). The reaction was stirred at 80 °C for 2 h. Brine (150 mL) and EtOAc (100 mL) were added to the reaction mixture, and the layers were separated. The aqueous layer was extracted with EtOAc (100 mL × 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO2, PE / EtOAc = 50 / 1 to 4 / 1) to give compound 57-3 (4.9 g, crude) as a yellow liquid. LCMS: t R = 0.363 min, MS (ESI+) m / z = 159.1 [M+1] + . 1 H NMR (400 MHz, CDCl3): δ = 7.32 (d, J = 8.8 Hz, 1H), 6.53 - 6.41 (m, 2H), 5.21 (m, 1H), 5.13 (s, 1H), 4.11 (s, 2H), 4.11 ( s, 2H),2.10 - 2.01 (m, 3H).

[0380] Procedure for the preparation of compound 57-4. A mixture of compound 57-3 (4.8 g, 30.34 mmol, 1 equiv.), Mn(dpm) (1.83 g, 3.03 mmol, 0.1 equiv.), and PhSiH (6.57 g, 60.68 mmol, 7.49 mL, 2 equiv.) in DCM (10 mL) and i-PrOH (200 mL) was degassed and purged with O (30.34 mmol, 1 equiv.) three times, and then the mixture was stirred at 0 °C under an atmosphere of O (30.34 mmol, 1 equiv.) (15 psi) for 2 h. The reaction mixture was quenched with 20% aqueous sodium sulfite solution. The organic volatiles were removed under reduced pressure. The aqueous mixture was extracted with EtOAc (50 mL × 3). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give compound 57-4 (5.8 g, crude) as a dark brown oil. LCMS: R =0.585 min, MS(ESI+)m / z=177.1[M+1] + .

[0381] Procedure for the preparation of compound 56-5. To a solution of compound 57-4 (5.8 g, 32.91 mmol, 1 equiv) in DMF (60 mL) and HO (60 mL) was added NaHCO (11.06 g, 131.66 mmol, 5.12 mL, 4 equiv). The mixture was stirred at 80 °C for 12 h. The reaction mixture was washed with brine (100 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 56-5 (1.3 g, 7.34 mmol, 22.29% yield) as a yellow oil. LCMS: t R = 0.375 min, MS (ESI+) m / z = 178.0 [M+1] + . 1 H NMR (400 MHz, CDCl3): δ = 7.63 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.52 (s, 1H), 4.26 (s, 2H), 1.61 (s, 6H).

[0382] Procedure for the preparation of compound 56-7. To a solution of compound 56-5 (500 mg, 2.82 mmol, 1 equiv.) and compound 56-6 (907.90 mg, 2.82 mmol, 1 equiv.) in NMP (3 mL) was added HCl / dioxane (4 M, 1.06 mL, 1.5 equiv.). The mixture was stirred at 80 °C for 12 h. The reaction was cooled to room temperature, quenched by the addition of triethylamine (1 mL), and diluted with EtOAc (20 mL) and ethanol (1 mL). The mixture was washed with brine (20 mL × 3), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 56-7 (1.13 g, 2.15 mmol, 76.20% yield) as a yellow solid. LCMS: t R = 0.445 min, MS (ESI+) m / z = 463.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.31 (s, 1H), 9.00 (d, J = 7.6 Hz, 1H), 8.68 (s, 1H), 7.95 (s, 1H), 7.73 - 7.56 (m, 2H), 7.44 - 7.35 (m, 4H), 7.30 - 7.20 (m, 1H), 5.38 - 5.27 (m, 1H), 5.19 (t, J = 4.8 Hz, 1H), 4.31 (m, 2H), 3.94 - 3.84 (m, 1H), 3.84 - 3.76 (m, 1H), 1.57 (s, 3H), 1.51 (s, 3H), 1.34 (t, J = 6.2 Hz, 3H).

[0383] Procedure for the preparation of compound 56-8. To a solution of compound 56-7 (1 g, 2.16 mmol, 1 equiv) in EtOH (50 mL) was slowly added N2H4·H2O (1.320 g, 26.37 mmol, 1.28 mL, 12.20 equiv) at 20 °C. The mixture was stirred at 70 °C for 3 h. After 36 h, N2H4·H2O (1.32 g, 26.38 mmol, 1.28 mL, 12.2 equiv) was added at 20 °C, and the mixture was stirred at 80 °C for 12 h. The residue was purified by preparative HPLC (10% to 40% ACN in water (0.05% HCl), 20 min) and lyophilized to give compound 56-8 (410 mg, 914.21 μmol, 42.28% yield) as a yellow solid. LCMS: t R =0.344 min, MS(ESI+)m / z=449.2[M+1] + .

[0384] Procedure for the preparation of compound 57-10. To a solution of compound 57-9 (273.27 mg, 1.00 mmol, 1.5 equiv) in DCM (10 mL), DCC (138.02 mg, 668.94 μmol, 135.31 μL, 1 equiv) and HOBt (90.39 mg, 668.94 μmol, 1 equiv) were added and stirred at 0 °C for 0.5 h. Compound 56-8 (300 mg, 668.94 μmol, 1 equiv) was then added to the reaction mixture, and the resulting mixture was warmed to 25 °C and stirred at 25 °C for another 1.5 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (DCM / MeOH = 100 / 1 to 10 / 1) to give compound 57-10 (240 mg, 341.49 μmol, 51.05% yield) as a yellow solid. LCMS: t R = 0.372 min, MS (ESI+) m / z = 703.5 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.25 - 10.08 (m, 2H), 9.83 - 9.72 (m, 1H), 9.54 (d, J = 8.3 Hz, 1H), 8.67 (s, 1H), 7.97 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.72 - 7.65 (m, 1H), 7.65 - 7.60 (m, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.34 - 7.21 (m, 3H), 5.34 - 5.25 (m, 1H), 5.15 (s, 1H), 4.21 - 4.00 (m, 3H), 3.89 - 3.73 (m, 3H), 3.17 (s, 6H), 2.29 (d, J = 2.8 Hz, 2H), 2.26 - 2.20 (m, 4H), 1.77 - 1.69 (m, 2H), 1.64 (dt, J = 4.4, 7.1 Hz, 2H), 1.40 (d, J = 1.5 Hz, 9H).

[0385] Procedure for the preparation of compound 57-11. To a solution of compound 57-10 (100 mg, 142.29 μmol, 1 equiv.) in DCM (2 mL), TosCl (27.13 mg, 142.29 μmol, 1 equiv.) followed by TEA (21.60 mg, 213.43 μmol, 29.71 μL, 1.5 equiv.) was added, and the mixture was stirred at 25° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (DCM / MeOH=100 / 1 to 10 / 1) to give compound 57-11 (70 mg, 102.22 μmol, 35.92% yield) as a yellow solid. LCMS: t R = 0.409 min, MS (ESI+) m / z = 685.5 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 8.98 (d, J = 4.4 Hz, 1H), 8.53 (s, 1H), 7.71 - 7.66 (m, 2H), 7.44 - 7.41 (m, 1H), 7.35 - 7.33 (m, 4H), 7.25 - 7.23 ( m, 1H), 5.49 - 5.44 (m, 1H), 3.98 (d, J = 5.2 Hz, 1H), 3.31 (s, 4H), 2.96 - 2.91 (m, 2H), 2.43 - 2.40 (m, 2H), 2.32 - 2.31 (m, 4H), 1.59 (d, J = 2.8 Hz, 1H), 1.38 (s, 9H), 1.18 - 0.80 (m, 3H), 0.78 - 0.76 (m, 4H).

[0386] Procedure for the preparation of compound 57-12. To a solution of compound 57-11 (60 mg, 87.62 μmol, 1 equiv.) in DCM (2 mL), HCl / dioxane (4 M, 43.81 μL, 2 equiv.) was added, and the mixture was stirred at 20° C. for 5 min. The reaction mixture was concentrated under reduced pressure to give compound 57-12 (60 mg, crude, HCl) as a white solid, which was used in the next step without further purification.

[0387] Procedure for the preparation of compound 57-16. A mixture of compound 57-15 (commercially available, 3 g, 10.86 mmol, 1 equiv.), compound 57-14 (2.20 g, 10.86 mmol, 2.26 mL, 1 equiv.), DIEA (4.21 g, 32.58 mmol, 5.68 mL, 3 equiv.), and DMAc (15 mL) was stirred at 90 °C for 2 h. Brine (50 mL) was added to the mixture. The mixture was extracted with ethyl acetate (50 mL × 3). The combined organic extracts were washed with brine (50 mL), dried, filtered, and concentrated. The residue was purified by flash silica gel chromatography (SiO2, PE / EA = 50 / 1 to 1 / 1) in petroleum ether to give compound 57-16 (2.7 g, 5.89 mmol, 54.22% yield) as a green oil. LCMS: t R= 0.469 min, MS (ESI+) m / z = 359.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.78 (d, J = 5.2 Hz, 1H), 6.53 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 12.8, 5.2 Hz, 1H), 3.28 (d, J = 6.4 Hz, 1H), 2.91 - 2.88 (m, 2H), 2.60 - 2.56 (m, 2H), 2.04 - 1.98 (m, 1H), 1.58 - 1.54 (m, 2H), 1.40 - 1.31 (m, 15H).

[0388] Procedure for the preparation of compound 57-17. To a solution of compound 57-16 (2.4 g, 5.23 mmol, 1 eq.) in DCM (15 mL) was added HCl / dioxane (4 M, 5.23 mL, 4 eq.). The mixture was stirred at 20° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 57-17 (1.34 g, 3.39 mmol, 64.83% yield, HCl) as a green solid. LCMS: t R = 0.459 min, MS (ESI+) m / z = 359.1 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 8.06 (s, 3H), 7.58 (dd, J = 8.8, 7.2 Hz, 1H), 7.20 - 6.97 (m, 2H), 5.04 (dd, J = 12.8, 5.2 Hz, 1H), 3.30 (t, J = 6.8 Hz, 2H), 2.92 - 2.83 (m, 1H), 2.77 - 2.70 (m, 2H), 2.65 - 2.56 (m, 1H), 2.53 (d, J = 4.4 Hz, 1H), 2.07 - 1.97 (m, 1H), 1.59 (m, 4H), 1.45 - 1.32 (m, 2H).

[0389] Procedure for the preparation of compound 57-13. To a solution of compound 57-18 (330 mg, 3.49 mmol, 392.86 μL, 1.38 equiv) in DMAc (10 mL) was added HATU (1.06 g, 2.79 mmol, 1.10 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h. To the cold solution, compound 57-17 (1.00 g, 2.53 mmol, 1 equiv, HCl) followed by DIEA (327.31 mg, 2.53 mmol, 441.12 μL, 1 equiv) were added. The reaction was stirred at 20 °C for 0.5 h. Brine (50 mL) and ethyl acetate (50 mL) were added to the reaction, and the layers were separated. The aqueous layer was extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine (50 mL × 2), dried, filtered, and concentrated. The residue was purified by preparative HPLC (22% to 52% ACN in water (0.225% FA), 20 min) and lyophilized to give compound 57-13 (380 mg, 873.82 μmol, 34.50% yield) as a yellow solid. LCMS: t R = 0.397 min, MS (ESI+) m / z = 435.0 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.09 (s, 1H), 8.19 (s, 1H), 7.59 (t, J = 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.54 (t, J = 6.0 Hz, 1H), 5.05 (d, J = 12.8, 5.2 Hz, 1H), 4.03 (s, 2H), 3.30 - 3.23 (m, 2H), 3.10 (m, 2H), 2.89 - 2.80 (m, 1H), 2.65 - 2.53 (m, 2H), 2.11 - 2.01 (m, 1H), 1.59 (m, 2H), 1.47 (m, 2H), 1.40 - 1.30 (m, 2H).

[0390] Procedure for the preparation of MS-5-007. To a solution of compound 57-12 (25 mg, 40.25 μmol, 1 equiv., HCl) in DMF (1 mL) was added DIEA (10.40 mg, 80.50 μmol, 14.02 μL, 2 equiv.) and compound 57-13 (17.50 mg, 40.25 μmol, 1 equiv.). The mixture was stirred at 50°C for 2 h. The residue was purified by preparative HPLC (20% to 50% ACN in water (0.225% FA), 9 min) and lyophilized to give MS-5-007 (13.13 mg, 11.84 μmol, 29.42% yield, 92.8% purity, FA) as a yellow solid. LCMS: t R = 0.426 min, MS (ESI+) m / z = 984.7 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 10.27 (s, 1H), 8.90 (d, J = 7.2 Hz, 1H), 8.65 (s, 1H), 8.23 ​​(s, 1H), 7.97 (d, J = 1.2 Hz, 1H), 7.73 - 7.68 (m, 1H), 7.65 - 7.55 (m, 3H), 7.43 - 7.34 (m, 4H), 7.29 - 7.23 (m, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 7.2 Hz, 1H), 6.54 - 6.49 (m, 1H), 5.43 (s, 1H), 5.23 (s, 1H), 5.04 (dd, J = 12.8, 5.2 Hz, 1H), 3.97 - 3.80 (m, 2H), 3.28 - 3.23 (m, 4H), 3.08 (d, J = 6.0 Hz, 2H), 2.94 (t, J = 6.4 Hz, 4H), 2.81 (s, 2H), 2.60 (d, J = 2.0 Hz, 2H), 2.39 (d, J = 6.4 Hz, 4H), 2.05 - 2.00 (m, 1H), 1.99 - 1.86 (m, 3H), 1.65 - 1.50 (m, 9H), 1.46 - 1.41 (m, 2H), 1.34 - 1.28 (m, 2H), 0.97 (s, 1H).

[0391] Example 3 Synthesis of MS-5-008

[0392] [ka]

[0393] The procedure for preparing 57-12 is described in the synthesis of MS-5-007. Procedure for the preparation of compound 58-10. A mixture of compound 57-15 (commercially available, 2 g, 7.24 mmol, 1 equiv.), compound 58-9 (1.77 g, 7.24 mmol, 1 equiv.), DIEA (2.81 g, 21.72 mmol, 3.78 mL, 3 equiv.), and DMAc (15 mL) was stirred at 90 °C for 12 h. LCMS (EC6213-3-P1B) showed the desired mass. Brine (50 mL) was added to the mixture. The mixture was extracted with ethyl acetate (50 mL × 3), and the combined organic layers were washed with brine (50 mL), dried, filtered, and concentrated. The crude product was purified by flash column chromatography (premixed solvent: 12% ethyl acetate / ethanol in petroleum ether (ratio: 3:1)) to give compound 58-10 (1.7 g, 3.40 mmol, 46.90% yield) as a green oil. LCMS:t R =0.528 min, MS(ESI+)m / z=501.2[M+1] + .

[0394] Procedure for the preparation of compound 58-11. To a solution of compound 58-10 (1.5 g, 3.00 mmol, 1 eq) in DCM (9 mL) was added HCl / dioxane (4 M, 3.00 mL, 4 eq). The mixture was stirred at 20 °C for 1 h. LCMS showed that the reactants were consumed and the desired mass was detected. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 58-11 (0.75 g, 1.72 mmol, 57.28% yield, HCl) as a green solid. LCMS: t R = 0.349 min, MS (ESI+) m / z = 401.2[M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 7.92 (s, 3H), 7.58 (dd, J = 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 5.05 (d, J = 7.6 Hz, 1H), 3.29 (t, J = 6.8 Hz, 2H), 2.92 - 2.82 (m, 1H), 2.77 - 2.67 (m, 2H), 2.64 - 2.55 (m, 1H), 2.53 (d, J = 5.6 Hz, 1H), 2.08 - 1.99 (m, 1H), 1.56 (m, 4H), 1.40 - 1.27 (m, 8H).

[0395] Procedure for the preparation of compound 58-7. To a solution of chloroacetic acid (182 mg, 1.93 mmol, 216.67 μL, 1.20 equiv) in DMAC (7 mL) was added HATU (664 mg, 1.75 mmol, 1.09 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h. Then compound 58-11 (700 mg, 1.60 mmol, 1 equiv, HCl) followed by DIEA (207.05 mg, 1.60 mmol, 279.05 μL, 1 equiv) were added. The reaction was stirred at 20 °C for 0.5 h. Brine (50 mL) and ethyl acetate (50 mL) were added to the reaction, and the layers were separated. The aqueous layer was extracted with ethyl acetate (30 mL × 2). The combined organic extracts were washed with brine (50 mL × 2), dried, filtered, and concentrated. The residue was purified by preparative HPLC (33% to 63% ACN in water (0.225% FA), 20 min) and lyophilized to give compound 58-7 (320 mg, 670.93 μmol, 41.88% yield) as a yellow solid. LCMS: t R = 0.462 min, MS (ESI+) m / z = 477.2[M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.09 (s, 1H), 8.16 (s, 1H), 7.59 (t, J = 8.0 Hz, 1H), 7.23 - 6.82 (m, 2H), 6.52 (t, J = 5.6 Hz, 1H), 5.05 (dd, J =12.8, 5.2 Hz, 1H), 4.02 (s, 2H), 3.29 (s, 2H), 3.07 (m, 2H), 2.96 - 2.78 (m, 1H), 2.65 - 2.54 (m, 2H), 2.10 - 2.01 (m, 1H), 1.67 - 1.51 (m, 2H), 1.44 - 1.24 (m, 10H).

[0396] Procedure for the preparation of compound MS-5-008. To a solution of compound 58-6 (26.05 mg, 41.93 μmol, 1 equiv., HCl) in DMF (2 mL), DIEA (16.26 mg, 125.80 μmol, 21.91 μL, 3 equiv.) and compound 58-7 (20 mg, 41.93 μmol, 1 equiv.) were added, and the mixture was stirred at 90° C. for 3 h. LCMS showed the desired m / z. The reaction mixture was filtered to obtain a residue. The residue was purified by preparative HPLC (26% to 56% ACN in water (0.225% FA), 9 min) to obtain compound MS-5-008 (9.75 mg, 8.94 μmol, 21.32% yield, 94% purity) as a yellow solid. LCMS: t R = 0.448 min, MS (ESI+) m / z = 1025.5[M+1] + . 1H NMR (400 MHz, DMSO-d6):δ = 11.09 (s, 1H), 10.27 (s, 1H), 8.91 (d, J = 8.0 Hz, 1H), 8.65 (s, 1H), 8.14 (s, 1H), 7.97 (s, 1H), 7.75 - 7.69 (m, 1H), 7.66 - 7.54 (m, 3H), 7.44 - 7.34 (m, 4H), 7.30 - 7.23 (m, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 6.8 Hz, 1H), 6.59 - 6.42 (m, 1H), 5.52 - 5.37 (m, 1H), 5.32 - 5.19 (m, 1H), 5.05 (dd, J = 5.6, 12.8 Hz, 1H), 3.97 - 3.89 (m, 1H), 3.88 - 3.81 (m, 1H), 3.10 - 3.01 (m, 3H), 2.95 (t, J = 7.2 Hz, 3H), 2.84 (s, 2H), 2.44 - 2.37 (m, 6H), 2.08 - 1.88 (m, 4H), 1.65 - 1.50 (m, 9H), 1.45 - 1.15 (m, 13H).

[0397] Example 4 Synthesis of MS-5-009

[0398] [ka]

[0399] The procedure for preparing 56-8 is described in the synthesis of MS-5-006. Procedure for the preparation of compound 59-3. To a solution of compound 59-2 (270.75 mg, 1.17 mmol, 1.5 eq) in DCM (10.5 mL) was added DCC (161.02 mg, 780.43 μmol, 157.87 μL, 1 eq) and HOBt (105.45 mg, 780.43 μmol, 1 eq) at 0° C. for 0.5 hours, and then compound 56-8 (350 mg, 780.43 μmol, 1 eq) was added. The mixture was stirred at 20° C. for 11.5 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (26% to 56% ACN in water (0.05% HCl), 10 min) and lyophilized to give compound 59-3 (135 mg, 204.01 μmol, 26.14% yield) as a dark brown solid. LCMS (EC6212-53-P1B): t R = 0.428 min, MS (ESI+) m / z = 662.2 [M+1] + . 1 H NMR (EC6212-53-P1A) (400 MHz, DMSO-d6): δ = 10.41 - 10.18 (m, 2H), 9.81 (s, 1H), 9.67 (d, J = 7.6 Hz, 1H), 8.67 (s, 1H), 7.94 (s, 1H), 7.76 - 7.57 (m, 2H), 7.47 - 7.31 (m, 4H), 7.26 (m, 1H), 6.79 ( s, 1H), 5.29 (m, 1H), 3.83 (d, J = 4.4 Hz, 1H), 3.79 - 3.74 (m, 1H), 2.91 (q, J = 6.4 Hz, 2H), 2.19 (t, J = 7.2 Hz, 2H), 1.56 (d, J = 16.0 Hz, 8H), 1.46 - 1.22 (m, 13H).

[0400] Procedure for the preparation of compound 59-4. To a solution of compound 59-3 (135 mg, 204.01 μmol, 1 equiv.) in DCM (1.5 mL), TsCl (38.89 mg, 204.01 μmol, 1 equiv.) and TEA (30.96 mg, 306.01 μmol, 42.59 μL, 1.5 equiv.) were added. The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (50% to 80% ACN in water (0.05% HCl), 8 min) and lyophilized to give compound 59-4 (174 mg, crude) as a yellow solid. LCMS: t R = 0.506 min, MS (ESI+) m / z = 644.2 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.32 (s, 1H), 8.93 (d, J = 7.6 Hz, 1H), 8.69 (s, 1H), 8.02 (s, 1H), 7.80 - 7.71 (m, 1H), 7.71 - 7.63 (m, 1H), 7.53 - 7.37 (m, 4H), 7.36 - 7.25 (m, 1H), 6.83 (t, J = 5.2 Hz, 1H), 5.53 - 5.43 (m, 1H), 5.27 (t, J = 4.8 Hz, 1H), 4.01 - 3.85 (m, 2H), 3.05 - 2.92 (m, 4H), 1.82 (m, 2H), 1.60 (d, J = 19.6 Hz, 6H), 1.50 - 1.35 (m, 13H).

[0401] Procedure for the preparation of compound 59-5. To a solution of compound 59-4 (90 mg, 139.81 μmol, 1 eq.) in DCM (1 mL) was added HCl / dioxane (4 M, 139.81 μL, 4 eq.). The mixture was stirred at 25° C. for 0.5 h. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 59-5 (76 mg, crude, HCl) as a yellow solid. LCMS: R =0.375 min, MS(ESI+)m / z=544.2[M+1] + .

[0402] Procedure for the preparation of MS-5-009. To a solution of compound 59-5 (76 mg, 131.02 μmol, 1 equiv., HCl) and compound 57-15 (40.40 mg, 146.27 μmol, 1 equiv.) in DMAc (3 mL) was added DIEA (50.80 mg, 393.05 μmol, 68.46 μL, 3 equiv.). The mixture was stirred at 90°C for 3 h. The residue was purified by preparative HPLC (46% to 76% ACN in water (0.225% FA), 9 min) and lyophilized to give MS-5-009 (22.64 mg, 26.75 μmol, 20.42% yield, 94.5% purity) as a yellow solid. LCMS: t R = 0.675 min, MS (ESI+) m / z = 800.4 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 10.27 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.64 (s, 1H), 7.98 (d, J = 1.2 Hz, 1H), 7.74 - 7.68 (m, 1H), 7.67 - 7.62 (m, 1H), 7.58 (dd, J = 8.4, 6.2 Hz, 1H), 7.44 - 7.33 (m, 4H), 7.31 - 7.23 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 6.8 Hz, 1H), 6.58 (t, J = 6.0 Hz, 1H), 5.47 - 5.39 (m, 1H), 5.22 (t, J = 4.8 Hz, 1H), 5.04 (dd, J = 12.8, 5.2 Hz, 1H), 3.97 - 3.88 (m, 1H), 3.87 - 3.80 (m, 1H), 3.39 - 3.33 (m, 2H), 3.04 - 2.94 (m, 2H), 2.92 - 2.82 (m, 1H), 2.59 (d, J = 2.4 Hz, 2H), 2.06 - 1.98 (m, 1H), 1.84 (m, 2H), 1.71 - 1.61 (m, 2H), 1.58 (s, 3H), 1.53 (s, 3H), 1.51 - 1.44 (m, 2H).

[0403] Example 5 Synthesis of MS-5-010

[0404] [ka]

[0405] The procedure for preparing 56-8 is described in the synthesis of MS-5-006. Procedure for the preparation of compound 510-3. To a solution of compound 510-2 (191.45 mg, 780.43 μmol, 1 equiv.) in DCM (10 mL), DCC (161.02 mg, 780.43 μmol, 157.87 μL, 1 equiv.) and HOBt (105.45 mg, 780.43 μmol, 1 equiv.) were added, and the mixture was stirred at 0° C. for 0.5 h. Compound 56-8 (350 mg, 780.43 μmol, 1 equiv.) was then added, and the mixture was warmed to 25° C. and stirred at 25° C. for an additional 1.5 h. The reaction mixture was filtered. The residue was purified by preparative TLC (SiO, ethyl acetate) to give compound 510-3 (200 mg, 295.96 μmol, 37.92% yield) as a brown solid. LCMS: t R = 0.442 min, MS (ESI+) m / z = 676.2[M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.18 (s, 1H), 10.14 (s, 1H), 9.76 (s, 1H), 9.54 (d, J = 8.0 Hz, 1H), 8.67 (s, 1H), 7.96 (d, J = 1.2 Hz, 1H), 7.76 - 7.59 (m, 2H), 7.46 - 7.20 (m, 5H), 6.84 - 6.71 (m, 1H), 5.37 - 5.24 (m, 1H), 5.14 (t, J = 4.8 Hz, 1H), 3.93 - 3.68 (m, 2H), 2.91 (q, J = 6.8 Hz, 2H), 2.19 (t, J = 7.2 Hz, 2H), 1.76 - 1.63 (m, 1H), 1.56 (d, J = 18.4 Hz, 9H), 1.38 (s, 9H), 1.34 - 1.24 (m, 5H).

[0406] Procedure for the preparation of compound 510-4. To a mixture of compound 510-3 (190 mg, 281.16 μmol, 1 equiv.) and TosCl (53.60 mg, 281.16 μmol, 1 equiv.) in DCM (4 mL), TEA (42.68 mg, 421.74 μmol, 58.70 μL, 1.5 equiv.) was added, and the mixture was stirred at 25° C. for 1 h. The reaction mixture was filtered. The residue was purified by preparative TLC (EtOAc) to give compound 510-4 (100 mg, 152.03 μmol, 54.07% yield) as a brown solid. LCMS: t R = 0.516 min, MS (ESI+) m / z = 658.1[M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.38 (s, 1H), 8.98 (d, J = 7.6 Hz, 1H), 8.73 (s, 1H), 8.07 (s, 1H), 7.85 - 7.69 (m, 2H), 7.53 - 7.42 (m, 4H), 7.39 - 7.28 (m, 1H), 6.91 - 6.80 (m, 1H), 5.52 (td, J = 4.4, 7.6 Hz, 1H), 5.32 (t, J = 4.9 Hz, 1H), 4.09 - 3.84 (m, 2H), 3.09 - 2.92 (m, 4H), 1.86 (quintet, J = 7.2 Hz, 3H), 1.67 (s, 3H), 1.62 (s, 3H), 1.51 - 1.43 (m, 14H).

[0407] Procedure for the preparation of compound 510-5. To a solution of compound 510-4 (90 mg, 136.83 μmol, 1 equiv.) in DCM (2 mL), HCl / dioxane (4 M, 2 mL, 58.47 equiv.) was added, and the mixture was stirred at 20° C. for 2 hours. The reaction mixture was concentrated to give compound 510-5 (80 mg, 134.66 μmol, 98.41% yield, HCl) as a white solid, which was used in the next step without further purification. LCMS: t R =0.379 min, MS(ESI+)m / z=558.2[M+1] + .

[0408] Procedure for the preparation of MS-5-010. To a solution of compound 510-6 (36.10 mg, 130.69 μmol, 1 equiv.) and compound 510-5 (80 mg, 134.66 μmol, 1.03 equiv., HCl) in DMAc (3 mL), DIEA (50.67 mg, 392.07 μmol, 68.29 μL, 3 equiv.) was added, and the mixture was stirred at 90 °C for 12 h. The mixture was filtered and purified by preparative HPLC (49% to 79% ACN in water (0.225% FA), 10 min) to give MS-5-010 (FA salt, 7.03 mg, 8.32 μmol, 6.37% yield, 96.34% purity) as a yellow solid. LCMS: t R= 0.510 min, MS (ESI+) m / z = 814.2[M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.09 (s, 1H), 10.29 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.65 (s, 1H), 8.41 (s, 1H), 7.98 (s, 1H), 7.73 - 7.69 (m, 1H), 7.66 - 7.62 (m, 1H), 7.61 - 7.55 (m, 1H), 7.43 - 7.35 (m, 4H), 7.30 - 7.24 (m, 1H), 7.11 (d, J = 8.8 Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.56 (t, J = 5.6 Hz, 1H), 5.48 - 5.40 (m, 1H), 5.24 (t, J = 4.8 Hz, 1H), 5.05 (dd, J = 12.8, 5.2 Hz, 1H), 3.98 - 3.78 (m, 2H), 3.01 - 2.82 (m, 4H), 2.61 (d, J = 2.4 Hz, 2H), 2.07 - 2.01 (m, 1H), 1.85 - 1.78 (m, 2H), 1.66 - 1.57 (m, 6H), 1.54 (s, 3H), 1.48 - 1.41 (m, 4H).

[0409] Example 6 Synthesis of MS-5-011

[0410] [ka]

[0411] The procedure for preparing 56-8 is described in the synthesis of MS-5-006. Procedure for the preparation of compound 511-3. To a solution of compound 511-2 (320.01 mg, 1.17 mmol, 1.5 eq) in DCM (10.5 mL) was added DCC (161.02 mg, 780.43 μmol, 157.87 μL, 1 eq) and HOBt (105.45 mg, 780.43 μmol, 1 eq) at 0° C. for 0.5 hours, and then compound 56-8 (350 mg, 780.43 μmol, 1 eq) was added. The mixture was stirred at 20° C. for 11.5 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (33% to 63% ACN in water (0.05% HCl), 10 min) and lyophilized to give compound 511-3 (344 mg, 488.76 μmol, 62.63% yield) as a dark brown solid. LCMS: t R = 0.469 min, MS (ESI+) m / z = 704.2 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.46 - 10.15 (m, 2H), 9.80 (s, 1H), 9.70 (d, J = 7.6 Hz, 1H), 8.67 (s, 1H), 7.93 (s, 1H), 7.71 - 7.60 (m, 2H), 7.48 - 7.31 (m, 4H), 7.30 - 7.19 (m, 1H), 6.75 (br s, 1H), 5.28 (m, 1H), 3.83 (d, J = 6.4 Hz, 1H), 3.78 - 3.73 (m, 1H), 2.91 - 2.87 (m, 2H), 2.20 - 2.17 (m, 2H), 1.58 (s, 3H), 1.54 (s, 3H), 1.37 (s, 15H), 1.24 (d, J = 10.8 Hz, 6H).

[0412] Procedure for the preparation of compound 511-4. To a solution of compound 511-3 (340 mg, 483.07 μmol, 1 equiv.) in DCM (6.5 mL) was added TsCl (92.10 mg, 483.07 μmol, 1 equiv.) and TEA (73.32 mg, 724.61 μmol, 100.86 μL, 1.5 equiv.). The mixture was stirred at 20° C. for 1 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (51% to 81% ACN in water (0.05% HCl), 8 min) and lyophilized to give compound 511-4 (90 mg, 131.23 μmol, 27.17% yield) as a yellow solid. LCMS: t R = 0.547 min, MS (ESI+) m / z = 686.1 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.29 (s, 1H), 8.89 (d, J = 7.6 Hz, 1H), 8.65 (s, 1H), 7.99 (s, 1H), 7.77 - 7.68 (m, 1H), 7.67 - 7.60 (m, 1H), 7.48 - 7.33 (m, 4H), 7.31 - 7.24 (m, 1H), 6.75 (s, 1H), 5.49 - 5.40 (m, 1H), 5.24 (t, J = 4.8 Hz, 1H), 3.98 - 3.80 (m, 2H), 3.01 - 2.84 (m, 4H), 1.78 (td, J = 7.3, 14.4 Hz, 2H), 1.56 (d, J = 19.5 Hz, 6H), 1.49 - 1.17 (m, 19H).

[0413] Procedure for the preparation of compound 511-5. To a solution of compound 511-4 (90 mg, 131.23 μmol, 1 eq.) in DCM (1 mL) was added HCl / dioxane (4 M, 131.23 μL, 4 eq.). The mixture was stirred at 25° C. for 0.5 h. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 511-5 (91 mg, crude, HCl) as a yellow solid. LCMS (EC6212-71-P1B): R =0.410 min, MS(ESI+)m / z=586.2[M+1]+ .

[0414] Procedure for the preparation of MS-5-011. To a solution of compound 511-5 (91 mg, 146.27 μmol, 1 equiv., HCl) and compound 57-15 (40.40 mg, 146.27 μmol, 1 equiv.) in DMAc (4 mL) was added DIEA (56.71 mg, 438.80 μmol, 76.43 μL, 3 equiv.). The mixture was stirred at 90°C for 3 h. The residue was purified by preparative HPLC (52% to 82% ACN in water (0.225% FA), 9 min) and lyophilized to give MS-5-011 (2.67 mg, 3.08 μmol, 2.11% yield, 97.09% purity) as a yellow solid. LCMS: t R = 0.536 min, MS (ESI+) m / z = 842.2 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 10.28 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.64 (s, 1H), 7.97 (s, 1H), 7.73 - 7.69 (m, 1H), 7.65 - 7.61 (m, 1H), 7.60 - 7.54 (m, 1H), 7.44 - 7.34 (m, 4H), 7.29 - 7.23 (m, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 6.8 Hz, 1H), 6.55 - 6.49 (m, 1H), 5.46 - 5.40 (m, 1H), 5.24 - 5.20 (m, 1H), 5.04 (dd, J =12.4, 4.8 Hz, 1H), 3.95 - 3.88 (m, 1H), 3.84 (dd, J = 10.4, 4.8 Hz, 1H), 3.29 - 3.25 (m, 2H), 2.97 - 2.91 (m, 2H), 2.90 - 2.81 (m, 1H), 2.60 (s, 2H), 2.05 - 2.00 (m, 1H), 1.81 - 1.75 (m, 2H), 1.55 (d, J = 19.6 Hz, 8H), 1.45 - 1.33 (m, 8H).

[0415] Example 7 Synthesis of MS-5-015

[0416] [ka]

[0417] The procedure for preparing 56-8 is described in the synthesis of MS-5-006. Procedure for the preparation of compound 515-3. To a solution of compound 515-2 (1.27 g, 6.69 mmol, 1 equiv.) in DCM (30 mL) was added EDCI (1.28 g, 6.69 mmol, 1 equiv.), HOBt (903.89 mg, 6.69 mmol, 1 equiv.), and TEA (744.58 mg, 7.36 mmol, 1.02 mL, 1.1 equiv.) at 0 °C for 0.5 h. Compound 56-8 (3 g, 6.69 mmol, 1 equiv.) was then added, and the mixture was stirred at 25 °C for 1.5 h. The reaction mixture was partitioned between DCM (50 mL) and water (50 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by preparative HPLC (FA conditions) and lyophilized to give compound 515-3 (1.48 g, 2.32 mmol, yield 34.68%, purity 97%) as a white solid. LCMS: t R = 0.408 min, MS (ESI+) m / z = 620.3 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.45 - 10.00 (m, 2H), 9.84 (s, 1H), 8.66 (s, 1H), 7.96 (s, 1H), 7.75 - 7.65 (m, 1H), 7.64 - 7.56 (m, 1H), 7.37 - 7.34 (m, 3H), 7.25 (m, 1H), 6.81 (t, J = 5.2 Hz, 1H), 5.36 - 5.23 (m, 1H), 5.15 (t, J = 4.8 Hz, 1H), 3.89 - 3.79 (m, 1H), 3.79 - 3.68 (m, 1H), 3.25 - 3.08 (m, 2H), 2.37 (t, J = 7.6 Hz, 2H), 1.57 (s, 3H), 1.53 (s, 3H), 1.39 (s, 9H).

[0418] Procedure for the preparation of compound 515-4. To a solution of compound 515-3 (1.4 g, 2.26 mmol, 1 equiv) in DCM (14 mL) was added TsCl (473.80 mg, 2.49 mmol, 1.1 equiv) and TEA (342.92 mg, 3.39 mmol, 471.69 μL, 1.5 equiv). The mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between EtOAc (30 mL) and water (30 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 515-4 (860 mg, 1.43 mmol, 63.27% yield) as a colorless solid. LCMS: t R = 0.468 min, MS (ESI+) m / z = 602.2 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ= 10.31 (s, 1H), 8.88 (d, J = 8.0 Hz, 1H), 8.64 (s, 1H), 7.98 (s, 1H), 7.75 - 7.67 (m, 1H), 7.67 - 7.60 (m, 1H), 7.45 - 7.32 (m, 4H), 7.31 - 7.23 (m, 1H), 7.08 (t, J = 5.6 Hz, 1H), 5.43 (m, 1H), 5.24 (t, J = 4.8 Hz, 1H), 3.98 - 3.88 (m, 1H), 3.87 - 3.78 (m, 1H), 3.42 - 3.35 (m, 2H), 3.11 - 2.99 (m, 2H), 1.58 (s, 3H), 1.53 (s, 3H), 1.36 (s, 9H).

[0419] Procedure for the preparation of compound 515-5. To a solution of compound 515-2 (860 mg, 1.43 mmol, 1 eq.) in DCM (10 mL) was added HCl / dioxane (4 M, 1.43 mL, 4 eq.). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 515-3 (2.2 g, crude) as a yellow solid. LCMS: t R = 0.357 min, MS (ESI+) m / z = 502.0[M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ= 10.55 (s, 1H), 9.03 (d, J = 8.0 Hz, 1H), 8.74 (s, 1H), 8.33 (s, 3H), 7.95 (s, 1H), 7.76 - 7.63 (m, 2H), 7.42 - 7.34 (m, 4H), 7.30 - 7.22 (m, 1H), 5.53 - 5.36 (m, 1H), 5.33 - 5.20 (m, 1H), 3.97 - 3.88 (m, 1H), 3.88 - 3.80 (m, 1H), 3.44 - 3.21 (m, 4H), 1.58 (s, 3H), 1.53 (s, 3H).

[0420] Procedure for the preparation of compound 515-7. To a solution of compound 515-5 (500 mg, 929.37 μmol, 1 equiv., HCl) and compound 515-6 (118.35 mg, 743.50 μmol, 0.8 equiv.) in THF (5 mL), HOAc (167.43 mg, 2.79 mmol, 159.46 μL, 3 equiv.) and borane; 2-methylpyridine (198.81 mg, 1.86 mmol, 2 equiv.) were added, and the mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched by the addition of ACN (20 mL) and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (12% to 42% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 515-7 (1.52 g, crude) as a yellow solid. LCMS: t R = 0.394 min, MS (ESI+) m / z = 645.2 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.30 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.78 - 8.53 (m, 1H), 8.19 (s, 1H), 7.98 (s, 1H), 7.82 - 7.68 (m, 1H), 7.67 - 7.57 (m, 1H), 7.48 - 7.33 (m, 4H), 7.31 - 7.06 (m, 1H), 6.74 (t, J = 5.2 Hz, 1H), 5.51 - 5.38 (m, 1H), 5.27 (s, 1H), 3.94 - 3.89 (m, 1H), 3.85 - 3.82 (m, 1H), 3.13 - 2.96 (m, 6H), 2.60 (t, J = 6.4 Hz, 2H), 1.67 - 1.48 (m, 6H), 1.35 (s, 9H).

[0421] Procedure for the preparation of compound 515-8. To a solution of compound 515-7 (117 mg, 181.47 μmol, 1 eq.) in DCM (1 mL), HCl / dioxane (4 M, 136.11 μL, 3 eq.) was added. The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 515-8 (108 mg, crude, HCl) as a dark brown solid. LCMS: R =0.329 min, MS(ESI+)m / z=545.2[M+1] + .

[0422] Procedure for the preparation of MS-5-015. To a solution of compound 515-8 (108 mg, 185.87 μmol, 1 equiv., HCl) and compound 57-15 (51.34 mg, 185.87 μmol, 1 equiv.) in DMAC (1 mL) was added DIEA (48.04 mg, 371.73 μmol, 64.75 μL, 2 equiv.). The mixture was stirred at 100° C. for 12 h. The residue was purified by preparative HPLC (16% to 46% ACN in water (0.05% HCl), 8 min) and lyophilized to give MS-5-015 (2.59 mg, 2.47 μmol, 1.33% yield, 76.38% purity) as a yellow solid. LCMS: t R = 1.236 min, MS (ESI+) m / z = 801.4 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.07 ( s, 1H), 10.26 (s, 1H), 8.88 (d, J = 6.0 Hz, 1H), 8.63 (d, J = 3.2 Hz, 1H), 7.97 (s, 1H), 7.77 - 7.67 (m, 1H), 7.66 - 7.61 (m, 1H), 7.60 - 7.52 (m, 1H), 7.46 - 7.32 (m, 4H), 7.30 - 7.22 (m, 1H), 7.11 (d, J = 8.8 Hz, 1H), 7.01 (d, J = 7.2 Hz, 1H), 6.83 - 6.66 (m, 1H), 5.51 - 5.34 (m, 1H), 5.28 - 5.16 (m, 1H), 4.99 (dd, J = 12.8, 5.2 Hz, 1H), 3.98 - 3.87 (m, 1H), 3.87 - 3.78 (m, 1H), 3.09 (d, J = 4.4 Hz, 4H), 3.02 - 2.70 (m, 4H), 2.08 - 1.85 (m, 2H), 1.58 (s, 3H), 1.53 (s, 3H).

[0423] Example 8 Synthesis of MS-5-016 The reaction scheme for the synthesis of MS-5-016 is shown in FIG. The procedure for preparing 56-8 is described in the synthesis of MS-5-006.

[0424] Procedure for the preparation of compound 516-13. Compound 516-10 (20 g, 190.23 mmol, 19.05 mL, 1 equiv) and compound 516-11 (30.99 g, 209.25 mmol, 1.1 equiv) were dissolved in toluene (150 mL). The mixture was stirred at 130 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give compound 516-12 (49.51 g, crude) as a yellow oil. LCMS: t R = 0.278 min, MS (ESI+) m / z = 235.8 [M+1] + . 1H NMR (400 MHz, CDCl3): δ = 7.87 (dd, J = 5.2, 2.8 Hz, 2H), 7.74 (dd, J =5.2, 2.8 Hz, 2H), 3.98 - 3.89 (m, 2H), 3.82 - 3.74 (m, 2H), 3.72 - 3.67 (m, 2H), 3.65 - 3.40 (m, 2H).

[0425] Procedure for the preparation of compound 516-7. To a solution of compound 516-12 (1 g, 4.25 mmol, 1 equiv) in DCM (15 mL) was added Dess-Martin (2.34 g, 5.53 mmol, 1.71 mL, 1.3 equiv). The mixture was stirred at 25 °C for 1 hour. Water (20 mL) was added to the mixture. The mixture was extracted with ethyl acetate (20 mL x 3). The combined organic extracts were washed with brine (50 mL x 3), dried, filtered, and concentrated to give compound 516-7 (523 mg, crude) as a colorless oil. LCMS: t R = 0.258 min, MS (ESI+) m / z = 233.8 [M+1] + . 1 H NMR (400 MHz, CDCl3): δ= 9.68 (s, 1H), 7.89 (dd, J = 5.2, 2.8 Hz, 2H), 7.75 (dd, J = 5.6, 2.8 Hz, 2H), 4.14 (s, 2H), 4.00 - 3.96 (m, 2H), 3.87 - 3.82 (m, 2H).

[0426] Procedure for the preparation of compound 516-3. To a solution of compound 516-2 (1.27 g, 6.69 mmol, 1 equiv.) in DCM (30 mL) was added EDCI (1.28 g, 6.69 mmol, 1 equiv.), HOBt (903.89 mg, 6.69 mmol, 1 equiv.), and TEA (744.58 mg, 7.36 mmol, 1.02 mL, 1.1 equiv.) at 0 °C for 0.5 h. Compound 56-8 (3 g, 6.69 mmol, 1 equiv.) was then added, and the mixture was stirred at 25 °C for 1.5 h. The reaction mixture was partitioned between DCM (50 mL) and water (50 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by preparative HPLC (FA conditions) and lyophilized to give compound 516-3 (2.2 g, crude) as a yellow solid. LCMS(EC6212-103-P1A):t R =0.476 min, MS(ESI+)m / z=791.3[M+1] + .

[0427] Procedure for the preparation of compound 516-4. To a solution of compound 516-3 (2.2 g, 2.78 mmol, 1 equiv) in DCM (22 mL) was added TosCl (583.37 mg, 3.06 mmol, 1.1 equiv) and TEA (422.23 mg, 4.17 mmol, 580.78 μL, 1.5 equiv). The mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between DCM (30 mL × 2) and water (30 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 516-4 (1.52 g, crude) as a yellow solid. LCMS: t R =0.534 min, MS(ESI+)m / z=773.4[M+1] + .

[0428] Procedure for the preparation of compound 516-5. To a solution of compound 516-4 (1.5 g, 1.94 mmol, 1 equiv.) in EtOH (15 mL), NaOH (2 M, 1.94 mL, 2 equiv.) was added. The mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between EtOAc (30 mL × 2) and water (30 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO2, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 516-5 (800 mg, 1.33 mmol, 68.51% yield) as a yellow solid. LCMS (EC6212-141-P1B): t R =0.462 min, MS(ESI+)m / z=602.1[M+1] + .

[0429] Procedure for the preparation of compound 516-6. To a solution of compound 516-5 (800 mg, 1.33 mmol, 1 eq.) in DCM (8 mL) was added HCl / dioxane (4 M, 1.33 mL, 4 eq.). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 516-6 (647 mg, crude, HCl) as a yellow solid. LCMS: t R = 0.355 min, MS (ESI+) m / z = 502.2 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.58 ( s, 1H), 9.05 (d, J = 7.6 Hz, 1H), 8.75 (s, 1H), 8.36 (s, 3H), 7.95 (s, 1H), 7.74 - 7.61 (m, 2H), 7.42 - 7.34 (m, 4H), 7.30 - 7.23 (m, 1H), 5.49 - 5.39 (m, 1H), 5.36 - 5.19 (m, 1H), 3.97 - 3.89 (m, 1H), 3.87 - 3.81 (m, 1H), 3.41 - 3.24 (m, 4H), 1.59 (s, 3H), 1.54 (s, 3H).

[0430] Procedure for the preparation of compound 516-8. To a solution of compound 516-6 (130 mg, 211.19 μmol, 1 equiv., TFA) and compound 516-7 (49.25 mg, 211.19 μmol, 1 equiv.) in MeOH (3 mL) was added, and the mixture was stirred at 25° C. for 1 h. NaBH(OAc) (134.28 mg, 633.57 μmol, 3 equiv.) was then added. The mixture was stirred at 25° C. for 1 h. The residue was purified by preparative HPLC (22% to 52% ACN in water (0.1% TFA), 10 min) and lyophilized to give compound 516-8 (32 mg, 44.52 μmol, 21.08% yield) as a white solid. LCMS: t R = 0.389 min, MS (ESI+) m / z = 719.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 10.31 (s, 1H), 8.87 (d, J = 8.0 Hz, 1H), 8.70 - 8.57 (m, 3H), 7.95 (s, 1H), 7.90 - 7.80 (m, 4H), 7.75 - 7.69 (m, 1H), 7.68 - 7.62 (m, 1H), 7.44 - 7.32 (m, 4H), 7.31 - 7.23 (m, 1H), 5.53 - 5.34 (m, 1H), 3.98 - 3.85 (m, 2H), 3.81 (t, J = 5.6 Hz, 2H), 3.75 - 3.70 (m, 4H), 3.45 (d, J = 5.6 Hz, 2H), 3.33 (d, J = 6.8 Hz, 2H), 3.22 (d, J = 4.4 Hz, 2H), 1.58 (s, 3H), 1.53 (s, 3H).

[0431] Procedure for the preparation of compound 516-9. To a solution of compound 516-8 (27 mg, 37.56 μmol, 1 equiv) in EtOH (1 mL) was added N2H4·H2O (0.020 g, 399.52 μmol, 19.42 μL, 10.64 equiv). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give compound 516-8 (38 mg, crude) as a white solid. LCMS: R=0.314 min, MS(ESI+)m / z=589.2[M+1] + .

[0432] Procedure for the preparation of MS-5-016. To a solution of compound 516-9 (38 mg, 64.55 μmol, 1 equiv.) and compound 57-15 (53.49 mg, 193.66 μmol, 3 equiv.) in DMAC (1 mL) was added DIEA (25.03 mg, 193.66 μmol, 33.73 μL, 3 equiv.). The mixture was stirred at 110 °C for 1 h. The residue was purified by preparative HPLC (18% to 48% ACN in water (0.225% FA), 9 min) and preparative HPLC (26% to 26% ACN in water (10 mM NH4HCO3), 2 min) and lyophilized to give MS-5-016 (2.06 mg, 2.19 μmol, 3.40% yield, 90% purity) as a yellow solid. LCMS: t R = 1.829 min, MS (ESI+) m / z = 845.3 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.08 ( s, 1H), 10.26 (s, 1H), 8.87 (d, J = 7.6 Hz, 1H), 8.62 (s, 1H), 7.97 (s, 1H), 7.73 - 7.67 (m, 1H), 7.66 - 7.61 (m, 1H), 7.56 - 7.51 (m, 1H), 7.42 - 7.33 (m, 4H), 7.29 - 7.23 (m, 1H), 7.10 (d, J = 7.2 Hz, 1H), 7.00 (d, J = 7.2 Hz, 1H), 6.61 (t, J = 5.2 Hz, 1H), 5.45 - 5.37 (m, 1H), 5.23 (t, J = 4.0 Hz, 1H), 5.09 - 4.99 (m, 1H), 4.15 - 3.98 (m, 1H), 3.91 - 3.81 (m, 2H), 3.61 (t, J = 4.8 Hz, 2H), 3.53 - 3.50 (m, 2H), 3.46 ( d, J = 6.0 Hz, 2H), 3.03 (dd, J = 12.4, 5.2 Hz, 4H), 2.91 - 2.83 (m, 1H), 2.73 (t, J = 5.2 Hz, 2H), 2.59 (dd, J = 4.0, 1.2 Hz, 2H), 2.06 - 1.99 (m, 1H), 1.58 (s, 3H), 1.53 (s, 3H).

[0433] Example 9 Synthesis of MS-5-017 The reaction scheme for the synthesis of MS-5-017 is shown in FIG. The procedure for preparing 515-5 is described in the synthesis of MS-5-015.

[0434] Procedure for the preparation of compound 517-3. To a solution of compound 57-15 (2 g, 7.24 mmol, 1 eq.) and compound 517-2 (1.62 g, 10.86 mmol, 1.5 eq.) in DMAc (10 mL), DIEA (2.81 g, 21.72 mmol, 3.78 mL, 3 eq.) was added, and the reaction mixture was stirred at 100 °C for 12 h. The reaction mixture was quenched by the addition of HO (10 mL), extracted with EtOAc (100 × 4 mL), and the combined organic layer was washed with brine (30 mL) and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO, PE / EA = 50 / 1 to 0 / 1) to give compound 517-3 (1.04 g, 2.57 mmol, 35.43% yield) as a green oil. LCMS: t R = 0.332 min, MS (ESI+) m / z = 405.9 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.10 (s, 1H), 7.59 (dd, J = 8.4, 7.2 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 6.8 Hz, 1H), 6.61 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 12.8, 5.2 Hz, 1H), 5.02 - 5.02 (m, 1H), 4.56 (t, J = 5.2 Hz, 1H), 3.65 - 3.61 (m, 2H), 3.58 (s, 4H), 3.51 - 3.46 (m, 4H), 3.44 - 3.41 (m, 2H), 2.91 - 2.81 (m, 1H), 2.64 - 2.53 (m, 2H), 2.07 - 2.01 (m, 1H).

[0435] Procedure for the preparation of compound 517-4. To a solution of compound 517-3 (300 mg, 740.01 μmol, 1 eq.) in DCM (5 mL), DMP (376.64 mg, 888.01 μmol, 274.92 μL, 1.2 eq.) was added, and the reaction mixture was stirred at 20° C. for 12 h. The reaction mixture was quenched by the addition of NaHCO (aq.) (40 mL), extracted with DCM (40×3 mL), and the combined organic layer was washed with brine (40 mL) and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO, PE / EA=50 / 1 to 0:1) to give compound 517-4 (339 mg, 840.39 μmol, 56.78% yield) as a yellow solid. LCMS: t R = 0.304 min, MS (ESI+) m / z = 404.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.10 (s, 1H), 9.61 - 9.51 (m, 1H), 7.63 - 7.51 (m, 1H), 7.22 - 7.08 (m, 1H), 6.61 (s, 1H), 5.83 - 5.66 (m, 1H), 5.06 (d, J = 8.4 Hz, 1H), 3.73 - 3.38 (m, 10H), 2.97 - 2.80 (m, 1H), 2.59 (d, J = 17.2 Hz, 2H), 2.10 - 1.96 (m, 1H).

[0436] Procedure for the preparation of MS-5-017. To a solution of compound 517-4 (66.79 mg, 165.57 μmol, 8.91 e-1 equivalents) and compound 515-5 (100 mg, 185.87 μmol, 1 equivalent, HCl) in THF (1 mL) was added HOAc (33.49 mg, 557.61 μmol, 31.89 μL, 3 equivalents) and borane; 2-methylpyridine (39.76 mg, 371.74 μmol, 2 equivalents). The mixture was stirred at 25 °C for 3 hours. The residue was purified by preparative HPLC (52% to 82% ACN in water (10 mM NH4HCO3), 9 min) and preparative TLC (SiO2, DCM / MeOH = 10:1) eluted with ACN (10 mL) to give MS-5-017 (5.59 mg, 6.21 μmol, 3.34% yield, 98.8% purity) as a yellow solid. LCMS: t R = 0.400 min, MS (ESI+) m / z = 889.4 [M+1] + . 1H NMR (400 MHz, CDCl3): δ = 8.80 - 8.70 (m, 1H), 8.26 (s, 1H), 8.12 (d, J = 7.2 Hz, 1H), 8.02 (s, 1H), 7.96 - 7.88 (m, 1H), 7.61 (dd, J = 8.4, 7.2 Hz, 1H), 7.42 (d, J = 6.8 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 6.17 (s, 1H), 5.23 (s, 2H), 4.98 (dd, J = 12.0, 5.2 Hz, 1H), 4.65 (q, J = 7.2 Hz, 2H), 4.25 - 4.14 (m, 1H), 3.88 - 3.80 (m, 2H), 3.66 (d, J = 2.4 Hz, 2H), 3.48 - 3.32 (m, 5H), 2.94 - 2.88 (m, 1H), 2.86 - 2.79 (m, 1H), 2.79 - 2.72 (m, 1H), 2.23 (s, 1H), 2.11 (dd, J = 11.2, 5.2 Hz, 2H), 2.04 - 2.01 (m, 2H), 1.98 (d, J = 7.2 Hz, 2H), 1.90 (t, J = 5.2 Hz, 4H), 1.75 - 1.71 (m, 1H), 1.26 (s, 3H), 0.89 (t, J = 6.4 Hz, 3H).

[0437] Example 10 Synthesis of MS-5-018

[0438] [ka]

[0439] The procedure for preparing 515-5 is described in the synthesis of MS-5-015. Procedure for the preparation of compound MS-5-018. To a solution of compound 518-1 (80 mg, 208.12 μmol, 1 equiv.) and compound 515-5 (104.38 mg, 208.12 μmol, 1 equiv.) in DMAc (1 mL), 2-Pic-BH (22.26 mg, 208.12 μmol, 1 equiv.) was added, and the mixture was stirred at 25 °C for 2 h. The reaction mixture was filtered and purified by preparative HPLC (25% to 55% ACN in water (10 mM NH4HCO3), 8 min) to give compound MS-5-018 (7.50 mg, 8.41 μmol, 4.04% yield, 97.58% purity) as a yellow solid. LCMS: t R = 0.379min, MS (ESI+) m / z = 870.5[M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.27 - 10.90 (m, 1H), 10.41 - 10.16 (m, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.67 (s, 1H), 7.96 (s, 1H), 7.74 - 7.68 (m, 1H), 7.67 - 7.62 (m, 1H), 7.61 - 7.54 (m, 1H), 7.42 - 7.38 (m, 2H), 7.37 - 7.33 (m, 2H), 7.31 - 7.18 (m, 3H), 5.46 - 5.38 (m, 1H), 5.24 (t, J = 4.8 Hz, 1H), 5.08 (dd, J = 5.2, 12.8 Hz, 1H), 3.95 - 3.81 (m, 2H), 3.24 (s, 4H), 3.14 - 3.00 (m, 4H), 2.92 - 2.82 (m, 1H), 2.71 (t, J = 6.0 Hz, 2H), 2.61 - 2.54 (m, 6H), 2.48 - 2.43 (m, 2H), 2.07 - 1.96 (m, 1H), 1.60 - 1.52 (m, 6H).

[0440] Example 11 Synthesis of MS-5-019 The reaction scheme for the synthesis of MS-5-019 is shown in FIG. The procedure for preparing 56-8 is described in the synthesis of MS-5-006.

[0441] Procedure for the preparation of compound 519-2. To a solution of compound 56-8 (2.78 g, 14.72 mmol, 1.2 equiv.) in DCM (55 mL) was added EDCI (3.53 g, 18.40 mmol, 1.5 equiv.), HOBt (1.66 g, 12.26 mmol, 1 equiv.), and TEA (3.72 g, 36.79 mmol, 5.12 mL, 3 equiv.) at 0 °C for 0.5 h. Compound 519-1 (5.5 g, 12.26 mmol, 1 equiv.) was then added, and the mixture was stirred at 25 °C for 1 h. The reaction mixture was partitioned between DCM (50 mL) and water (100 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO2, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 519-2 (3.71 g, 5.99 mmol, 48.82% yield) as a white solid. LCMS: t R = 0.406 min, MS (ESI+) m / z = 620.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ = 10.23 (s, 1H), 10.16 (s, 1H), 9.86 (s, 1H), 9.53 (d, J = 8.0 Hz, 1H), 8.67 (s, 1H), 7.96 (s, 1H), 7.72 - 7.66 (m, 1H), 7.65 - 7.56 (m, 1H), 7.36 (d, J = 4.4 Hz, 4H), 7.29 - 7.18 (m, 1H), 6.83 (t, J = 5.2 Hz, 1H), 5.39 - 5.23 (m, 1H), 5.16 (t, J = 4.8 Hz, 1H), 3.90 - 3.79 (m, 1H), 3.78 - 3.69 (m, 1H), 3.19 (m, 2H), 2.37 (t, J = 7.2 Hz, 2H), 1.55 (d, J = 18.8 Hz, 6H), 1.39 (s, 9H)

[0442] Procedure for the preparation of compound 519-3. To a solution of compound 519-2 (3.71 g, 5.99 mmol, 1 equiv) in DCM (40 mL) was added TosCl (1.26 g, 6.59 mmol, 1.1 equiv) and TEA (908.74 mg, 8.98 mmol, 1.25 mL, 1.5 equiv). The mixture was stirred at 25 °C for 12 h. The reaction mixture was partitioned between DCM (30 mL) and water (30 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 519-3 (3.11 g, 5.17 mmol, 86.34% yield) as a colorless solid. LCMS: t R = 0.456 min, MS (ESI+) m / z = 602.3 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ = 10.31 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.64 (s, 1H), 7.98 (s, 1H), 7.75 - 7.68 (m, 1H), 7.67 - 7.61 (m, 1H), 7.45 - 7.33 (m, 4H), 7.30 - 7.23 (m, 1H), 7.08 (t, J = 5.6 Hz, 1H), 5.50 - 5.36 (m, 1H), 5.24 (t, J = 4.8 Hz, 1H), 3.99 - 3.88 (m, 1H), 3.87 - 3.77 (m, 1H), 3.39 (q, J = 5.6 Hz, 2H), 3.05 (t, J = 6.4 Hz, 2H), 1.58 (s, 3H), 1.53 (s, 3H), 1.36 (s, 9H).

[0443] Procedure for the preparation of compound 519-4. To a solution of compound 519-3 (500 mg, 831.05 μmol, 1 eq.) in DCM (5 mL), HCl / dioxane (4 M, 623.28 μL, 3 eq.) was added. The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give 519-4 (460 mg, 641.27 μmol, 77.16% yield, 75% purity, HCl) as a white solid. LCMS: t R =0.338 min, MS(ESI+)m / z=502.1[M+1] +

[0444] Procedure for the preparation of compound 519-9. To a solution of compound 519-8 (5 g, 28.70 mmol, 4.72 mL, 1 equiv) in DCM (30 mL) was added TEA (5.81 g, 57.39 mmol, 7.99 mL, 2 equiv) and BocO (6.89 g, 31.57 mmol, 7.25 mL, 1.1 equiv), and the mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO, PE / EA = 50 / 1 to 0 / 1) to give compound 519-9 (6 g, 21.87 mmol, 76.21% yield) as a yellow oil. LCMS: t R = 0.208 min, MS (ESI+) m / z = 275.2 [M+1] + . 1 H NMR (400 MHz, CDCl3): δ = 3.65 - 3.52 (m, 6H), 3.42 - 3.36 (m, 4H), 2.56 - 2.50 (m, 2H), 2.45 - 2.36 (m, 4H), 1.39 (s, 9H).

[0445] Procedure for the preparation of compound 519-5. To a solution of DMSO (1.42 g, 18.22 mmol, 1.42 mL, 5 eq.) in DCM (20 mL) was added a mixture of (COCl) (925.27 mg, 7.29 mmol, 638.11 μL, 2 eq.) in DCM (20 mL) and stirred at −78° C. for 30 min. Compound 519-9 (1 g, 3.64 mmol, 1 eq.) in DCM (20 mL) was then added, followed by TEA (2.95 g, 29.16 mmol, 4.06 mL, 8 eq.), and the resulting mixture was stirred at −78° C. for another 1.5 h. The reaction mixture was concentrated under reduced pressure to give compound 519-5 (896 mg, crude) as a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 9.72 (s, 1H), 4.13 (s, 2H), 3.71 - 3.68 (m, 2H), 3.44 (d, J = 5.2 Hz, 4H), 2.47 (d, J = 4.8 Hz, 6H), 1.46 (s, 9H).

[0446] Procedure for the preparation of compound 519-6. To a solution of compound 519-4 (460 mg, 641.27 μmol, 75% purity, 1 eq., HCl) and compound 519-5 (261.96 mg, 961.90 μmol, 1.5 eq.) in MeOH (2 mL) and HOAc (0.2 mL), borane; 2-methylpyridine (68.59 mg, 641.27 μmol, 1 eq.) was added. The mixture was stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (15% to 45% ACN in water (0.05% HCl), 20 min) and lyophilized to give compound 519-6 (196 mg, 258.62 μmol, 40.33% yield) as a white solid. LCMS: t R = 0.351 min, MS (ESI+) m / z = 758.0 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.29 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.65 (s, 1H), 7.98 (s, 1H), 7.75 - 7.68 (m, 1H), 7.66 - 7.60 (m, 1H), 7.46 - 7.32 (m, 4H), 7.30 - 7.22 (m, 1H), 5.48 - 5.37 (m, 1H), 5.23 (s, 1H), 3.97 - 3.88 (m, 1H), 3.87 - 3.77 (m, 1H), 3.47 (m, 4H), 3.28 - 3.24 (m, 4H), 3.07 (dd, J = 14.0, 5.2 Hz, 4H), 2.74 (t, J = 4.8 Hz, 2H), 2.47 - 2.43 (m, 2H), 2.33 (t, J = 4.4 Hz, 4H), 1.58 (s, 3H), 1.53 (s, 3H), 1.36 (s, 9H).

[0447] Procedure for the preparation of compound 519-7. To a solution of compound 519-6 (196 mg, 258.62 μmol, 1 eq.) in DCM (2 mL), HCl / dioxane (4 M, 193.96 μL, 3 eq.) was added. The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 519-7 (226 mg, crude, HCl) as a white solid. LCMS: t R =0.319 min, MS(ESI+)m / z=658.2[M+1] +

[0448] Procedure for the preparation of MS-5-019. To a solution of compound 519-7 (30 mg, 45.61 μmol, 1 equiv.) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (10.71 mg, 38.77 μmol, 0.85 equiv.) in DMSO (0.5 mL) was added DIEA (8.84 mg, 68.41 μmol, 11.92 μL, 1.5 equiv.). The mixture was stirred at 120 °C for 2 h. The residue was purified by preparative HPLC (26% to 56% ACN in water (10 mM NH4HCO3), 8 min) and lyophilized to give MS-5-019 (3.87 mg, 4.11 μmol, 9.01% yield, 97% purity) as a yellow solid. LCMS: t R = 1.145 min, MS (ESI+) m / z = 914.3 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 10.28 (s, 1H), 8.94 - 8.81 (m, 1H), 8.65 (s, 1H), 7.96 (s, 1H), 7.76 - 7.68 (m, 1H), 7.67 - 7.59 (m, 2H), 7.44 - 7.20 (m, 7H), 5.50 - 5.35 (m, 1H), 5.23 (s, 1H), 5.08 (dd, J = 13.2, 5.2 Hz, 1H), 3.96 - 3.88 (m, 1H), 3.87 - 3.78 (m, 1H), 3.58 - 3.51 (m, 4H), 3.26 (s, 4H), 3.15 (s, 4H), 2.94 - 2.78 (m, 3H), 2.62 - 2.53 (m, 8H), 2.04 - 1.98 (m, 1H), 1.57 (s, 3H), 1.52 (s, 3H).

[0449] Example 12 Synthesis of MS-5-021

[0450] [ka]

[0451] The procedure for preparing compound 521-1 is described in the synthesis of MS-6-019. The procedure for preparing 56-14 is described in the synthesis of MS-5-006.

[0452] Procedure for the preparation of compound 521-2. To a solution of compound 521-1 (1 g, 2.01 mmol, 1 eq.) in DCM (10 mL), HCl / dioxane (4 M, 1.51 mL, 3 eq.) was added. The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 521-2 (677 mg, 1.56 mmol, 77.65% yield, HCl) as a yellow solid. LCMS: R =0.262 min, MS(ESI+)m / z=397.0[M+1] +

[0453] Procedure for the preparation of compound 521-3. To a solution of compound 521-2 (300.00 mg, 693.00 μmol, 1 equiv., HCl) and compound 56-14 (567.57 mg, 693.00 μmol, 1 equiv.) in DMAc (5 mL) was added DIEA (358.26 mg, 2.77 mmol, 482.83 μL, 4 equiv.). The mixture was stirred at 100° C. for 12 h. The residue was purified by preparative HPLC (41% to 71% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 521-3 (123 mg, 109.89 μmol, 15.86% yield) as a yellow solid. LCMS: t R = 0.526 min, MS (ESI+) m / z = 1119.9 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.09 (s, 1H), 10.50 - 10.15 (m, 1H), 9.25 (d, J = 8.0 Hz, 1H), 8.71 (s, 1H), 7.87 (s, 1H), 7.78 - 7.49 (m, 5H), 7.48 - 7.19 (m, 15H), 5.64 - 5.50 (m, 1H), 5.09 (dd, J = 12.8, 4.4 Hz, 1H), 4.08 - 3.94 (m, 2H), 3.55 (s, 1H), 3.68 - 3.50 (m, 1H), 3.27 (d, J = 9.6 Hz, 6H), 2.90 - 2.83 (m, 1H), 2.64 - 2.56 (m, 2H), 1.96 (d, J = 2.0 Hz, 1H), 1.81 - 1.63 (m, 4H), 1.52 (d, J = 7.6 Hz, 6H), 1.40 (s, 2H), 1.17 (t, J = 7.2 Hz, 2H), 0.92 (s, 9H).

[0454] Procedure for the preparation of MS-5-021. To a solution of compound 521-3 (100 mg, 89.34 μmol, 1 equiv.) in DMSO (2 mL) was added CsF (135.71 mg, 893.38 μmol, 32.94 μL, 10 equiv.). The mixture was stirred at 50° C. for 1 h. The residue was purified by preparative HPLC (33% to 63% ACN in water (0.225% FA), 10 min) and lyophilized to give MS-5-021 (22.89 mg, 24.27 μmol, 27.16% yield, 98.27% purity, FA) as a yellow solid. LCMS: t R = 1.330 min, MS (ESI+) m / z = 881.5 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 11.08 (s, 1H), 10.30 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.66 (s, 1H), 8.24 (s, 1H), 7.97 (s, 1H), 7.76 - 7.59 (m, 3H), 7.46 - 7.30 (m, 6H), 7.29 - 7.22 (m, 1H), 5.52 - 5.37 (m, 1H), 5.33 - 5.17 (m, 1H), 5.08 (dd, J = 12.8, 5.2 Hz, 1H), 4.02 - 3.88 (m, 1H), 3.87 - 3.76 (m, 1H), 3.23 (s, 6H), 3.13 (t, J = 7.2 Hz, 2H), 2.94 - 2.82 (m, 3H), 2.65 - 2.53 (m, 4H), 2.06 - 1.94 (m, 1H), 1.73 - 1.60 (m, 6H), 1.58 (s, 3H), 1.53 (s, 3H).

[0455] Example 13 Synthesis of MS-5-022

[0456] [ka]

[0457] The procedure for preparing compound 522-1 is described in the synthesis of MS-6-031. The procedure for preparing 56-14 is described in the synthesis of MS-5-006.

[0458] Procedure for the preparation of compound 522-2. To a solution of compound 522-1 (280 mg, 646.80 μmol, 1 equiv., HCl) and compound 56-14 (529.74 mg, 646.80 μmol, 1 equiv.) in DMAc (5 mL) was added DIEA (334.38 mg, 2.59 mmol, 450.64 μL, 4 equiv.). The mixture was stirred at 100° C. for 12 h. The residue was purified by preparative HPLC (41% to 71% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 522-2 (151 mg, 134.90 μmol, 20.86% yield) as a yellow solid. LCMS: t R = 0.528 min, MS (ESI+) m / z = 1119.4 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.06 (s, 1H), 10.31 (s, 1H), 9.23 (d, J = 8.4 Hz, 1H), 8.69 (s, 1H), 7.88 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.65 - 7.48 (m, 4H), 7.46 - 7.02 (m, 15H), 5.65 - 5.51 (m, 1H), 5.06 (dd, J = 12.0, 5.2 Hz, 1H), 4.20 - 4.10 (m, 1H), 4.00 - 3.94 (m, 1H), 3.68 - 3.55 (m, 2H), 3.52 - 3.39 (m, 4H), 3.23 - 3.06 (m, 2H), 2.88 - 2.82 (m, 1H), 2.66 - 2.52 (m, 4H), 1.95 (s, 1H), 1.81 (dd, J = 4.0, 2.8 Hz, 2H), 1.52 (d, J = 5.6 Hz, 9H), 1.17 (t, J = 7.2 Hz, 2H), 0.91 (s, 9H).

[0459] Procedure for the preparation of MS-5-022. To a solution of compound 522-3 (100 mg, 89.34 μmol, 1 equiv.) in DMSO (0.5 mL) was added CsF (135.71 mg, 893.38 μmol, 32.94 μL, 10 equiv.). The mixture was stirred at 50° C. for 1 h. The residue was purified by preparative HPLC (33% to 63% ACN in water (0.05% HCl), 10 min) and lyophilized to give MS-5-022 (22.64 mg, 25.15 μmol, 28.16% yield, 97.88% purity) as a yellow solid. LCMS: t R = 1.346 min, MS (ESI+) m / z = 881.3 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.06 (s, 1H), 10.29 (s, 1H), 8.88 ( d, J = 7.6 Hz, 1H), 8.65 (s, 1H), 8.19 (s, 1H), 7.98 (s, 1H), 7.76 - 7.68 (m, 1H), 7.66 - 7.61 (m, 1H), 7.59 - 7.52 (m, 1H), 7.46 - 7.32 (m, 4H), 7.31 - 7.23 (m, 1H), 7.18 - 7.04 (m, 2H), 5.55 - 5.38 (m, 1H), 5.36 - 5.15 (m, 1H), 5.06 (dd, J = 12.8, 5.2 Hz, 1H), 4.05 - 3.88 (m, 1H), 3.88 - 3.78 (m, 1H), 3.61 (t, J = 6.0 Hz, 2H), 3.46 - 3.42 (m, 2H), 3.13 (t, J = 7.2 Hz, 2H), 2.93 - 2.78 (m, 3H), 2.63 - 2.53 (m, 4H), 2.47 - 2.36 (m, 2H), 2.05 - 1.94 (m, 1H), 1.81 (t, J = 6.4 Hz, 2H), 1.55 (d, J = 19.6 Hz, 10H).

[0460] Example 14 Synthesis of MS-5-024

[0461] [ka]

[0462] The procedure for preparing compound 527-6 is described in the synthesis of MS-5-027. Procedure for the preparation of compound 524-3. To a solution of compound 524-1 (commercially available, 500 mg, 2.45 mmol, 1 equiv.) and compound 524-2 (commercially available, 676.13 mg, 2.45 mmol, 1 equiv.) in DMAc (5 mL) was added DIEA (632.72 mg, 4.90 mmol, 852.72 μL, 2 equiv.). The mixture was stirred at 100° C. for 2 h. The residue was purified by preparative HPLC (26% to 56% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 524-3 (112 mg, 243.22 μmol, 9.94% yield) as a yellow solid. LCMS: t R = 0.394 min, MS (ESI+) m / z = 361.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ = 11.06 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.12 (t, J = 5.2 Hz, 1H), 7.01 (d, J = 1.2 Hz, 1H), 6.90 (dd, J = 8.4, 1.6 Hz, 1H), 6.80 (s, 1H), 5.03 (dd, J = 12.8, 5.2 Hz, 1H), 3.57 (t, J = 5.6 Hz, 2H), 3.41 (t, J = 6.0 Hz, 4H), 3.09 (q, J = 5.6 Hz, 2H), 2.87 (m, 1H), 2.60 - 2.53 (m, 2H), 2.05 - 1.90 (m, 1H), 1.36 (s, 9H).

[0463] Procedure for the preparation of compound 524-4. Compound 524-3 (90 mg, 195.45 μmol, 1 eq.) was dissolved in HBr (1 M, 586.35 μL, 40% purity, 3 eq.). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to give compound 524-4 (80 mg, crude) as a yellow solid. LCMS: R =0.222 min, MS(ESI+)m / z=361.2[M+1] +

[0464] Procedure for the preparation of compound 524-7. To a solution of compound 527-6 (181.82 mg, 222.00 μmol, 1 equiv.) and compound 524-4 (80 mg, 222.00 μmol, 1 equiv.) in DMAc (1 mL) was added DBU (101.39 mg, 665.99 μmol, 100.39 μL, 3 equiv.). The mixture was stirred at 80 °C for 1 h. The residue was purified by preparative HPLC (58% to 88% ACN in water (10 mM NH4HCO3), 8 min) and lyophilized to give compound 524-7 (20 mg, 18.46 μmol, 8.32% yield) as a yellow solid. LCMS: R =0.884 min, MS(ESI+)m / z=1083.0[M+1] +

[0465] Procedure for the preparation of MS-5-024. To a solution of compound 527-7 (20 mg, 18.46 μmol, 1 equiv.) in DMSO (0.2 mL) was added CsF (14.02 mg, 92.31 μmol, 3.40 μL, 5 equiv.). The mixture was stirred at 50° C. for 1 h. The residue was purified by preparative HPLC (16% to 46% ACN in water (0.225% FA), 10 min) and lyophilized to give MS-5-024 (2.95 mg, 3.17 μmol, 17.18% yield, 95.8% purity, FA) as a yellow solid. LCMS: t R = 0.348 min, MS (ESI+) m / z = 845.5 [M+1] + . 1H NMR (400 MHz, DMSO-d6) δ = 11.05 (s, 1H), 10.27 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.63 (s, 1H), 8.22 (s, 1H), 7.97 (s, 1H), 7.75 - 7.67 (m, 1H), 7.66 - 7.60 (m, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.45 - 7.34 (m, 4H), 7.29 - 7.22 (m, 1H), 7.18 - 7.10 (m, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.88 (dd, J = 8.4, 1.2 Hz, 1H), 5.42 (dd, J = 5.6, 3.6 Hz, 1H), 5.27 - 5.14 (m, 1H), 5.01 (dd, J = 12.4, 4.8 Hz, 1H), 3.96 - 3.81 (m, 2H), 3.70 - 3.53 (m, 4H), 3.52 - 3.48 (m, 2H), 3.03 (dd, J = 14.8, 5.2 Hz, 4H), 2.83 (dd, J = 12.8, 5.6 Hz, 1H), 2.73 (t, J =4.8 Hz, 2H), 2.56 (d, J = 2.0Hz, 2H), 2.00 - 1.92 (m, 1H), 1.58 (s, 3H), 1.53 (s, 3H).

[0466] Example 15 Synthesis of MS-5-026

[0467] [ka]

[0468] The procedure for preparing compound 519-4 is described in the synthesis of MS-5-019. Procedure for the preparation of compound 526-2. To a solution of DMSO (3.39 g, 43.42 mmol, 3.39 mL, 5 equiv) in DCM (40 mL) was added a mixture of (COCl) (2.20 g, 17.37 mmol, 1.52 mL, 2 equiv) in DCM (40 mL) and stirred at −78° C. for 30 min. Compound 526-1 (commercially available, 2 g, 8.68 mmol, 1 equiv) in DCM (40 mL) was then added, followed by the addition of TEA (7.03 g, 69.47 mmol, 9.67 mL, 8 equiv), and the resulting mixture was stirred at −78° C. for an additional 1.5 h. The reaction mixture was quenched by the addition of water (100 mL) and extracted with DCM (50 mL × 3). The combined organic layers were dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to give compound 526-2 (1.9 g, crude) as a yellow oil. 1 H NMR (400 MHz, CDCl3): δ = 9.69 (t, J = 1.2 Hz, 1H), 3.65 - 3.59 (m, 2H), 3.45 - 3.39 (m, 4H), 2.49 - 2.43 (m, 4H), 1.44 (s, 9H).

[0469] Procedure for the preparation of compound 526-3. To a solution of compound 526-2 (195.15 mg, 854.84 μmol, 1.5 equiv.) and compound 519-4 (420 mg, 569.89 μmol, 73% purity, 1 equiv. HCl) in MeOH (4 mL) and HOAc (0.4 mL) was added 2-Pic-BH3 (60.96 mg, 569.89 μmol, 1 equiv.). The mixture was stirred at 25° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (21% to 41% ACN in water (0.05% HCl), 20 min) and lyophilized to give compound 526-3 (43 mg, 60.24 μmol, 10.57% yield) as a white solid. LCMS: t R = 0.395 min, MS (ESI+) m / z = 714.2 [M+1] + . 1H NMR (400 MHz, DMSO-d6): δ = 10.30 (s, 1H), 8.95 - 8.83 (m, 1H), 8.65 (s, 1H), 7.98 (s, 1H), 7.75 - 7.67 (m, 1H), 7.66 - 7.59 (m, 1H), 7.43 - 7.33 (m, 4H), 7.30 - 7.20 (m, 1H), 5.52 - 5.37 (m, 1H), 5.24 (s, 1H), 3.96 - 3.88 (m, 1H), 3.87 - 3.79 (m, 1H), 3.29 (s, 4H), 3.15 - 3.00 (m, 4H), 2.79 - 2.63 (m, 2H), 2.54 (s, 2H), 2.46 - 2.39 (m, 2H), 2.38 - 2.24 (m, 4H), 1.58 (s, 3H), 1.53 (s, 3H), 1.45 - 1.33 (m, 8H).

[0470] Procedure for the preparation of compound 526-4. To a solution of compound 526-3 (43 mg, 60.24 μmol, 1 eq.) in DCM (0.5 mL), HCl / dioxane (4 M, 45.18 μL, 3 eq.) was added. The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered, and the filter residue was concentrated under reduced pressure to give compound 526-4 (30 mg, crude) as a white solid. LCMS: t R =0.326 min, MS(ESI+)m / z=614.3[M+1] + .

[0471] Procedure for the preparation of MS-5-026. To a solution of compound 526-4 (25 mg, 40.74 μmol, 1 equiv.) and compound 524-2 (commercially available, 11.25 mg, 40.74 μmol, 1 equiv.) in DMSO (0.5 mL) was added DIEA (7.90 mg, 61.10 μmol, 10.64 μL, 1.5 equiv.). The mixture was stirred at 120° C. for 2 h. The residue was purified by preparative HPLC (12% to 42% ACN in water (0.1% TFA), 10 min) and lyophilized to give MS-5-026 (7.01 mg, 7.25 μmol, 17.80% yield, 90% purity) as a yellow solid. LCMS: t R= 0.373 min, MS (ESI+) m / z = 870.5 [M+1] + . 1 H NMR (400 MHz, DMSO-d6): δ = 11.07 (s, 1H), 10.26 (s, 1H), 8.89 (d, J = 7.8 Hz, 1H), 8.66 (s, 1H), 8.20 (s, 1H), 7.95 (s, 1H), 7.73 - 7.66 (m, 1H), 7.66 - 7.53 (m, 2H), 7.44 - 7.28 (m, 5H), 7.28 - 7.21 (m, 1H), 7.18 - 7.12 (m, 1H), 5.49 - 5.34 (m, 1H), 5.29 - 5.19 (m, 1H), 5.10 - 4.98 (m, 1H), 3.95 - 3.87 (m, 1H), 3.86 - 3.80 (m, 1H), 3.53 - 3.38 (m, 10H), 3.12 - 3.07 (m, 2H), 3.06 - 2.98 (m, 2H), 2.90 - 2.84 (m, 1H), 2.72 (t, J = 5.6 Hz, 2H), 2.64 - 2.58 (m, 2H), 2.07 - 1.93 (m, 1H), 1.58 (s, 3H), 1.53 (s, 3H).

[0472] Example 16 Synthesis of MS-5-027 The reaction scheme for the synthesis of MS-5-027 is shown in FIG. The procedure for preparing compound 527-6 is described in the synthesis of MS-5-029. The procedure for preparing compound 527-3 is described in the synthesis of MS-6-046.

[0473] Procedure for the preparation of compound 527-2. To a solution of DMSO (1.90 g, 24.36 mmol, 1.90 mL, 5 eq) in DCM (20 mL) was added (COCl) (1.24 g, 9.74 mmol, 852.96 μL, 2 eq) in DCM (20 mL) at −78° C. for 0.5 h. Compound 527-1 (1 g, 4.87 mmol, 1 eq) in DCM (20 mL) was then added, followed by TEA (3.94 g, 38.98 mmol, 5.43 mL, 8 eq). The mixture was stirred at −78° C. for 1.5 h. The reaction mixture was partitioned between DCM (30 mL) and water (100 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated to give compound 527-2 (819 mg, crude) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ = 9.57 (s, 1H), 6.89 - 6.67 (m, 1H), 3.51 - 3.45 (m, 2H), 3.39 (d, J = 7.6 Hz, 2H), 3.10 - 3.05 (m, 2H), 1.38 (s, 9H).

[0474] Procedure for the preparation of compound 527-4. To a solution of compound 527-2 (445.24 mg, 2.19 mmol, 5 equiv.) and compound 527-3 (150 mg, 438.15 μmol, 1 equiv.) in HOAc (0.3 mL) and i-PrOH (3 mL), borane; 2-methylpyridine (93.73 mg, 876.30 μmol, 2 equiv.) was added. The mixture was stirred at 25° C. for 12 h. The residue was purified by preparative HPLC (2% to 32% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 527-4 (135 mg, 254.92 μmol, 58.18% yield) as a yellow solid. LCMS: t R = 0.317 min, MS (ESI+) m / z = 530.2 [M+1] + . 1H NMR (400 MHz, DMSO-d6) δ = 11.07 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.33 (s, 1H), 7.25 (d, J = 8.4 Hz, 1H), 6.86 - 6.70 (m, 1H), 5.07 (dd, J = 13.2, 5.2 Hz, 1H), 3.53 (t, J = 5.2 Hz, 2H), 3.46 - 3.36 (m, 6H), 3.07 (q, J = 5.2 Hz, 2H), 2.97 - 2.79 (m, 1H), 2.64 - 2.51 (m, 8H), 2.08 - 1.99 (m, 1H), 1.36 (s, 9H).

[0475] Procedure for the preparation of compound 527-5. To a solution of compound 527-4 (130 mg, 245.48 μmol, 1 eq) in DCM (1 mL) was added TFA (0.1 mL). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to give compound 527-5 (150 mg, crude) as a green oil. LCMS: R =0.171 min, MS(ESI+)m / z=430.1[M+1] + .

[0476] Procedure for the preparation of compound 527-6. To a solution of compound 529-6 (1 g, 1.35 mmol, 1 equiv) in DCM (10 mL) was added MsO (705.32 mg, 4.05 mmol, 3 equiv) and TEA (682.86 mg, 6.75 mmol, 939.29 μL, 5 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give compound 527-6 (1.13 g, 1.10 mmol, 81.78% yield, 80% purity) as a yellow solid. LCMS: t R =0.599 min, MS(ESI+)m / z=819.2[M+1] +

[0477] Procedure for the preparation of compound 527-7. To a solution of compound 527-5 (140 mg, 325.98 μmol, 1 equiv.) in DMAC (2 mL) was added DBU (148.88 mg, 977.95 μmol, 147.41 μL, 3 equiv.) and compound 527-6 (333.73 mg, 325.98 μmol, 80% purity, 1 equiv.) at 80 °C. The mixture was stirred at 80 °C for 1 h. The residue was purified by preparative HPLC (34% to 64% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 527-7 (96 mg, 83.31 μmol, 25.56% yield) as a yellow solid. LCMS: t R =0.461 min, MS(ESI+)m / z=1152.4[M+1] +

[0478] Procedure for the preparation of MS-5-027. To a solution of compound 527-7 (90 mg, 78.10 μmol, 1 equiv.) in DMSO (1 mL) was added CsF (59.32 mg, 390.50 μmol, 14.40 μL, 5 equiv.). The mixture was stirred at 50° C. for 1 h. The residue was purified by preparative HPLC (9% to 39% ACN in water (0.225% FA), 10 min) and lyophilized to give MS-5-027 (38.29 mg, 39.49 μmol, 50.56% yield, 99% purity, FA) as a yellow solid. LCMS: t R = 0.331 min, MS (ESI+) m / z = 914.4 [M+1] + . 1H NMR (400 MHz, DMSO-d6) δ = 11.07 ( s, 1H), 10.27 (s, 1H), 8.88 (d, J = 7.6 Hz, 1H), 8.64 (s, 1H), 8.18 (s, 1H), 7.95 (d, J = 1.2 Hz, 1H), 7.74 - 7.66 (m, 1H), 7.66 - 7.53 (m, 2H), 7.48 - 7.32 (m, 4H), 7.31 - 7.21 (m, 2H), 7.17 (dd, J =8.4, 2.0 Hz, 1H), 5.41 - 5.41 (m, 1H), 5.47 - 5.37 (m, 1H), 5.05 (dd, J = 12.8, 5.6 Hz, 1H), 3.93 - 3.88 (m, 1H), 3.83 (dd, J = 11.2, 4.8 Hz, 1H), 3.53 (s, 2H), 3.50 (s, 2H), 3.49 (s, 2H), 3.39 - 3.35 (m, 4H), 3.15 - 3.05 (m, 4H), 2.92 - 2.82 (m, 1H), 2.78 (t, J = 5.6 Hz, 2H), 2.62 - 2.51 (m, 6H), 2.06 - 1.92 (m, 1H), 1.57 (s, 3H), 1.52 (s, 3H).

[0479] Example 17 Synthetic route for MS-5-028 The reaction scheme for the synthesis of MS-5-028 is shown in FIG. The procedure for preparing compound 527-6 is described in the synthesis of MS-5-027. The procedure for preparing compound 527-3 is described in the synthesis of MS-6-046.

[0480] Procedure for the preparation of compound 528-2. To a solution of DMSO (1.57 g, 20.06 mmol, 1.57 mL, 5 eq) in DCM (20 mL) was added (COCl) (1.02 g, 8.02 mmol, 702.24 μL, 2 eq) in DCM (20 mL) at −78° C. for 0.5 h. Compound 528-1 (1 g, 4.01 mmol, 1 eq) in DCM (20 mL) was then added, followed by TEA (3.25 g, 32.09 mmol, 4.47 mL, 8 eq). The mixture was stirred at −78° C. for 1.5 h. The reaction mixture was partitioned between DCM (50 mL) and HO (50 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated to give compound 528-2 (1.45 g, crude) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ = 9.58 (s, 1H), 6.76 (d, J = 5.6 Hz, 1H), 3.64 - 3.46 (m, 4H), 3.40 - 3.35 (m, 4H), 3.06 ( d, J = 7.6 Hz, 2H), 1.38 (s, 9H).

[0481] Procedure for the preparation of compound 528-3. To a solution of compound 528-2 (1.44 g, 5.84 mmol, 5 equiv.) and compound 527-3 (400 mg, 1.17 mmol, 1 equiv.) in HOAc (0.5 mL) and i-PrOH (5 mL) was added 2-Pic-BH3 (249.95 mg, 2.34 mmol, 2 equiv.). The mixture was stirred at 25 °C for 1 h. The residue was purified by preparative HPLC (4% to 34% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 528-3 (374 mg, 651.98 μmol, 55.80% yield) as a yellow solid. LCMS: t R = 0.315 min, MS (ESI+) m / z = 574.3[M+1] + . 1H NMR (400 MHz, DMSO-d6) δ = 11.07 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 2.4 Hz, 1H), 7.25 (dd, J = 8.8, 2.0 Hz, 1H), 6.81 - 6.67 (m, 1H), 5.14 - 4.97 (m, 1H), 3.55 (t, J = 6.0 Hz, 2H), 3.50 (s, 4H), 3.44 - 3.38 (m, 6H), 3.15 - 2.99 (m, 2H), 2.98 - 2.79 (m, 1H), 2.65 - 2.51 (m, 8H), 2.06 - 1.99 (m, 1H), 1.36 (s, 9H).

[0482] Procedure for the preparation of compound 528-4. To a solution of compound 528-3 (374 mg, 651.98 μmol, 1 eq) in DCM (3 mL) was added TFA (0.3 mL). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to give compound 528-4 (701 mg, crude) as a yellow oil. LCMS: R =0.138 min, MS(ESI+)m / z=474.2[M+1] + .

[0483] Procedure for the preparation of compound 528-5. To a solution of compound 528-4 (300 mg, 633.55 μmol, 1 equiv.) in DMAc (3 mL) was added DBU (289.35 mg, 1.90 mmol, 286.49 μL, 3 equiv.) and compound 527-6 (259.44 mg, 316.78 μmol, 0.5 equiv.) at 100° C. The mixture was stirred at 100° C. for 1 h. The residue was purified by preparative HPLC (23% to 53% ACN in water (0.225% FA), 10 min) and lyophilized to give compound 528-5 (53 mg, 44.30 μmol, 6.99% yield) as a yellow solid. LCMS: t R =0.470 min, MS(ESI+)m / z=1197.7[M+1] + .

[0484] Procedure for the preparation of MS-5-028. To a solution of compound 528-5 (38 mg, 31.76 μmol, 1 equiv.) in DMSO (1 mL) was added CsF (4.82 mg, 31.76 μmol, 1.17 μL, 1 equiv.). The mixture was stirred at 60° C. for 2 h. The residue was purified by preparative HPLC (10% to 40% ACN in water (0.225% FA), 8 min). The collected fractions were lyophilized to give MS-5-028 (9 mg, 8.81 μmol, 27.74% yield, 98.3% purity, FA) as a yellow solid. LCMS: t R = 0.327 min, MS (ESI+) m / z = 958.8[M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ = 11.07 (s, 1H), 10.28 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.64 (s, 1H), 8.18 (s, 1H), 7.96 (d, J = 0.8 Hz, 1H), 7.76 - 7.67 (m, 1H), 7.63 (dd, J = 2.4, 8.4 Hz, 2H), 7.43 - 7.34 (m, 4H), 7.31 - 7.23 (m, 2H), 7.19 (dd, J = 2.1, 8.4 Hz, 1H), 5.48 - 5.37 (m, 1H), 5.34 - 5.13 (m, 1H), 5.05 (dd, J = 5.6, 13.2 Hz, 1H), 3.90 (s, 1H), 3.86 - 3.82 (m, 1H), 3.51 (s, 14H), 3.19 - 2.97 (m, 8H), 2.88 (d, J = 2.4 Hz, 1H), 2.76 - 2.71 (m, 2H), 2.61 - 2.54 (m, 2H), 2.06 - 1.94 (m, 1H), 1.57 (s, 3H), 1.52 (s, 3H).

[0485] Example 18 Synthetic route for MS-5-029 The reaction scheme for the synthesis of MS-5-029 is shown in FIG. The procedure for preparing compound 56-7 is described in the synthesis of MS-5-006.

[0486] Procedure for the preparation of compound 529-1. To a solution of compound 56-7 (10 g, 21.62 mmol, 1 equiv) in EtOH (500 mL) was slowly added NH2NH2·H2O (32.47 g, 648.65 mmol, 31.53 mL, 30 equiv) at 20 °C. The mixture was stirred at 90 °C for 96 h. The reaction mixture was quenched by the addition of water (100 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO2, DCM / MeOH = 100 / 1 to 10 / 1) to give compound 529-1 (24.53 g, 54.71 mmol, 84.34% yield) as a white solid. LCMS: t R = 0.329 min, MS (ESI+) m / z = 449.0 [M+1] + . 1 H NMR (400 MHz, DMSO-d6) δ = 10.04 (s, 1H), 9.76 - 9.60 (m, 2H), 8.53 (s, 1H), 7.96 (d, J = 1.2 Hz, 1H), 7.72 - 7.64 (m, 1H), 7.64 - 7.58 (m, 1H), 7.42 - 7.31 (m, 4H), 7.30 - 7.21 (m, 1H), 5.28 (m, 1H), 5.13 (t, J = 4.8 Hz, 1H), 4.44 (s, 2H), 3.93 - 3.80 (m, 1H), 3.79 - 3.69 (m, 1H), 1.57 (s, 3H), 1.53 (s, 3H).

[0487] Procedure for the preparation of compound 529-12. To compound 529-10 (25 g, 211.63 mmol, 1 eq.) in DCM (250 mL) was added PPTS (2.66 g, 10.58 mmol, 0.05 eq.) and compound 529-11 (24.92 g, 296.28 mmol, 27.09 mL, 1.4 eq.). The mixture was stirred at 25 °C for 3 h. The reaction mixture was partitioned between DCM (150 mL × 2) and water (150 mL). After the reaction was quenched, the reaction mixture was poured into a separatory funnel and separated. The residue was purified by flash silica gel chromatography (SiO, PE / EA = 100 / 1 to 4 / 1) to give 529-12 (39.72 g, 196.39 mmol, 92.80% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ = 4.63 (t, J = 2.8 Hz, 1H), 4.23 - 4.07 (m, 2H), 4.00 (m, 1H), 3.86 (m,...

Claims

1. A bivalent compound comprising an HPK1 ligand conjugated via a linker to a degradation / destruction tag, the HPK1 ligand being Part according to formula 1: 【Chemistry 1】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 is independently attached to (indicated by the dotted line); The "linker" portion of the bivalent compound is R 2 If attached to; R 1 is hydrogen, halogen, oxo, CN, NO 2 , OR 4 , S.R. 4 , N.R. 4 R 5 , C(O)R 4 , C(O)OR 4 , C(O)NR 4 R 5 , S(O)R 4 , S(O) 2 R 4 , S(O) 2 NR 4 R 5 , N.R. 6 C(O)OR 4 , N.R. 6 C(O)R 4 , N.R. 6 C(O)NR 4 R 5 , N.R. 6 S(O)R 4 , N.R. 6 S(O) 2 R 4 , N.R. 6 S(O) 2 NR 4 R 5 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 4 , R 5 , and R 6 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 , R 4 and R 6 , R 5 and R 6 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; The "linker" portion of the bivalent compound is R 1 If attached to; R 1 For each occurrence, OR 4 , S.R. 4 , N.R. 4 R 5 , C(O)R 4 , C(O)OR 4 , C(O)NR 4 R 5 , S(O)R 4 , S(O) 2 R 4 , S(O) 2 NR 4 R 5 , N.R. 6 C(O)OR 4 , N.R. 6 C(O)R 4 , N.R. 6 C(O)NR 4 R 5 , N.R. 6 S(O)R 4 , N.R. 6 S(O) 2 R 4 , N.R. 6 S(O) 2 NR 4 R 5 , C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxylenes, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted C 3 ~C 8 independently selected from cycloalkoxylenes, optionally substituted 3- to 8-membered heterocyclylenes, optionally substituted arylenes, and optionally substituted heteroarylenes; R 4 is absent or optionally replaced by C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 5 and R 6 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 , R 4 and R 6 , R 5 and R 6 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; The "linker" portion of the bivalent compound is R 1 If attached to; R 2 is absent, hydrogen, C(O)R at each occurrence. 7 , C(O)OR 7 , C(O)NR 7 R 8 , S(O)R 7 , S(O) 2 R 7 , S(O) 2 NR 7 R 8 , N.R. 9 C(O)OR 7 , N.R. 9 C(O)R 7 , N.R. 9 C(O)NR 7 R 8 , N.R. 9 S(O)R 7 , N.R. 9 S(O) 2 R 7 , N.R. 9 S(O) 2 NR 7 R 8 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 7 , R 8 , and R 9 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 7 and R 8 , R 7 and R 9 , R 8 and R 9 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; The "linker" portion of the bivalent compound is R 2 If attached to; R 2 is, for each occurrence, C(O)R 7 , C(O)OR 7 , C(O)NR 7 R 8 , S(O)R 7 , S(O) 2 R 7 , S(O) 2 NR 7 R 8 , N.R. 9 C(O)OR 7 , N.R. 9 C(O)R 7 , N.R. 9 C(O)NR 7 R 8 , N.R. 9 S(O)R 7 , N.R. 9 S(O) 2 R 7 , N.R. 9 S(O) 2 NR 7 R 8 , optionally replaced by C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxylenes, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted C 3 ~C 8 independently selected from cycloalkoxylenes, optionally substituted 3- to 8-membered heterocyclylenes, optionally substituted arylenes, and optionally substituted heteroarylenes; R 7 is absent or optionally replaced by C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 8 and R 9 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 7 and R 8 , R 7 and R 9 , R 8 and R 9 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; The part according to formula 2: 【Chemistry 2】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 is independently attached to (indicated by the dotted line); R 1 and R 2 The definition of is the same as for Equation 1; Ar, at each occurrence, is independently selected from absent, aryl, or heteroaryl, each of which is R 1 Substituted with hydrogen, halogen, oxo, CN, NO 2 , OR 12 , S.R. 12 , N.R. 12 R 13 , O.C.O.R. 12 , O.C.O. 2 R 12 ,OCONR 12 R 13 , C.O.R. 12 , CO 2 R 12 ,CONR 12 R 13 , SOR 12 , S.O. 2 R 12 , S.O. 2 NR 12 R 13 , N.R. 14 CO 2 R 12 , N.R. 14 COR 12 , N.R. 14 C(O)NR 12 R 13 , N.R. 14 SOR 12 , N.R. 14 SO 2 R 12 , N.R. 14 SO 2 NR 12 R 13 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 optionally substituted with one or more substituents independently selected from cycloalkoxy, optionally substituted 4-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 12 , R 13 , and R 14 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 4-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 12 and R 13 , R 12 and R 14 , R 13 and R 14 together with the atom(s) to which they are attached form a 4- to 20-membered heterocyclyl ring); Part according to formula 2A: 【Chemistry 3】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 is independently attached to (indicated by the dotted line); R 1 , R 2 and Ar are defined as for Eq. 2); Part according to formula 2B: 【Chemistry 4】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 is independently attached to (indicated by the dotted line); R 1 and R 2 The definitions of are the same as for Eq. 2); Part according to formula 2C: 【Chemistry 5】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 2 is independently attached to (indicated by the dotted line); R 1 and R 2 The definition of is the same as for Equation 2; R 3 is hydrogen, halogen, oxo, CN, NO 2 , OR 15 , S.R. 15 , N.R. 15 R 16 , C(O)R 16 , C(O)OR 15 , C(O)NR 15 R 16 , S(O)R 15 , S(O) 2 R 15 , S(O) 2 NR 15 R 16 , N.R. 17 C(O)OR 15 , N.R. 6 C(O)R 15 , N.R. 17 C(O)NR 15 R 16 , N.R. 17 S(O)R 15 , N.R. 17 S(O) 2 R 15 , N.R. 17 S(O) 2 NR 15 R 16 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 15 , R 16 , and R 17 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 15 and R 16 , R 15 and R 17 , R 16 and R 17 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; n is independently selected from 0, 1, 2, 3 and 4; The part according to formula 3: 【Chemistry 6】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 3 is independently attached to (indicated by the dotted line); The "linker" portion of the bivalent compound is R 3 If attached to; R 1 and R 2 is absent, hydrogen, C(O)R at each occurrence. 10 , C(O)OR 10 , C(O)NR 10 R 11 , S(O)R 10 , S(O) 2 R 10 , S(O) 2 NR 10 R 11 , N.R. 12 C(O)OR 10 , N.R. 12 C(O)R 10 , N.R. 12 C(O)NR 10 R 11 , N.R. 12 S(O)R 10 , N.R. 12 S(O) 2 R 10 , N.R. 12 S(O) 2 NR 10 R 11 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 10 , R 11 , and R 12 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 10 and R 11 , R 10 and R 12 , R 11 and R 12 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 and R 2 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 3 OR 13 , S.R. 13 , N.R. 13 R 14 , C.H. 2 NR 13 R 14 , C.H. 2 CH 2 NR 13 R 14 , C 1 ~C 8 Alkylene NR 13 R 14 , C(O)R 13 , C(O)OR 13 , C(O)NR 13 R 14 , S(O)R 13 , S(O) 2 R 14 , S(O) 2 NR 13 R 14 , N.R. 15 C(O)OR 13 , N.R. 15 C(O)R 13 , N.R. 15 C(O)NR 13 R 14 , N.R. 15 S(O)R 32 , N.R. 15 S(O) 2 R 32 , N.R. 15 S(O) 2 NR 13 R 14 Optionally replaced C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 selected from alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 13 is absent or optionally replaced by C 1 ~C 8 Alkylenyl, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 14 and R 15 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 13 and R 14 , R 13 and R 15 , R 14 and R 15 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 4 is hydrogen, halogen, oxo, CN, NO 2 , OR 16 , S.R. 16 , N.R. 16 R 17 , C(O)R 16 , C(O)OR 16 , C(O)NR 16 R 17 , S(O)R 16 , S(O) 2 R 16 , S(O) 2 NR 16 R 17 , N.R. 18 C(O)OR 16 , N.R. 18 C(O)R 16 , N.R. 18 C(O)NR 16 R 17 , N.R. 18 S(O)R 16 , N.R. 18 S(O) 2 R 16 , N.R. 18 S(O) 2 NR 16 R 15 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 16 , R 17 , and R 18 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 16 and R 17 , R 16 and R 18 , R 17 and R 18 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; The "linker" portion of the bivalent compound is R 1 If attached to; R 1 OR 19 , S.R. 19 , N.R. 19 R 20 , C.H. 2 NR 19 R 20 , C.H. 2 CH 2 NR 19 R 20 , C 1 ~C 8 Alkylene NR 19 R 20 , C(O)R 19 , C(O)OR 19 , C(O)NR 19 R 20 , S(O)R 19 , S(O) 2 R 20 , S(O) 2 NR 19 R 20 , N.R. 21 C(O)OR 19 , N.R. 21 C(O)R 19 , N.R. 21 C(O)NR 19 R 20 , N.R. 21 S(O)R 19 , N.R. 21 S(O) 2 R 19 , N.R. 21 S(O) 2 NR 19 R 20 Optionally replaced C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 selected from alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 19 is absent or optionally replaced by C 1 ~C 8 Alkylenyl, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 20 and R 21 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 19 and R 20 , R 19 and R 21 , R 20 and R 21 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 2 is absent, hydrogen, C(O)R at each occurrence. 10 , C(O)OR 10 , C(O)NR 10 R 11 , S(O)R 10 , S(O) 2 R 10 , S(O) 2 NR 10 R 11 , N.R. 12 C(O)OR 10 , N.R. 12 C(O)R 10 , N.R. 12 C(O)NR 10 R 11 , N.R. 12 S(O)R 10 , N.R. 12 S(O) 2 R 10 , N.R. 12 S(O) 2 NR 10 R 11 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 10 , R 11 , and R 12 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 10 and R 11 , R 10 and R 12 , R 11 and R 12 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 3 and R 4 is hydrogen, halogen, oxo, CN, NO 2 , OR 16 , S.R. 16 , N.R. 16 R 17 , C(O)R 16 , C(O)OR 16 , C(O)NR 16 R 17 , S(O)R 16 , S(O) 2 R 16 , S(O) 2 NR 16 R 17 , N.R. 18 C(O)OR 16 , N.R. 18 C(O)R 16 , N.R. 18 C(O)NR 16 R 17 , N.R. 18 S(O)R 16 , N.R. 18 S(O) 2 R 16 , N.R. 18 S(O) 2 NR 16 R 15 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 16 , R 17 , and R 18 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 16 and R 17 , R 16 and R 18 , R 17 and R 18 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; Part according to formula 3A: 【Chemistry 7】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 3 is independently attached to (indicated by the dotted line); R 1 , R 2 and R 3 The definition of is the same as for Equation 3; R 5 is absent, hydrogen, C(O)R at each occurrence. 22 , C(O)OR 22 , C(O)NR 22 R 23 , S(O)R 22 , S(O) 2 R 22 , S(O) 2 NR 22 R 23 , N.R. 24 C(O)OR 22 , N.R. 24 C(O)R 22 , N.R. 24 C(O)NR 22 R 23 , N.R. 24 S(O)R 22 , N.R. 24 S(O) 2 R 22 , N.R. 24 S(O) 2 NR 22 R 23 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 22 , R 23 , and R 24 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 22 and R 23 , R 22 and R 24 , R 23 and R 24 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 6 is hydrogen, halogen, oxo, CN, NO 2 , OR 25 , S.R. 25 , N.R. 25 R 26 , C(O)R 25 , C(O)OR 25 , C(O)NR 25 R 26 , S(O)R 25 , S(O) 2 R 25 , S(O) 2 NR 25 R 26 , N.R. 27 C(O)OR 25 , N.R. 27 C(O)R 25 , N.R. 21 C(O)NR 25 R 26 , N.R. 27 S(O)R 25 , N.R. 27 S(O) 2 R 25 , N.R. 27 S(O) 2 NR 25 R 26 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 25 , R 26 , and R 27 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 25 and R 26 , R 25 and R 26 , R 26 and R 27 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; Part according to formula 3B: 【Chemistry 8】 (In the formula, The "linker" portion of a bivalent compound is R 1 or R 7 is independently attached to (indicated by the dotted line); R 5 and R 6 are the same as for formula 3A; The "linker" portion of the bivalent compound is R 1 If attached to; R 1 OR 28 , S.R. 28 , N.R. 28 R 29 , C.H. 2 NR 28 R 29 , C.H. 2 CH 2 NR 28 R 29 , C 1 ~C 8 Alkylene NR 28 R 29 , C(O)R 28 , C(O)OR 28 , C(O)NR 28 R 29 , S(O)R 28 , S(O) 2 R 29 , S(O) 2 NR 28 R 29 , N.R. 30 C(O)OR 28 , N.R. 30 C(O)R 28 , N.R. 30 C(O)NR 28 R 29 , N.R. 30 S(O)R 28 , N.R. 30 S(O) 2 R 28 , N.R. 30 S(O) 2 NR 28 R 29 Optionally replaced C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 selected from alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 28 is absent or optionally replaced by C 1 ~C 8 Alkylenyl, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 29 and R 30 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 28 and R 29 , R 28 and R 29 , R 29 and R 30 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 2 , R 7 and R 8 is absent, hydrogen, C(O)R at each occurrence. 31 , C(O)OR 31 , C(O)NR 31 R 32 , S(O)R 31 , S(O) 2 R 31 , S(O) 2 NR 31 R 32 , N.R. 33 C(O)OR 31 , N.R. 33 C(O)R 31 , N.R. 33 C(O)NR 31 R 32 , N.R. 33 S(O)R 31 , N.R. 33 S(O) 2 R 31 , N.R. 33 S(O) 2 NR 31 R 32 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 31 , R 32 , and R 33 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 31 and R 32 , R 31 and R 33 , R 32 and R 33 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 7 and R 8 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; The "linker" portion of the bivalent compound is R 7 If attached to; R 7 OR 28 , S.R. 28 , N.R. 28 R 29 , C.H. 2 NR 28 R 29 , C.H. 2 CH 2 NR 28 R 29 , C 1 ~C 8 Alkylene NR 28 R 29 , C(O)R 28 , C(O)OR 28 , C(O)NR 28 R 29 , S(O)R 28 , S(O) 2 R 29 , S(O) 2 NR 28 R 29 , N.R. 30 C(O)OR 28 , N.R. 30 C(O)R 28 , N.R. 30 C(O)NR 28 R 29 , N.R. 30 S(O)R 28 , N.R. 30 S(O) 2 R 28 , N.R. 30 S(O) 2 NR 28 R 29 Optionally replaced C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 selected from alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 28 is absent or optionally replaced by C 1 ~C 8 Alkylenyl, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 29 and R 30 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 28 and R 29 , R 28 and R 29 , R 29 and R 30 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 , R 2 and R 8 is absent, hydrogen, C(O)R at each occurrence. 31 , C(O)OR 31 , C(O)NR 31 R 32 , S(O)R 31 , S(O) 2 R 31 , S(O) 2 NR 31 R 32 , N.R. 33 C(O)OR 31 , N.R. 33 C(O)R 31 , N.R. 33 C(O)NR 31 R 32 , N.R. 33 S(O)R 31 , N.R. 33 S(O) 2 R 31 , N.R. 33 S(O) 2 NR 31 R 32 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 31 , R 32 , and R 33 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 31 and R 32 , R 31 and R 33 , R 32 and R 33 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; R 1 and R 2 each occurrence optionally forms, together with the atom to which they are attached, an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; The part according to formula 4: 【Chemistry 9】 (In the formula, The "linker" portion of a bivalent compound is R 3 is independently attached to (indicated by the dotted line); R 1、 R 2 and R 4 is hydrogen, halogen, oxo, CN, NO 2 , OR 5 , S.R. 5 , N.R. 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , S(O)R 5 , S(O) 2 R 5 , S(O) 2 NR 5 R 6 , N.R. 7 C(O)OR 5 , N.R. 7 C(O)R 5 , N.R. 7 C(O)NR 5 R 26 , N.R. 7 S(O)R 5 , N.R. 7 S(O) 2 R 5 , N.R. 7 S(O) 2 NR 5 R 6 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 independently selected from cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 5 , R 6 , and R 7 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 10 Cycloalkyl, optionally substituted 3- to 20-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 5 and R 6 , R 5 and R 7 , R 6 and R 7 together with the atom to which they are attached form an optionally substituted 3- to 20-membered cycloalkyl or heterocyclyl ring; n is independently selected from 0, 1, 2, 3, and 4; R 3 OR 8 , S.R. 8 , N.R. 8 R 9 , C.H. 2 NR 8 R 9 , C.H. 2 CH 2 NR 8 R 9 , C 1 ~C 8 Alkylene NR 8 R 9 , C(O)R 8 , C(O)OR 9 , C(O)NR 8 R 9 , S(O)R 8 , S(O) 2 R 9 , S(O) 2 NR 8 R 9 , N.R. 10 C(O)OR 9 , N.R. 10 C(O)R 9 , N.R. 10 C(O)NR 8 R 9 , N.R. 10 S(O)R 8 , N.R. 10 S(O) 2 R 8 , N.R. 10 S(O) 2 NR 8 R 9 Optionally replaced C 1 ~C 8 Alkylene, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkylene, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 selected from alkylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted aryl, and optionally substituted heteroaryl, wherein R 8 is absent or optionally replaced by C 1 ~C 8 Alkylenyl, optionally substituted C 2 ~C 8 Alkenylene, optionally substituted C 2 ~C 8 Alkynylene, optionally substituted C 3 ~C 8 a divalent moiety selected from cycloalkylene, optionally substituted 3- to 8-membered heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene; R 9 and R 10 is optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 independently selected from alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 8 and R 9 , R 8 and R 10 , R 9 and R 10 together with the atom to which they are attached form a 3- to 20-membered cycloalkyl or heterocyclyl ring; Part according to formula 4A: 【Chemistry 10】 (In the formula, The "linker" portion of a bivalent compound is R 3 is independently attached to (indicated by the dotted line); R 3 The definition of is the same as for Equation 4); and pharma- ceutically acceptable salts thereof.

2. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 1:

3. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 2:

4. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 2A.

5. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 2B.

6. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 2C.

7. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 3:

8. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 3A.

9. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 3B.

10. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 4:

11. 2. The bivalent compound of claim 1, wherein the HPK1 ligand is a moiety according to formula 4A.

12. Disassembly / destruction tags A moiety according to one of formulas 12A, 12B, 12C and 12D: 【Chemistry 11】 (In the formula, V, W, and X are CR 2 and N are independently selected; Y is CO, CR 3 R 4 and N=N; Z is absent, CO, CR 5 R 6 , N.R. 5 , O, optionally substituted C 1 ~C 10 Alkylene, optionally substituted C 1 ~C 10 Alkenylene, optionally substituted C 1 ~C 10 alkynylene, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, optionally substituted C 3 ~C 13 Fused Cycloalkyl, Optionally Substituted C 3 ~C 13 Fused Heterocyclyl, Optionally Substituted C 3 ~C 13 Bridged Cycloalkyl, Optionally Substituted C 3 ~C 13 Bridged Heterocyclyl, Optionally Substituted C 3 ~C 13 Spirocycloalkyl, optionally substituted C 3 ~C 13 Preferably, Z is selected from absent, CH 2 , CH=CH, C≡C, NH and O; R 1 , and R 2 is hydrogen, halogen, cyano, nitro, optionally substituted C 1 ~C 6 independently selected from alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; R 3 , and R 4 is hydrogen, halogen, cyano, nitro, optionally substituted C 1 ~C 6 independently selected from alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 3 and R 4 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; R 5 and R 6 is absent, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C 1 ~C 6 independently selected from alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 5 and R 6 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; A moiety according to one of formulas 12E, 12F, 12G, 12H, and 12I: 【Chemistry 12】 (In the formula, U, V, W, and X are CR 2 and N are independently selected; Y is CR 3 R 4 , N.R. 3 and O; preferably, Y is CH 2 , N.H., N.C.H. 3 and O; Z is absent, CO, CR 5 R 6 , N.R. 5 , O, optionally substituted C 1 ~C 10 Alkylene, optionally substituted C 1 ~C 10 Alkenylene, optionally substituted C 1 ~C 10 alkynylene, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 4- to 10-membered heterocyclyl, optionally substituted C 3 ~C 13 Fused Cycloalkyl, Optionally Substituted C 3 ~C 13 Fused Heterocyclyl, Optionally Substituted C 3 ~C 13 Bridged Cycloalkyl, Optionally Substituted C 3 ~C 13 Bridged Heterocyclyl, Optionally Substituted C 3 ~C 13 Spirocycloalkyl, optionally substituted C 3 ~C 13 Preferably, Z is selected from absent, CH 2 , CH=CH, C≡C, NH and O; R 1 , and R 2 is hydrogen, halogen, cyano, nitro, optionally substituted C 1 ~C 6 independently selected from alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; R 3 , and R 4 is hydrogen, halogen, cyano, nitro, optionally substituted C 1 ~C 6 independently selected from alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 3 and R 4 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; R 5 and R 6 is absent, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C 1 ~C 6 independently selected from alkyl, optionally substituted 3- to 6-membered carbocyclyl, and optionally substituted 4- to 6-membered heterocyclyl; or R 5 and R 6 together with the atom to which they are attached form a 3- to 6-membered carbocyclyl or a 4- to 6-membered heterocyclyl; Part according to formula 13A: 【Chemistry 13】 (In the formula, R 1 and R 2 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Aminoalkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 7 Cycloalkyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, and optionally substituted C 2 ~C 8 independently selected from alkynyl; R 3 is hydrogen, optionally substituted C(O)C 1 ~C 8 Alkyl, optionally substituted C(O)C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C(O)C 1 ~C 8 Haloalkyl, optionally substituted C(O)C 1 ~C 8 Hydroxyalkyl, optionally substituted C(O)C 1 ~C 8 Aminoalkyl, optionally substituted C(O)C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C(O)C 3 ~C 7 Cycloalkyl, optionally substituted C(O)(3- to 7-membered heterocyclyl), optionally substituted C(O)C 2 ~C 8 Alkenyl, optionally substituted C(O)C 2 ~C 8 Alkynyl, optionally substituted C(O)OC 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C(O)OC 1 ~C 8 Haloalkyl, optionally substituted C(O)OC 1 ~C 8 Hydroxyalkyl, optionally substituted C(O)OC 1 ~C 8 Aminoalkyl, optionally substituted C(O)OC 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C(O)OC 3 ~C 7 Cycloalkyl, optionally substituted C(O)O(3- to 7-membered heterocyclyl), optionally substituted C(O)OC 2 ~C 8 Alkenyl, optionally substituted C(O)OC 2 ~C 8 Alkynyl, optionally substituted C(O)NC 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C(O)NC 1 ~C 8 Haloalkyl, optionally substituted C(O)NC 1 ~C 8 Hydroxyalkyl, optionally substituted C(O)NC 1 ~C 8 Aminoalkyl, optionally substituted C(O)NC 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C(O)NC 3 ~C 7 Cycloalkyl, optionally substituted C(O)N(3- to 7-membered heterocyclyl), optionally substituted C(O)NC 2 ~C 8 Alkenyl, optionally substituted C(O)NC 2 ~C 8 Alkynyl, optionally substituted P(O)(OH) 2 , optionally substituted P(O)(OC 1 ~C 8 Alkyl) 2 and optionally substituted P(O)(OC 1 ~C 8 Aryl) 2 is); A moiety according to one of formulas 13B, 13C, 13D, 13E and 13F: 【Chemistry 14】 (In the formula, R 1 and R 2 are hydrogen, halogens, OH, NH 2 , CN, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Aminoalkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 7 Cycloalkyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, and optionally substituted C 2 ~C 8 alkynyl; (preferably, R 1 is selected from iso-propyl or tert-butyl; R 2 is selected from hydrogen or methyl; R 3 is hydrogen, optionally substituted C(O)C 1 ~C 8 Alkyl, optionally substituted C(O)C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C(O)C 1 ~C 8 Haloalkyl, optionally substituted C(O)C 1 ~C 8 Hydroxyalkyl, optionally substituted C(O)C 1 ~C 8 Aminoalkyl, optionally substituted C(O)C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C(O)C 3 ~C 7 Cycloalkyl, optionally substituted C(O)(3- to 7-membered heterocyclyl), optionally substituted C(O)C 2 ~C 8 Alkenyl, optionally substituted C(O)C 2 ~C 8 Alkynyl, optionally substituted C(O)OC 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C(O)OC 1 ~C 8 Haloalkyl, optionally substituted C(O)OC 1 ~C 8 Hydroxyalkyl, optionally substituted C(O)OC 1 ~C 8 Aminoalkyl, optionally substituted C(O)OC 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C(O)OC 3 ~C 7 Cycloalkyl, optionally substituted C(O)O(3- to 7-membered heterocyclyl), optionally substituted C(O)OC 2 ~C 8 Alkenyl, optionally substituted C(O)OC 2 ~C 8 Alkynyl, optionally substituted C(O)NC 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C(O)NC 1 ~C 8 Haloalkyl, optionally substituted C(O)NC 1 ~C 8 Hydroxyalkyl, optionally substituted C(O)NC 1 ~C 8 Aminoalkyl, optionally substituted C(O)NC 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted C(O)NC 3 ~C 7 Cycloalkyl, optionally substituted C(O)N(3- to 7-membered heterocyclyl), optionally substituted C(O)NC 2 ~C 8 Alkenyl, optionally substituted C(O)NC 2 ~C 8 Alkynyl, optionally substituted P(O)(OH) 2 , optionally substituted P(O)(OC 1 ~C 8 Alkyl) 2 and optionally substituted P(O)(OC 1 ~C 8 Aryl) 2 and; R 4 and R 5 is hydrogen, COR 6 , CO 2 R 6 ,CONR 6 R 7 , SOR 6 , S.O. 2 R 6 , S.O. 2 NR 6 R 7 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 6 and R 7 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 4 and R 5 ;R 6 and R 7 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; Ar is selected from aryl and heteroaryl, each of which is selected from F, Cl, CN, NO 2 , OR 8 , N.R. 8 R 9 , C.O.R. 8 , CO 2 R 8 ,CONR 8 R 9 , SOR 8 , S.O. 2 R 8 , S.O. 2 NR 9 R 10 , N.R. 9 COR 10 , N.R. 8 C(O)NR 9 R 10 , N.R. 9 SOR 10 , N.R. 9 SO 2 R 10 , optionally replaced by C 1 ~C 6 Alkyl, optionally substituted C 1 ~C 6 Alkoxyalkyl, optionally substituted C 1 ~C 6 Haloalkyl, optionally substituted C 1 ~C 6 Hydroxyalkyl, optionally substituted C 1 ~C 6 Alkylamino C 1 ~C 6 Alkyl, optionally substituted C 3 ~C 7 Cycloalkyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted C 2 ~C 6 Alkenyl, optionally substituted C 2 ~C 6 Alkynyl, optionally substituted aryl, and optionally substituted C 4 ~C 5 optionally substituted with one or more substituents independently selected from heteroaryl; R 8 , R 9 , and R 10 is absent, hydrogen, optionally substituted by C 1 ~C 6 Alkyl, optionally substituted C 2 ~C 6 Alkenyl, optionally substituted C 2 ~C 6 Alkynyl, optionally substituted C 3 ~C 7 independently selected from cycloalkyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 8 and R 9 ; R 9 and R 10 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring; Part according to formula 14A: 【Chemistry 15】 (In the formula, V, W, X, and Z are CR 4 and N are independently selected; R 1 , R 2 , R 3 , and R 4 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 3 ~C 7 Cycloalkyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, and optionally substituted C 2 ~C 8 alkynyl); and Part according to formula 14B: 【Chemistry 16】 (In the formula, R 1 , R 2 , and R 3 is hydrogen, halogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 3 ~C 7 Cycloalkyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted C 2 ~C 8 Alkenyl, and optionally substituted C 2 ~C 8 independently selected from alkynyl; R 4 and R 5 is hydrogen, COR 6 , CO 2 R 6 ,CONR 6 R 7 , SOR 6 , S.O. 2 R 6 , S.O. 2 NR 6 R 7 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 Alkyl, optionally substituted aryl-C 1 ~C 8 independently selected from alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R 6 and R 7 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R 6 and R 7 together with the atom to which they are attached form a 4- to 8-membered cycloalkyl or heterocyclyl ring.

2. The divalent compound of claim 1, selected from the group consisting of:

13. 13. The bivalent compound of claim 12, wherein the degradation / destruction tag is a moiety of one of formulas 12A, 12B, 12C, and 12D.

14. 13. The bivalent compound of claim 12, wherein the degradation / destruction tag is a moiety of one of formulas 12E, 12F, 12G, 12H and 12I.

15. 13. The bivalent compound of claim 12, wherein the degradation / destruction tag is a moiety of formula 13A.

16. 13. The bivalent compound of claim 12, wherein the degradation / destruction tag is a moiety of one of formulas 13B, 13C, 13D, 13E, and 13F.

17. 13. The bivalent compound of claim 12, wherein the degradation / destruction tag is a moiety of formula 14A.

18. 13. The bivalent compound of claim 12, wherein the degradation / destruction tag is a moiety of formula 14B.

19. Disassembly / destruction tags 【Chemical 17A】 【Chemistry 17B】 2. The divalent compound of claim 1, selected from the group consisting of:

20. 20. The bivalent compound of claim 19, wherein the degradation / destruction tag is one of formulas 15A-15R.

21. 20. The bivalent compound of claim 19, wherein the degradation / destruction tag is one of formulas 15AM-15BN.

22. The linker: The part according to Equation 16: 【Chemistry 18】 (In the formula, A, W, and B are absent, CO, CO at each occurrence. 2 , C(O)NR 1 , C(S)NR 1 , O, S, SO, SO 2 , S.O. 2 NR 1 , N.R. 1 , N.R. 1 CO, NR 1 CONR 2 , N.R. 1 C(S), optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 ~C 13 Fused Cycloalkyl, Optionally Substituted C 3 ~C 13 Fused Heterocyclyl, Optionally Substituted C 3 ~C 13 Bridged Cycloalkyl, Optionally Substituted C 3 ~C 13 Bridged Heterocyclyl, Optionally Substituted C 3 ~C 13 Spirocycloalkyl and optionally substituted C 3 ~C 13 spiroheterocyclyl; R 1 and R 2 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted 3- to 8-membered cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino and optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; m is 0 to 15); Part according to formula 16A: 【Chemistry 19】 (In the formula, R 1 , R 2 , R 3 , and R 4 represents hydrogen, halogen, CN, OH, NH 2 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 3 ~C 8 Cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino and optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; A, W, and B are absent, CO, CO at each occurrence. 2 , C(O)NR 5 , C(S)NR 5 , O, S, SO, SO 2 , S.O. 2 NR 5 , N.R. 5 , N.R. 5 CO, NR 5 CONR 6 , N.R. 5 C(S), optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 ~C 13 Fused Cycloalkyl, Optionally Substituted C 3 ~C 13 Fused Heterocyclyl, Optionally Substituted C 3 ~C 13 Bridged Cycloalkyl, Optionally Substituted C 3 ~C 13 Bridged Heterocyclyl, Optionally Substituted C 3 ~C 13 Spirocycloalkyl and optionally substituted C 3 ~C 13 spiroheterocyclyl; R 5 and R 6 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino and optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; m is from 0 to 15; n, at each occurrence, is 0 to 15; o is between 0 and 15); Part according to formula 16B: 【Chemistry 20】 (In the formula, R 1 and R 2 represents hydrogen, halogen, CN, OH, NH 2 , and optionally substituted C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino or C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; A and B are absent, CO, CO at each occurrence. 2 , C(O)NR 3 , C(S)NR 3 , O, S, SO, SO 2 , S.O. 2 NR 3 , N.R. 3 , N.R. 3 CO, NR 3 CONR 4 , N.R. 3 C(S) and optionally substituted C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 ~C 13 Fused Cycloalkyl, Optionally Substituted C 3 ~C 13 Fused Heterocyclyl, Optionally Substituted C 3 ~C 13 Bridged Cycloalkyl, Optionally Substituted C 3 ~C 13 Bridged Heterocyclyl, Optionally Substituted C 3 ~C 13 Spirocycloalkyl, or C 3 ~C 13 spiroheterocyclyl; R 3 and R 4 is hydrogen and optionally substituted C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino or C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; Each m is from 0 to 15; n is 0 to 15); The part according to formula 16C: 【Chemistry 21】 (In the formula, X is O, NH, or NR 7 Selected from; R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 represents hydrogen, halogen, CN, OH, NH 2 , optionally replaced by C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino and optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; A and B are, at each occurrence, absent, CO, NH, NH-CO, CO-NH, CH 2 -NH-CO, CH 2 -CO-NH, NH-CO-CH 2 , CO-NH-CH 2 , C.H. 2 -NH-CH 2 -CO-NH, CH 2 -NH-CH 2 -NH-CO, -CO-NH, CO-NH-CH 2 -NH-CH 2 , C.H. 2 -NH-CH 2 , CO 2 , C(O)NR 7 , C(S)NR 7 , O, S, SO, SO 2 , S.O. 2 NR 7 , N.R. 7 , N.R. 7 CO, NR 7 CONR 8 , N.R. 7 C(S), optionally replaced by C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxy C 1 ~C 8 Alkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 2 ~C 8 Alkenyl, optionally substituted C 2 ~C 8 Alkynyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C 3 ~C 13 Fused Cycloalkyl, Optionally Substituted C 3 ~C 13 Fused Heterocyclyl, Optionally Substituted C 3 ~C 13 Bridged Cycloalkyl, Optionally Substituted C 3 ~C 13 Bridged Heterocyclyl, Optionally Substituted C 3 ~C 13 Spirocycloalkyl and optionally substituted C 3 ~C 13 spiroheterocyclyl; R 7 and R 8 is hydrogen, optionally substituted C 1 ~C 8 Alkyl, optionally substituted 3- to 8-membered cycloalkyl, optionally substituted C 3 ~C 8 Cycloalkoxy, optionally substituted 3- to 8-membered heterocyclyl, optionally substituted C 1 ~C 8 Alkoxy, optionally substituted C 1 ~C 8 Alkoxyalkyl, optionally substituted C 1 ~C 8 Haloalkyl, optionally substituted C 1 ~C 8 Hydroxyalkyl, optionally substituted C 1 ~C 8 Alkylamino and optionally substituted C 1 ~C 8 Alkylamino C 1 ~C 8 independently selected from alkyl; m, in each occurrence, is from 0 to 15; n, at each occurrence, is 0 to 15; o is from 0 to 15; p is 0 to 15); and Moieties according to one of the formulae C1, C2, C3, C4 and C5: 【Chemical 22】 2. The divalent compound of claim 1, selected from the group consisting of:

23. 23. The bivalent compound of claim 22, wherein the linker is a moiety of formula 16.

24. 23. The bivalent compound of claim 22, wherein the linker is a moiety of formula 16A.

25. 23. The bivalent compound of claim 22, wherein the linker is a moiety of formula 16B.

26. 23. The bivalent compound of claim 22, wherein the linker is a moiety of formula 16C.

27. 23. The bivalent compound of claim 22, wherein the linker is a moiety of one of the formulas C1-C5.

28. 2. The bivalent compound of claim 1, wherein the linker is selected from the group consisting of a ring selected from the group consisting of 3- to 13-membered rings; 3- to 13-membered fused rings; 3- to 13-membered bridged rings; and 3- to 13-membered spiro rings.

29. A divalent compound selected from the group consisting of: MS-5-006, MS-5-007, MS-5-008, MS-5-009, MS-5-010, MS-5-011, MS-5-015, MS-5-016, MS-5-017, MS-5-018 , MS-5-019, MS-5-021, MS-5-022, MS-5-024, MS-5-026, MS-5-027, MS-5-028, MS-5-029, MS-5-030, MS-5-03 3, MS-5-034, MS-5-035, MS-5-036, MS-5-037, MS-5-038, MS-5-039, MS-5-040, MS-5-041, MS-5-042, MS-5-0 43, MS-5-044, MS-5-045, MS-5-046, MS-6-003, MS-6-004, MS-6-005, MS-6-006, MS-6-007, MS-6-008, MS-6- 009, MS-6-013, MS-6-014, MS-6-015, MS-6-016, MS-6-017, MS-6-018, MS-6-019, MS-6-020, MS-6-021, MS-6 -022, MS-6-023, MS-6-024, MS-6-025, MS-6-026, MS-6-027, MS-6-028, MS-6-029, MS-6-037, MS-6-038, MS- 6-039, MS-6-040, MS-6-041, MS-6-043, MS-6-044, MS-6-045, MS-6-046, MS-6-047, MS-6-048, MS-6-049, MS -6-050, MS-6-051, MS-6-052, MS-6-053, MS-6-054, MS-6-055, MS-6-058, MS-6-059, MS-6-060 and MS-6-061.

30. A divalent compound selected from the group consisting of: MS-5-006, MS-5-007, MS-5-008, MS-5-009, MS-5-010, MS-5-011, MS-5-015, MS-5-016, MS -5-017, MS-5-018, MS-5-019, MS-5-021, MS-5-022, MS-5-024, MS-5-026, MS-5-027, MS-5- 028, MS-5-029, MS-5-030, MS-5-033, MS-5-034, MS-5-035, MS-5-036, MS-5-037, MS-5-03 8, MS-5-039, MS-5-040, MS-5-041, MS-5-042, MS-5-043, MS-5-044, MS-5-045 and MS-5-046.

31. A divalent compound selected from the group consisting of: MS-6-003, MS-6-004, MS-6-005, MS-6-006, MS-6-007, MS-6-008, MS-6-009, MS-6-013, MS-6-014, MS-6-015, MS-6-016, MS-6 -017, MS-6-018, MS-6-019, MS-6-020, MS-6-021, MS-6-022, MS-6-023, MS-6-024, MS-6-025, MS-6-026, MS-6-027, MS-6-028, MS-6-029, MS-6-037, MS-6-038, MS-6-039, MS-6-040, MS-6-041, MS-6-043, MS-6-044, MS-6-045, MS-6-046, MS-6-047, MS-6- 048, MS-6-049, MS-6-050, MS-6-051, MS-6-052, MS-6-053, MS-6-054, MS-6-055, MS-6-058, MS-6-059, MS-6-060 and MS-6-061.

32. A divalent compound selected from the group consisting of: a) 2-(4-(3-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)propyl)piperazin-1-yl)-N-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)acetamide (MS-5-007); b) 2-(4-(3-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)propyl)piperazin-1-yl)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide (MS-5-008); c) 4-((5-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)pentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (MS-5-009); d) 4-((6-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)hexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5MS-5-010); and e) 4-((8-(5-(2-((3,3-dimethyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)amino)-4-(((S)-2-hydroxy-1-phenylethyl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)octyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (MS-5-011).

33. A divalent compound selected from the group consisting of: f) 2-(2,6-dioxopiperidin-3-yl)-4-((3-(((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)(methyl)amino)propyl)amino)isoindoline-1,3-dione (MS-6-007); g) 2-(2,6-dioxopiperidin-3-yl)-4-((4-(((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)(methyl)amino)butyl)amino)isoindoline-1,3-dione (MS-6-008); h) 2-(2,6-dioxopiperidin-3-yl)-4-((6-(((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)(methyl)amino)hexyl)amino)isoindoline-1,3-dione (MS-6-009); and i) 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-((2-(6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-((R)-2-methylpyrrolidin-1-yl)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl)-N-methylacetamide (MS-6-024).

34. A divalent compound according to any one of claims 1 to 33; and Pharmaceutically acceptable carriers 23. A pharmaceutical composition comprising:

35. 35. A method of treating an HPK1 mediated disease, comprising administering to a subject in need thereof the pharmaceutical composition of claim 34.

36. 36. The method of claim 35, wherein the HPK1 mediated disease is cancer.